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ABSTRACT 
The thesis entitled ^^Quantitative Analysis of Drugs in Pliarmaceutical 
Preparations" is comprised of five chapters. The first chapter describes a 
general introduction of the subject matter. The very relevant matters 
include: 
• a brief discussion on analytical chemistry, its relation with our daily life 
from old age, role played in the field of pharmaceutical and biomedical 
analysis. 
• various types of analytical techniques and procedure involving 
sophisticated instruments, which are in use nowadays. 
• important parameters are discussed for the individual validation 
characteristics and their interpretation by statistical treatment of the 
data in order to facilitate the selection of parameters which are relevant 
to the performance and suitability of the given analytical procedure. 
Before or during the development of analytical method, it is necessary to 
be very careful of certain important things. These concepts have been 
discussed briefly. Once the analytical method is advent, it is necessary 
to decide its suitability for the intended purpose. This is known as the 
method validation. Brief discussions of the validation and its components 
have been presented. Now a day, a variety of strict demands are posed 
by numerous international organizations namely International Union of 
Pure and Applied Chemistry, International Laboratory Accreditation 
Conference, Western European Laboratory Accreditation Cooperation, 
International Conference on Harmonisation, and International 
Organization for Standardization on sucli metliods, ttie most important 
parameters being accuracy, precision, selectivity, specificity and 
detectability. 
A description of the classification of drugs based on pharmacological 
action on human organs is included and finally a brief literature and 
chemical structures of the four drugs, i.e., norfloxacin, nicorandil, ramipril 
and silymarin are presented. An abundant and well-composed list of 
references is given at the end of this chapter, comprises 231 citations, 
taken from the world's leading scientific journals in the field. 
The second chapter describes a simple and sensitive kinetic 
spectrophotometric method, based on the oxidation of the norfloxacin with 
alkaline potassium permanganate. The reaction is followed 
spectrophotometrically by measuring the rate of change of absorbance at 
603 nm. The initial rate and fixed time (at 3 min) methods are utilized for 
constructing the calibration graphs to determine the concentration of the 
drug. The calibration graphs are linear in the concentration ranges of 2.0-20 
Jig ml"^ and 1.0-20 jxg ml'^ using the initial rate and fixed time methods, 
respectively. The regression analysis of calibration data yielded the 
regression equations: 
log (rate) = 3.213 + 0.9975 log C 
and A = 2.905 x 10"^  + 1.500 x lO'^ C 
for initial-rate and fixed time (at 3 min) methods, respectively. The 
detection limits of initial-rate and fixed time methods have been calculated 
and found to be 0.0031 ^g ml'^ and 0.08 \ig m l ^ respectively. 
The results are validated statistically and through recovery studies. The 
method has been successfully applied to the determination of norfloxacin in 
commercial dosage forms. Statistical comparison of the results with the 
reference method shows excellent agreement and indicates no significant 
difference in accuracy and precision. 
In Chapter three, two simple and sensitive validated 
spectrophotometric methods have been described for the assay of nicorandil 
in drug formulations. Method A is based on the reaction of the drug with 
phloroglucinol-sulfanilic acid reagent in sulphuric acid medium to give 
yellow-coloured product, which absorbs maximally at 425 nm. Method B 
uses the oxidative coupling of 3-methyl-2-benzothiazolinone hydrazone 
hydrochloride (MBTH) with DL-3,4-dihydroxyphenylalanine (DL-dopa) in the 
presence of nicorandil as oxidant in sulphuric acid medium to form an 
intensely coloured product having maximum absorbance at 530 nm. Beer's 
law is obeyed in the concentration range 2.5 to 50.0 and 1.0 to 15.0 ng ml"^ 
with molar absorptivity of 5.914x10^ and l.SOOxlO'' I mol"^ cm'^ for 
methods A and B, respectively. The detection limit and recovery for 
methods A and B were also calculated and found to be 0.267 ^g ml"^; 
99.95-100.17% and 0.017 ^g ml"^; 99.99-100.11%, respectively. Both 
methods have been successfully applied for the analysis of drug in 
pharmaceutical formulations. The reliability and the performance of the 
proposed methods are established by point and interval hypothesis and 
through recovery studies. The experimental true bias of all samples is 
smaller than ±2%. 
The fourth chapter describes a simple and sensitive kinetic 
spectrophotometric method for the assay of ramipril in drug formulations. 
The method is based on the reaction of carboxylic acid group of the drug 
with a mixture of potassium iodate (KIO3) and potassium iodide (KI) in 
aqueous medium at room temperature. The reaction is followed 
spectrophotometrically by measuring the increase in absorbance at 352 nm 
as a function of time. The effect of variables on the reaction product is 
carefully studied to optimize the reaction conditions. The initial-rate and 
fixed-time methods are adopted for constructing the calibration curves. The 
estimation of ramipril is carried out in the concentration ranges of 10.0 -
70,0 |ig ml"^ by initial rate and fixed time methods. The proposed methods 
are validated statistically and through recovery studies. The methods have 
been successfully applied to the determination of ramipril in pharmaceutical 
formulations. The point and interval hypothesis tests have been performed 
confirming that there is no significant difference between the proposed 
methods and the reference method. The experimental true bias of all 
samples is less than ± 2%. 
The fifth chapter includes a simple and sensitive kinetic 
spectrophotometric method for the determination of silymarin in drug 
formulations. The method is based on the oxidation of drug with potassium 
persulphate in alkaline medium and further coupling of the oxidized product 
of drug with the electrophilic intermediate of 3-methyl-2-benzothiazolinone-
hydrazone hydrochloride (MBTH) resulting in the formation of an Intensely 
coloured species. The reaction is followed spectrophotometrically by 
measuring the increase in absorbance with time (for 15 min) at 430 nm. For 
determination of silymarin, a pseudo first order condition was worked out 
by using a large excess of potassium persulphate, sodium carbonate and 
MBTH solution with respect to the initial concentration of silymarin. Under 
this condition, the regression of log rate versus log of silymarin 
concentration gave the rate equation: 
log (rate) = 2.798+ 1.00 log C 
with a correlation coefficient of 0.9999. The two-calibration procedures i.e. 
initial rate and fixed time methods (at 12 min) are utilized for the assay of 
drug in the concentration range of 16.0 - 192.0 ^g m r \ The results are 
optimized and validated statistically and through recovery studies. The 
methods have been successfully applied to the determination of silymarin in 
pharmaceutical formulations. The results of the proposed methods are 
compared with those of the reference method by means of point and 
interval hypothesis tests confirming excellent agreement and showing no 
significant difference between the proposed methods (initial rate or fixed 
time) with the reference method. 
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CHAPTER-1 
GENERAL INTRODUCTION 
The history of drugs is shrouded in the beginnings of the human race. Many 
drugs in use today have been known for hundreds or thousands of years. A 
remarkable range of drugs, to combat infectious diseases, control cardiovascular 
ailments, treat cancers and provide palliatives in the case of central nervous system 
disorders, have completely transform the practice of medicine over the past half a 
century. Together with significant advances in diagnostics and vaccines for the early 
and definitive detection of disease and the prevention of infection, the progress of 
drug research has contributed to the advancement of the human health care in both 
the developed and developing countries of the world. 
Drugs are chemical compounds that modify the way the body and mind work. 
Most people think that these biological activities should help or heal sick people or 
animals. There is, however, no known drug that is not harmful or even poisonous at 
high doses. In a way that neither condemns nor condones drug use, a single example 
will suffice to illustrate the point. In his book "Confessions of an English Opium-
Eater" the man of letters Thomas De Quincey [1] described in a footnote the 
dilemma of his friend, a surgeon, who was suffering fi-om a lingering and fatal 
malady. Yet he had a family to support and had to continue working for as long as 
possible. Because of his professional knowledge he saw the necessity of reducing 
the daily dose of opium that he took to alleviate his pain to a minimum. I now quote 
the words used by De Quincey: "But to do this he must first obtain the means of 
measuring the quantities of opium; not the apparent quantities as determined by 
weighing, but the virtual quantities after allowing for the alloy of varying amounts 
of impurity". With the knowledge available at that time De Quincey's friend was 
unable to form such an assessment. He did, however, achieve a uniform method of 
extracting the opium so as to give a fairly constant potency. 
The gradual change from the use of natural products in their entire state to 
either purified extracts from those products or to synthetic chemically - produced 
materials can be said to have been taking place between the time of Paracelsus, who 
lived in Basel during the first half of the sixteenth century, to that of Ehrlich, to 
whom the award of a Nobel prize in 1909 was a fitting reward for his remarkable 
researches and breakthrough during the first decade of this century. This period has 
been described as that leading from Quintessence to the Chemical and has been 
fascinatingly reviewed by H. J. Barber [2]. This transition from the Quintessence to 
the Chemical stimulated a very considerable amount of interest in the analysis of 
natural products to determine, as De Quincey had said one hundred years earlier, not 
the apparent quantities as determined by weighing but the virtual quantities after 
allowing for the alloy of impurity. Thus, there is no doubt that nearly a century of 
pharmaceutical research has contributed spectacularly to improvement in human 
health and quality of life. 
The growing awareness of the need to analyze drug substances was also 
apparent before any synthetic materials found regular using medicine. Higher 
standards for the preparation of pharmaceutical ingredients had been set, following 
the 1858 Medical Act's stipulation that the General Medical Council (U.K.) should 
produce a list of medicines and compounds and manner of preparing them together 
with true weights and measures by which they are to be prepared and mixed [3]. The 
first editions of British Pharmacop)oeia and Japanese Pharmacopoeia were published 
in 1864 and 1886, respectively. Thereafter, pharmaceutical and fine chemical 
manufacturers laid greater emphasis on meeting the standards set by 
pharmacopoeias. In 1890, Jesse Boot established an analytical laboratory and its 
staff were involved mainly for analyzing proprietaiy medicines of competitors in 
order that Boots should develop new and / or cheaper formulations [4]. 
The increase in use of classical analysis to quantitate and define materials used 
in medicine, together with the increase in the use of materials of synthetic origin and 
of increasing complexity, is evident from a study of pharmacopoeias of various 
covmtries issued between 1900 and 1950. Shortly after this period one can see the 
exciting beginnings of a completely new era in the analysis of drugs based on the 
introduction of new concepts of analytical methodology that found no reference in 
the classical analytical textbooks of the time. The introduction of complexometric 
and non-aqueous titrimetry in the early 1950s, gas liquid chromatography in 1952, 
thin layer chromatography in 1956 together with the increasing applications of ultra-
violet and infra-red spectroscopy during this period, can all be followed in the pages 
of any national pharmacopoeia that was being published regularly during this period. 
This brings us to the early 1960s and at those times any regulatory interest in the 
quality of drugs rested almost entirely on the pharmacopoeias. 
In the European Community of countries, directives have been issued to 
ensure that the legislation in each member state shall provide for the comprehensive 
examination of intended drug materials before they are allowed to enter the market. 
Mutagenicity, carcinogenecity, toxicity, effect of reproductive function, 
pharmacodynamics and pharmacokinetics are among the properties to be studied and 
material must be unequivocally characterized with respect to the substance itself and 
the amounts of impurity that are likely to arise during the course of validated 
production processes. 
Purity, a metaphysical concept, has always been considered as an essential 
factor in ensuring drug quality. Absolute purity does not exist and the degree of 
purity of a product is only a reflection of the analytical techniques used for its 
assessment. All pharmaceutical substances unavoidably contain impurities resulting 
from many sources like raw materials and reagents, as reaction by products, and 
through degradation during manufacture and storage or extraneous contamination. 
Chemical impurities are classified into three classes for regulatory purpose as 
organic, inorganic and residual solvents. 
• Organic impurities may arise from starting materials (most often from isomeric 
impurities), synthetic intermediates (incomplete reaction or excess reagent used) 
and degradation product which may depend on alteration in reaction conditions 
such as temperature, pH or in storage condition (hydrolysis, ring opening etc.). 
• Inorganic impurities present in pharmaceutical products originate from the 
equipment used and from reagents, catalysts, drying agents and filter aids. 
• Residual solvents and other volatile impurities must be detected and assayed, not 
only because of their potential toxicity and deleterious environmental effects, but 
also because they can impart undesirable organoleptic characteristics to drugs. 
Since residual solvents arise in excipients and occasionally in the manufacture of 
drug products, it was decided to draft a separate guideline to address appropriate 
levels. A key component of the guideline and a fimdamental concept is 
qualification [5]. "Qualification is defined as the process of acquiring and 
evaluating data that establishes the biological safety of an individual impurity or 
a given impurity profile at the level (s) specified". In view of this concept, the 
pharmaceutical analyst must give usefiil thoughts to the analytical methods, 
especially in the development phases. Therefore, it is an important task for the 
pharmaceutical analyst to select an assay procedure, which provides the best 
solutions to the problems. At a later stage, once the pharmaceutical product has 
entered the open market, there should be every opportunity given for external 
independent challenge. The possibility of deterioration on storage, criminal 
substitution, counterfeiting and irmocent mistake must all be considered. In some 
areas of the world these possibilities are, regrettably, very much more likely than 
in others and circumstantial evidence suggests that they are on the increase. 
However, they should be guarded against everywhere. It is for this reason that 
sound, publicly available specification are an essential part of the regulatory 
control system, notwithstanding the advance procedures of licensing and 
inspection in many countries. 
Over the last 30 years the very existence of searching analytical methods has 
contributed quite considerably to an improvement in the general quality of the drugs. 
We are all familiar with adage that "Quality must be built into a product - it can 
never be analyzed into it". The most frequently used analytical techniques in 
pharmaceutical analysis are titrimetry, chromatography, electrochemical methods 
and spectroscopy. Sometimes these techniques are combined with other supporting/ 
subsidiary instruments like flow injection analysis system or kinetic type of analysis. 
Thus making them more sensitive, selective and fast. 
In the field of drug analysis volumetric methods, either direct or indirect, have 
their own importance due to their inherent simplicity. This is the reason why still a 
large number of official methods for the determination of pharmaceuticals in the 
pharmacopocieas are based on titrimetry. Though it is the oldest technique in the 
market now but still having their recognition in the field of scientific research. 
Recently titrimetric methods have been used for the determination of albendazole 
[6], gatifloxacin [7], promethazine theodate [8] and procaine hydrochloride [9] in 
commercial dosage forms. 
Chromatographic methods have many applications in trace analysis and 
sometimes prove it as the only way. The different types of chromatography such as 
i, 
thin layer chromatography, high performance thin layer chromatography, column 
chromatography, high performance liquid chromatography, gas chromatography and 
capillary electro-chromatography have most frequent applications in the field of 
pharmaceutical as well as biomedical analyses. 
Thin layer chromatography (TLC) has enjoyed widespread popularity in 
modem pharmaceutical analysis because of its sensitivity and speed of analysis. A 
TLC method has been developed for the determination of oxysterols in plasma using 
plates coated with either RP-C18 or silica gel F254 [10]. In two other accounts, thin 
layer chromatography has been employed to identify an unknown compound in 
hydroquinine that has a higher Rf value and forms during migration when 
dichloromethane and methanol are used as the development solvent [11] and to 
I 
estimate the level of quinine, cinchonine and cinconidine in natural products and 
marketed formulations in combination with fluorescence enhanced detection [12]. 
This technique has also been used to analyse celecoxib in commercial dosage forms 
[13]. The contents of gestodene and cyproterone have been determined in raw 
material and dosage forms by thin layer chromatography [14]. 
High performance thin layer chromatography (HPTLC) is an Off-Line 
technique whose every stage of analysis can be visualized. Review papers [15,16] by 
! 
Renger have discussed development and validation of thin layer chromatographic 
and high performance thin layer chromatographic methods in pharmaceutical quality 
control analyses. The advantages stated are as follows: 
• simple to handle the instrument 
THESIS 
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• short analysis time to analyze complex or crude samples with minimum sample 
clean up 
• evaluate the entire chromatogram with a wide variety of techniques and 
parameters without time constraints 
• simultaneous but independent development of multiple sample and standards on 
each plate, leading to an increased reliability of results (in-system calibrations) 
• robustness for easy transfer of samples. 
Several drugs have been successfully investigated by HPTLC in pharmaceutical 
preparations [17-20]. 
Among all chromatographic methods, high performance liquid 
chromatography (HPLC) is most acceptable now a day due to its simplicity, high 
specificity and sensitivity for the analysis of drugs in both dosage forms and in 
biological fluids. For example, captopril can be measured in pharmaceutical tablets 
by anion exchange HPLC using indirect photometric detection [21]. HPLC is also 
useful in analyzing vitamin B12 [22]. Dexamethasone has been estimated by HPLC 
using isocratic reversed-phased procedure in cream formulations [23] and a gradient 
method for evaluating its stability as the unformulated drug substance and in 
formulated products [24]. This method can also be used to measure impurities, 
degradation products and product preservatives at levels between 0.05 and 0.1%. 
HPLC assay procedures have been developed for cephalexin and cefadroxil, cefaclor 
and cefataxim in pharmaceuticals [25] and for cefixime trihyrate in bulk drugs [26]. 
Because of the specificity and sensitivity afforded by gas chromatography 
(GC), it has been widely used for the detection and determination of trace level 
contaminants in pure substances and also in pharmacokinetic studies. The use of 
mass spectrometer (MS) as the gas chromatographic detector provides additional 
sensitivity and specificity over other analytical methods and can yield qualitative 
and quantitative information not available from other analytical techniques [27]. 
Capillary gas chromatography-mass spectrometry is utilized for monitoring 
anticancer drugs [28]. A number of papers have been published on the applications 
of gas chromatography in pharmaceutical analysis both in dosage forms and 
biological fluids [29-33]. 
Capillary electrophoresis (CE) is a relatively new analytical techniques based 
on the separation of charged analytes through a small capillary under the influence 
of an electric field. Additionally, CE is based on a separation mechanism, which 
differs from all types of chromatography, which makes it either a potential 
alternative analytical technique capable of faster analysis and higher efficiency than 
HPLC, or complimentary technique to HPLC to augment the information obtained 
fi-om the analysis. CE is becoming popular for the analysis of drugs in 
pharmaceutical preparations. Several reports have appeared on the application of this 
technique in routine drug analysis [34-40]. Different modes of CE such as capillary 
zone electrophoresis (CZE) [41,42], micellar electrokinetic chromatography 
(MEKC) [43,44], isotachophoresis (ITP) [45,46], capillary-electrokinetic (CEC) 
[47,48], capillary gel electrophoresis (CGE) [49,50], iso-electric focusing (lEF) 
[51,52] and affinity capillary electrophoresis (ACE) [53, 54] have been developed 
and applied for pharmaceutical purity testing and in bioanalysis of drugs. 
The use of electrochemical (EC) methods for the analysis of drugs and other 
compounds of biological interest has increased greatly over the last few years. The 
reason for this increase is simple, a wide variety of electrode materials^ electrocells, 
electrochemical instruments, and electrochemical techniques that can be used with 
convenience and reliability are now commercially available. 
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Important electrochemical techniques such as amperometry, conductometry, 
potentiometry, anodic and cathodic stripping voltammetry, differential pulse 
voltammetry and polarography have been used in drug analysis. Potentiometric 
titrations are also reported in the pharmacopoeias as the standard method for the 
determination of certain drug substances [55-57]. Despite the wide use of 
spectrometry and chromatography analysts are choosing polarography and 
voltammetry [58-63] as an alternative due to their selectivity and sensitivity. 
The simplicity of UV-spectrophotometry is best known and most widely 
accepted for qualitative and quantitative analysis and in structure identification. UV-
spectrophotometry, a non-destructive technique usually does not require elaborate 
sample preparation step prior to assay. Therefore, the sample can be recovered for 
further testing or subsequent analytical procedures. However, these methods are 
inadequate when two or more drugs showing similar UV spectra in the presence of 
other components present in the drug sample like excipients or decomposition 
products. The use of UV-spectrophotometry for drug analysis, especially in 
pharmaceutical prepartions has been increased rapidly in the last few years [64-67]. 
Photometric methods of analysis are performed in the visible region of light. 
These methods are usually based on the following aspects: 
• complex-formation reaction 
• oxidation-reduction process 
• a catalytic effect 
In each type of reaction the absorbance of coloured compounds is measured. Usually 
the analyte imder investigation being colourless, they are reacted with suitable 
chemical reagents in order to convert them in coloured compounds. Simple 
colorimetric and UV methods continue to be popular for carrying out single-
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component assays on a variety of formulated products. Representative examples of 
UV-visible methods of drug analysis for some pharmaceuticals that have been 
published [68-99] are given in Table 1.1. 
In the course of this discussion, the importance of computer-aided 
spectrophotometric determination of multicomponent systems cannot by ignored. 
Pharmaceutical preparations are usually mixtures of the active principle and various 
excipients that absorb in the same region as the component of interest, thereby 
resulting in band overlap and impending the use of the technique with simple 
calibration methods. The inception of microcomputers and spectrophotometers that 
allow absorbance spectra to be expeditiously recorded at many wavelengths has 
enable the development of analytical methods based on the mathematical resolution 
of multivariate signals for the rapid quantitation of mixtures of analytes in control 
analyses. The application of multivariate calibration methods to spectral data in the 
biomedical and pharmaceutical fields has acquired a routine nature [100-104]. 
Partial least square (PLS) has become the de facto standard for multivariate 
calibration because of the quality of the obtained calibration models, the ease of its 
implementation and the availability of software [105]. It shows the advantage of 
using full spectra, which is critical for the spectroscopic resolution of complex 
mixtures of analytes. It allows for a rapid determination of components, usually with 
no need of a prior separation. An additional advantage of robust multivariate 
methods, PLS, is that calibration can be performed by ignoring the concentration of 
all other components except the analyte of interest. This makes these methods 
especially appealing for the determination of the active components in ophthalmic 
and nasal solutions as well as in the syrups, whose expcipients may show absorption 
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Table 1.1 
Assays of drugs in pharmaceutical formulations by 
spectrophotometric procedures 
Name of drug Reagents used ^ m i ax (nm) 
UV-visible 
References 
Acetoaminophen 
Amiodarone HCl 
Amlodipine besylate 
Amoxycillin & 
ampiciliin 
Ampicillin, amoxycillin 
& carbeniciilin 
Ascorbic acid 
Benidipine HCl 
Diclofenac sodium 
Diltiazem HCl 
Famotidine 
Flunarizine 
dihydrochloride 
Levodopa 
Menadione 
Methyldopa 
2-methyl-l, 4-naptho-
m-cresol 
p-chioranilic acid 
2,3-dichloro 5,6- dicyano 
1,4-benzoqui none 
p-chloranilic acid 
Ninhydrin in DMF medium 
2,3-dichloro 5,6- dicyano 
1,4- benzoquinone 
Ascorbic acid 
KIO3 
Folin ciocalteau phenol 
l-chloro-2,4-dinitrobenzene 
Methanol 
Tris buffer 
Sodium metavanadate 
Bromothymol blue 
Bromophenol blue 
Bromocresol green 
KMn04 in alkaline medium 
Ninhydrin 
Iodine 
Ce(IV) nitrate in H2SO4 
medium 
NaOH 
NaOH in the presence of 
amine 
Ce(IV) nitrate in H2SO4 
medium 
Ethyl aceto acetate & 
640 
535 
575 
540 
595 
580 
530 
520 
750, 770 
&750 
380 
238 
284, 305 
750 
415 
415 
415 
610 
590 
295, 355 
510 
300 
450 
550 
550 
68 
69 
69 
70 
71 
72 
72 
73 
74 
75 
76 
77 
78 
79 
79 
79 
80 
81 
82 
83 
84 
85 
83 
86 
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quinone 
Mometasone fiiroate 
Nalidixic acid 
Nicorandil 
Nifedipine 
Norfloxacin 
Ofloxacin 
Silymarin 
Trimethoprim 
Thyroxine 
Verapamil HCI 
ethanolic ammonia 
Methanol 
Persulfate in alkaline 
medium 
Brucine-sulfanilic acid in 
H2SO4 medium 
3-methyl-2-benzothiazoline 
hydrazone HCl-metol 
KMn04 in neutral medium 
4-methyl amino phenol and 
KjCrjO, 
Bromocresol green 
Bromophenol blue 
Bromothymol blue 
Eriochrome Black T 
KMn04 in alkaline medium 
Cerium 
KMn04 in neutral medium 
Persulfate in alkaline 
medium 
Nitrous acid 
Chloramine T 
N-Bromosuccinimide 
248 
320,390 
410 
560 
530 
525 
415 
415 
415 
520 
603 
243 
530 
355 
420 
425 
415 
87 
88 
89 
89 
90 
91 
92 
92 
92 
92 
93 
94 
95 
96 
97 
98 
99 
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spectra that are severely overlapped with those from the analytes. The 
complementary use of PLS multivariate calibration and artificial neural networks 
(ANNs) for the simultaneous spectrophotometric determination of three active 
components such as chlorpheniramine, nephazoline and dexamethasone in a 
pharmaceutical formulation has been successfully explored [106]. 
Difference spectrophotometry is an important and useful technique used in the 
determination of medicinal substances by eliminating specific interference from the 
degradation products, co-formulated drugs and non-specific irrelevant absorption 
from the formulation matrix. The technique involves reproducible attraction of the 
spectral properties of the absorbance difference between two solutions, provided that 
the absorbance of the other absorbing substance is not affected by the reagent(s) 
used to alter the spectral property [107]. 
Derivative spectrophotmetry is an analytical technique of great utility for both 
qualitative and quantitative information from spectra composed of uraesolved bands. 
Although it was introduced more than thirty years ago [108-110] and has advantages 
for the solution of specific analytical problems. The derivative method has found 
applications not only in the UV-visible spectrometry but also in infrared [111], 
atomic absorption [112], flame emission spectrometry [113] and fluorimetry 
[114,115]. The use of derivative spectrophotometry is not restricted to special cases, 
but may be of advantage whenever quantitative study of normal spectra is difficult. 
Its disadvantage is that the differentiation degrades the signal-to-noise ratio, so that 
some form of smoothing is required in conjunction with the differentiation [116]. 
As an analytical tool for the pharmaceutical analytical laboratory, near-
infrared spectroscopic methods have the potential to dramatically improve the 
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quality of the drug manufacturing process from assessing incoming raw materials to 
the final drug product. There are several advantages associated wdth this technique 
such as reduction in the cost of testing, require no reagents, associated reagent 
preparation steps, sample preparation steps and generally require only one working 
analyst day to complete testing. The instrumentation used is eminently suited to 
being used in production facilitates and on-line measurements are routinely used in 
various industries [117,118]. When introducing NIR analysis into a regulated 
industry, such as pharmaceutical industry, special attention must be paid to 
satisfying the regulatory requirements for analytical procedures. The US 
pharmacopoeia has proposed guidelines [119,120] for this technique. 
Fluorimetry and phosphorimetry find wide applications in quantitative studies 
of rates of degradation, metabolism, and excretion of drugs where other analytical 
techniques are not sufficiently sensitive. A gradual increase in the number of papers 
on the potential applications of fluoimetry and phosphorimetry in the field of 
pharmaceutical analysis has been noticed during the last few years [121-124]. 
The analytical measurement of elemental concentrations is important for the 
analysis of the major and minor constituents of pharmaceutical products. Metals are 
the major constituents of several pharmaceuticals such as dialysis solutions, lithium 
carbonate tablets, antacids and multi-vitamin and mineral tablets. The metal ions in 
pharmaceuticals are determined more accurately and conveniently by atomic 
absorption spectrometry. The use of atomic absorption spectrometry in this regard 
has been the subject of several reviews and papers [125-130]. 
Nuclear Magnetic Resonance (NMR) spectroscopy has been mainly used for 
the elucidation and confirmation of structures. For the last decade, NMR methods 
have been introduced to quantitative analysis in order to determine the impurity 
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profile of a drug, to characterize the composition of drug products in body fluids, in 
solid state measurements to provide the information about polymorphism of drug 
powders, quantification of drugs in tablets [131-137] and for micro-imaging to study 
the dissolution of tablets [138-140]. 
One of the significant analytical developments in the last two decades has 
been the wide spread utilization of Flow Injection Analysis (FIA) assay of drugs in 
pharmaceutical laboratories. It has several advantages: 
• reduced reagent consumption, 
• high sampling frequency 
• safety in applying toxic reagents because the whole analysis proceeds in a closed 
system. 
An additional advantage observed in flow injection analysis is increased selectivity 
when the analyte is accompanied by more slowly reacting compound. This 
technique has been utilized successfiilly in the determination of some compoimds of 
pharmaceutical interest [141-146]. 
Whenever the question of mathematical and statistical treatment arises, the 
role of chemometrics cannot be ignored. Chemometrics is the chemical discipline 
concerned with the application of mathematical, statistical methods as well as those 
other methods based on mathematical logic, to chemistry, in order to design or select 
optimal procedures and experiments, and provide maximum chemical information 
by analyzing chemical data [147,148]. Several reviews have been reported on 
applications of chemometric methods in biomedical and pharmaceutical analysis 
[149-153]. 
17 
The principles and applications of the kinetic methods have been reviewed 
[154,155,156]. Essentially, kinetic methods rely on the measurements of 
concentration changes (detected via signal changes) in a reactant (which may be the 
analyte itself) with time after the sample and reagents have been mixed. The sample 
and reagent can be mixed manually or automatically. Only slow enough reaction 
tolerate manual mixing and even so, they are better handled automatically, not only 
to obtain more rapid and reproducible results, but also to increase the reaction rate in 
some cases. There are several approaches that can be used for the determination of 
single components in the absence of any kinetic interference (Table 1.2). However 
fixed-time and initial rate methods have been used more fi:equently for the 
determination of drugs in pharmaceutical formulations and biological fluids [157-
160]. Kinetic automatic techniques are generally based on open systems among the 
most popular of which are stopped flow (SF) system [161] and the continuous 
addition of reagent (CAR) technique [162-164]. Several drugs have been determined 
by using the CAR technique with photometric [165,166] and fluorimetric detection 
[167]. On the other hand, the CAR technique has been extended to 
chemiluminescence (CL) reaction as CAR chemiluminescence spectrometry 
(CAROL), a new approach that have proved outstanding for the analysis of drugs 
and other substances of analytical interest. The use of catalysts to accelerate 
analytical reactions is feasible with both reaction rate and equilibrium 
determinations. In this concern, the use of micellar media in kinetic method is 
recently encouraged to enhance the rate of reaction (through micellar catalysis) and 
may additionally improves the sensitivity and selectivity which in turn reduce the 
analysis time for the analyte [168-170]. Multicomponent kinetic determinations, 
often called as differential rate methods, are also receiving popularity in the field of 
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Table 1.2 
Single-component methods without error compensation 
A. Direct-computation methods B. Curve-fitting methods 
1. Integral methods 
a. Fixed-time 
i. One-point 
ii. Two-point 
iii. Multipoint 
b. Variable-time 
i. One-point 
ii. Two-point 
2. Rate methods 
a. hiitial-rate 
b. Intermediate-rate 
3. Integrated-signal methods 
1. Integral methods 
a. Linear responses 
b. Non-linear response 
i. Direct computation 
ii. Predictive (extrapolation) 
2. Rate methods 
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pharmaceutical research [171,172]. Two new approaches i.e. kinetic wavelength pair 
method [173] and H-point standard addition method [174] have been proposed for 
dealing with overlapping spectra of components in the binary mixtures. 
METHOD VALIDATION 
The ability to provide timely, accurate, and reliable data is central to the role 
of analytical chemists and is especially true in discovery, development and 
manufacture of pharmaceuticals. Analytical data are used to screen potential drug 
candidates, aid in the development of drug synthesis, support formulation studies, 
monitor the stability of bulk pharmaceuticals and formulated products, and test final 
products for release. The quality of analytical data is a key factor in the success of a 
drug development program. The process of method development and validation has 
a direct impact on the quality of these data. 
The initial step in the analytical method development procedure is to establish 
what is to measure and how accurately it should be measured. Quite often method 
validation evolves from method development and so the two activities are often 
closely tied, with the validation. The process for the development, validation and use 
of an analytical method is shovm in Fig. 1.1. 
Once an analytical method is advent. It is important to validate the 
method before it should be recommended for the routine analysis. Method validation 
of analytical procedure, i.e. the process of defining an analytical requirement and 
confirms that the method under consideration has performance capabilities 
consistent with what the application requires in determining the reliability and 
reproducibility of the method with respect to regulatory requirement in order to get 
the reliable data by incorporating statistical analysis to evaluate its performance. 
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Calibration model, 
range and linearity 
Define performance 
specifications 
Devise development 
experiments 
i 
Execute and 
evaluate results 
Plan method validation 
experiments 
Precision and accuracy 
I 
Collate results 
Write validation report 
Apply validated 
method 
Fig. 1.1: The process of development, validation and routine 
use of an analytical method 
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Several International Organization and Regulatory Authorities, which are 
involved in fixing the criteria for the validations are listed in Table 13. In the field 
of analysis, it is very clear that the definitions cover the entire field of analytical 
chemistry fi-om bioanalysis to substance and product analysis 
It has been agreed that the key for evaluation of method reliability and overall 
performances are: 
• confirmation of identity 
• analyte stability 
• selectivity/ specificity 
• precision and accuracy 
• limit ofdetection and quantitation 
• recovery 
• robustness/ruggedness 
The overall validation strategy consists of four components, which are 
prevalidation, validation proper, study proper and statistical analysis. 
The strategy is most effective if statistical design is used in all stages of 
development and not only for screening or optimizing the process. 
Prevalidation 
During method optimization some performance parameters should be 
investigated in order to avoid serious problems during the validation step. The 
performance parameters to evaluate, before actually beginning the validation process 
are accuracy, precision and robustness, and evaluation of these parameters can be 
called prevalidation [175]. In contrary to, validation is defined as a process of 
demonstrating that analytical procedure is suitable for its intended purpose 
[176,177], prevalidation is defined as the formal evidence that an analytical system 
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Table 1.3 
Validation of analytical methods International definitions 
Organization Applicability Remarks 
lUPAC 
ILAC 
WELAC 
ICH 
ISO 
Worldwide 
Worldwide 
Europe 
Europe, Japan, USA 
Worldwide 
Only pharmaceutical products 
Lack definition of selectivity and specificity 
Abbreviations: 
lUPAC, International Union of Pure and Applied Chemistry 
ILAC, International Laboratory Accreditation Conference 
WELAC, Western European Laboratory Accreditation Co-operation 
ICH, International Conference on Harmonisation 
ISO, International Organization for Standardization 
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does what it is supposed to do so. This definition has some implications by analogy 
with Tranter [178], as it presupposes that there is a description of what the analytical 
system should do. 
The aim of prevalidation is to obtain knowledge about analytical procedure 
and validation characteristics. This process serves to test validation parameters with 
the purpose of proving suitability of analytical procedure. The basis for useful 
prevalidation procedure is to obtain the most appropriate calibration function (often 
linear calibration function) covering at least a working range of one power of ten. 
The efficiency of prevalidation procedure is given by characteristic data such as 
constants of calibration and as analytical evaluation function, standard deviation of 
procedure, limit of quantitation, metrological characteristics of analytical procedure 
and other. It should be emphasized that for prevalidation process, the complete 
analytical procedure is very important, i.e. procedure that is defined by specifying all 
conditions under which the measurements must be made [179-181]. 
Moreover, even though the prevalidation concept is originally developed for 
pharmaceutical applications, it can reasonably be applied to many analytical 
procedures in different fields with similar specifications (toxicology, environmental, 
food chemistry etc.). 
Validation Proper 
Among all of the International Organization, the ICH guidelines achieved a 
great deal in harmonising the definitions of the required validation characteristic and 
their basic requirements. 
The International Conference on Harmonisation of the Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH) has 
harmonized the requirements in two guidelines [176, 177]. The first one summarizes 
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and defines the validation characteristics needed for various types of test procedure. 
The second one extends the previous test to include the experimental data required 
and some statistical interpretation. These guidelines serve as a basis worldwide both 
for regulatory authorities and industry and bring the importance of a proper 
validation to the attention of all those involved in the process submission. In order to 
fulfill the validation responsibilities properly, the background of the validation 
parameters and their consequences must be understood. Normally, evaluated 
validation characteristic and their minimum number of determinations required if 
applicable are given in Table 1.4 [177]. 
Stability-Indicating Assay (SIAM) 
With the advent of ICH [182-1S5], US-FDA [186,187], WHO, European 
committee for Directorates [188-190] guidelines, the requirement of establishment 
of stability indicating assay (SIAM) become more clearly mandated. These 
guidelines explicitly require conduct of forced decomposition studies under a variety 
explicitly require conduct of forced decomposition studies under a variety of 
conditions like pH, light, oxidation, dry heat, etc. and separation of drug from 
degradation products. In definition "A stability-indicating assay (SIAM) is a 
validated quantitative analytical procedure that can detect the changes with time in 
the pertinent properties of the drug substance and drug product." A stability-
indicating assay (SIAM) accurately measures the active ingredients, without 
interferences from degradation products, process impurities, excipients, or other 
potential impurities. Overall there are two stages in the validation of SIAM. First 
stage is early in the development cycle when drug substance is subjected to forced 
decomposition studies and the SIAM is established based on the knowledge of drug 
degradation behaviour. The main focus of validation at this stage is on establishment 
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Table 1.4 
Validation characteristics normally evaluated for the different types of test procedure 
[176] and the minimum number of determinations required (if applicable) [177]. 
Validation 
characteristics 
Specificity'' 
Linearity 
Range 
Accuracy 
Precision 
Repeatability 
Intermediate 
Precision/ rep-
roducibility' 
Detection limit 
Quantitation 
limit 
Minimum 
number 
. 
5 concentrations 
-
9 determinations 
over 3 concen-
tration levels 
(e.g.3X 3) 
6 determinations 
at 100% or 
9 determinations 
over 3 concen-
tration levels 
(e.g. 3 X 3) 
2-series 
-
-
Test procedure 
Identity 
Yes 
No 
No 
No 
No 
No 
No 
No 
Impurities 
Quantitative 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No"* 
Yes 
Limit 
Yes 
No 
No 
No 
No 
No 
Yes 
No 
Assay" 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
"Including dissolution, content potency 
""Lack of specificity of one analytical procedure could be compensated by other 
supporting analytical procedure (s). 
'^Intermediate precision sufficient for submission. 
"^ May be needed in some cases. 
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of specificity/selectivity, followed by other parameters like accuracy, precision, 
linearity, range, robustness etc. This validated method finds application in the 
analysis of stability samples of bulk drug for determination of its retest or expiry 
period. In the second stage, when the SIAM so developed is extended to 
formulations or other matrics. The emphasis gets limited to just prove the pertinence 
in the presence of excipients or other formulation constituents. Here only parameters 
of critical importance like specificity, selectivity, accuracy and precision are 
revalidated. 
There are several other reports in literature on the development of stability 
indicating assays of specific drugs [191-196]. If one critically evaluates the literature 
reports, derivatives spectroscopy [197-200] and chromatographic techniques [201-
205] have been commonly employed for this purpose. 
Confirmation of identity 
In general analytical methods consist of a measurement stage, which may be 
preceded by an isolation stage. It is necessary to establish that the signal or reaction 
produced at measurement stage is only due to the analyte and not due to something 
chemically or physically similar or arising as a coincidence. This is the confirmation 
of identity. Whether or not other compounds interfere with the measurement of the 
analyte will depend on the effectiveness of the isolation stage if it was part of the 
method, as well as the specificity/selectivity of the measurement stage. 
Selectivity/ Specificity 
There has been some controversy regarding the technical term for this 
validation characteristic i.e. specificity vs selectivity [206]. The terms selectivity and 
specificity are often used interchangeably. A detailed discussion of this term as 
defined by different organizations has been made by Vessamarm [207]. 
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The term specific generally refers to a method that produces a response for a 
single analyte only while the term selective refers to a method, which provides 
responses for a number of chemical entities that may or may not be distinguished 
from each other. If the response is distinguished from all other responses the method 
is said to be selective. Since there are very few methods that respond to only one 
analyte, the term selectivity is usually more appropriate. 
In addition, where it is unclear whether or not the interferences are already 
present, the selectivity of the method can be investigated by studying its ability to 
measure compared to other independent method/ techniques. These parameters 
apply to both qualitative and quantitative analysis. 
Accuracy and Precision 
Accuracy expresses the closeness of a result to a true value. Method validation 
seeks to quantify the likely accuracy of the results by assessing systematic and 
random effects on results. Accuracy is therefore, normally studied as two 
components: 'trueness' and 'precision'. The trueness (of a method) is an expression 
of how close the mean of a set of results (produced by the method) is to the true 
value. Trueness is normally expressed quantitatively in terms of "bias" which 
provides a measure of systematic or determinate error of an analytical method. 
Precision is a measure of how close results are to one another, and is usually 
expressed by measures such as standard deviation which describe the spread of 
results, relative standard deviation, coefficient of variation, and variance. 
Generally, the precision of an analytical method is readily obtained by simply 
repeating the measurements. The two most common precision are: 
• repeatability (Intra day assay) 
• reproducibility (Inter day assay) 
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They represent two extreme measure of precision, which can be obtained. 
Repeatability, also termed 'Intra day assay' precision (the smallest expected 
precision) will give an idea of the sort of variability to be expected when a method is 
performed by a single analyst on one piece of equipment over a Short time scale by 
applying the whole analytical procedure to the sample i.e. the sort of variability to be 
expected between the results when a sample is analysed in duplicate. If a sample is 
to be analysed by a number of laboratories for comparative purposes then a more 
meaningful precision measure is reproducibility (this is the largest measure of 
precision normally encountered). Sometime also termed as 'Inter day assay'. Both 
repeatability and reproducibility are generally dependent on analyte concentration, 
and should be determined at different concentration levels and if relevant, the 
relationship between precision and analyte concentration should hp established. 
Repeatability and intermediate precision can be calculated by an analysis of 
variances [208, 209]. No acceptance limit for accuracy and precision for an assay 
method is reported in the main regulatory guidelines [210, 177^  211], and only a 
document of the European community commission deals with the performance of 
analytical methods and the interpratation of results [212]. Several approaches 
discussed in the ICH guideline are given in Table 1.5. 
Linearity and calibration curve 
The linearity of an analytical method is its ability to elicit test results that are 
directly, or by means of well-defined mathematical transformation, proportional to 
the concentration of analytes in samples within a given range, is widely used in 
pharmaceutical analysis [213]. 
Acceptability of linearity data is often judged by examining the correlation 
coefficient and y-intercept of the linear regression line for the response versus 
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Table 1.5 
Quantitative approaches to demonstrate accuracy according to ICH [177] 
Drug substance 
Drag Product 
Impurities 
(quantitative) 
Application of the analytical procedure to a reference material. 
Comparison of the results with those of a second, well 
characteristic procedure. 
Application of the analytical procedure to synthetic mixtures of 
drug product components. 
Spiking of analyt to drug product. 
Comparison of the results with those of a second, well characterized 
procedure. 
Spiking of the impurity to drug substances or product. 
Comparison of the results with those of a second, well characterized 
procedure. 
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concentration plot. A correlation coefficient of >0.999 is generally considered as 
evidence of acceptable fit of data to the regression line. The y-intercept should be 
less than a few percent of the response obtained for the analyte at the target level. 
The requirements and relevant parameter for the various calibrations are given in 
Table 1.6. 
Limit of detection, Limit of quantiflcation and Sensitivity 
The limit of detection (LOD) of a technique can be conceived of as the 
smallest concentration, or amount of analyte that can be established as being 
different, at a reasonable statistical confidence level, from a blank (a material similar 
is composition to the sample except that the analyte is absent) [214-216]. One 
common defintion of LOD is the concentration (or quantity) of analyte that produces 
a signal that exceeds the signal observed from a blank by an amount equal to three 
times the standard deviation for the measurement on the blank [216, 217]. 
At analyte concentrations at or near the LOD, the precision of the measured 
data is usually poor. Thus, it is inadvisable to attempt to quantify the analyte unless 
its concentration is well above the LOD. 
A limit of quantification (LOQ), defined as the analyte concentration for 
which the signal exceeds that for a realistic analytical blank by 10 times the standard 
deviation, is often specified as the smallest analyte concentration that one should 
attempt to quantify [216]. Several approaches have been given in the ICH guideline 
to determine the detection and quantitation limit (Table L7.). 
Methods that can detect small concentration of analytes often are called 
"sensitive" methods and the maimer in which a change in analyte concentration 
produces a change in the resulting signal is known as sensitivity [218]. It is therefore 
possible for a method to be very sensitive but to exhibit relatively poor limits of 
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Table 1.6 
Requirements for different calibration modes with relevant parameters 
Quantitation Requirements Relevant parameters 
Single-point calibration 
External standard 
Multiple-point 
calibration 
Linear, unweighted 
Linear, weighted 
Linear function 
Non-significant 
ordinate intercept 
Homogenity of 
variances 
Linear function 
Homogenity of 
variances 
Linear function 
Standard error of slope (residual 
standard deviation), sensitivities 
(relative standard deviation, 
graph), residual analysis, 
statistical tests (vs. quadratic 
regression). 
Inclusion of zero in confidence 
interval of the ordinate intercept, 
magnitude of the intercept (as 
percent of the signal 100% test 
concentration). 
F-test of the variances at the 
at the lower and upper limit of the 
range. 
Standard error of slope (residual 
standard deviation), sensitivities 
(relative standard deviation, 
graph), residual analysis, 
statistical tests (vs. quadratic 
regression). 
F-test of the variances at the 
at the lower and upper limit of the 
range. 
Standard error of slope (residual 
standard deviation), sensitivities 
(relative standard deviation, 
graph), residual analysis, 
statistical tests (vs. quadratic 
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Non-linear 
100%-method (area 
normalization for 
impurities): 
Continuous function 
For main peak: linear 
function 
Non-significant 
ordinate intercept 
Homogenity of 
variances' 
For impurities: linear 
function 
regression). 
Appropriate equation 
Standard error of slope (residual 
standard deviation), sensitivities 
(relative standard deviation, 
graph), residual analysis, 
statistical tests (vs. quadratic 
regression). 
Inclusion of zero in confidence 
interval of the ordinate intercept, 
magnitude of the intercept (as 
percent of the signal 100% test 
concentration). 
F-test of the variances at the 
at the lower and upper limit of the 
range. 
Standard error of slope (residual 
standard deviation), sensitivities 
(relative standard deviation, 
graph), residual analysis, 
statistical tests (vs. quadratic 
regression). 
May be presumed for a limited range (factor 10-20). 
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Table 1.7 
Approaches for determining the detection and quantitation limit [177] ' 
Approach Detection limit Quantitation limit 
Visual evaluation 
Signal-to-noise 
Standard deviation of 
the response (So)'' and the 
slope (b) 
Minimum level detectable 
3:1 or 2:1 
3.3xSo/b 
Minimum level quantifiable 
10: 1 
10.0 X So/b 
" verification with a suitable number of samples. 
'' Standard deviation of the blank, residual standard deviation of the calibration line, 
or standard deviation of the intercept. 
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detection. On the other hand, an insensitive method is very unHkely to exhibit a low 
LOD. Thus, sensitivity is a necessary but not sufficient condition for the 
achievement of low LOD. 
Range and dynamic range 
The range of analytical method is the concentration interval over which 
acceptable accuracy, linearity, and precision are obtained. In practice, the range is 
determined using data from the linearity and accuracy studies. 
Fig. 1.2 illustrates the definition of the dynamic range of an analytical 
method, which extends from the lowest concentration at which quantitative 
measurements can be made (limit of quantitation, or LOQ) to the concentration at 
which the calibration curve departs from linearity (limit of linearity, or LOL). To be 
very usefiil, an analytical method should have a dynamic range of at least two orders 
of magnitude. Some methods have applicable concentration range of five to six 
orders of magnitude. 
Robustness/ ruggedness 
Robustness testing is now a days best known and most widely applied in the 
pharmaceutical world because of the strict regulations in that domain set by 
regulatory authorities which require extensively validated methods. International 
conference on Harmonisation of technical requirements for Human use (ICH) [219] 
defines "the robustness/ruggedness of an analytical procedure as a measure of its 
capacity to remain unaffected by small, but deliberate variations in method 
parameters and provides an indication of its reliability diuing normal usage [220]. 
The term ruggedness is frequently used as a synonym [221-224]. The ICH 
guidelines [220] also recommend that "one consequence of the evaluation of 
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Fig. 1.2: Useful range of an analytical method: LOQ = Limit of 
quantitative measurement and LOL = Limit of linear response. 
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robustness should be that a series of system suitability parameters (e.g. resolution 
test) is established to ensure that the validity of the analytical procedure is 
maintained whenever used". Several definitions for robustness or ruggedness exist 
which are, however, all closely related [225-228]. 
The Dutch pharmacists guideline [225], the ICH guidelines [229] as well as 
some authors working in bio-analysis [230] consider robustness a method validation 
topic performed during the development and optimization phase of a method, while 
others [231] consider it as belonging to the development of the analytical procedure. 
Therefore, the robustness test can be viewed as a part of method validation 
that is performed at the end of the method development or at the beginning of the 
validation procedure. 
STUDY PROPER AND STATISTICAL ANALYSIS 
Daily standard curves are generated to determine the sample concentrations. 
All calibrators and quality control samples are analyzed in duplicate. Sample 
concentrations are based on single determination. The quality control sample 
sequence is carefully monitored for systematic errors. For each standard curve, the 
slope, intercept, variance, correlation coefficient and the interpolated calibrated 
concentrations are reported. 
Acceptance of the assay results are determined by monitoring the quality 
control results. If the interpolated concentrations are within the control charts 
confidence limits, established during the method validation, the data are considered 
valid. Upon completing a study proper and accepting the analytical runs, the quality 
control results are incorporated into their respective data basis to update their 
confidence limits. 
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Correlation and regression 
When using instrumental methods it is often necessary to carry out a 
caUbration procedure by using a series of samples (standards) each having a known 
concentration of the analyte. Two statistical procedures should be applied to a 
calibration curve: 
• test whether the graph is linear or in the form of a curve. 
• find the best straight line (or curve) through the data points. 
Linearity is often tested by the correlation coefficient, 'r', which can be calculated 
for a calibration curve to ascertain the degree of correlation between the measured 
instrumental variables and the sample concentration. 
r = 
^l(Ixf-nx\i:yf-n/) 
where 
X = Mean of all the values of x, 
y = Mean of all the values of y^ 
n = Number of data points 
The maximum value of r is 1. When this occurs there is exact correlation 
between the two variables (x and y). When the value of r is zero (xy = 0), there is 
complete independence of the variables. The minimum value of r is -1, indicates that 
the assumed dependence is opposite to what exists. As a general rule, 0.90 < r < 0.95 
indicates a fair curve, 0.95 < r < 0.99 as a good curve, and r > 0.99 includes 
excellent linearity. 
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Linear least squares 
Once a linear relationship has been shown to a high probability by the value of 
the correlation coefficient, r, then the best straight line through the data points has to 
be evaluated by linear regression (the method of least square). The equation of the 
straight line is A= a + b C where A is usually the measured variable that is 
absorbance, plotted as a function of changing C that is the concentrations of the 
standards in a spectrophotometric calibration. To obtain the regression line A on C, 
the slope b of the line and the intercept 'a' on the Y-axis are given by following 
equations. 
Zx/-[(Zx,)V«] 
a = y-bx 
Errors in the slope and the intercept 
where y values are obtained from calculated regression line for given values of x; 
once the value So has been obtained, both the standard deviations of the slope Sb and 
the intercept Sa can be obtained from the following equations 
S, = S^yjlx,'/nlix,-xf 
Error in the estimation of concentration 
l . i . .<^-^' ' 
n b^lix-xY 
1/2 
where xand y are the average concentration and absorbance values, respectively for 
n standard solutions. 
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Confidence limit 
The confidence limit defined by the experiment means ' x ' of 'n' repUcate 
measurements and the standard deviation (s) within the range where the true value 
falls is given by 
— ts C.L. for ^ = x± —j= 
V« 
where 
\i = true mean 
t = statistical factor that depends on the number of degrees of freedom and 
the confidence level desired. 
Significance of testing 
An important property of an analytical method is that it should be free from 
the systematic error (bias). Determining bias involve analyzing one or more standard 
reference materials whose analyte concentration is known. However, random errors 
make it unlikely that the measured amount will equal the known amount even when 
no systematic errors are present. In order to decide whether the difference between 
the observed and standard values can be accounted for by random variation, a 
statistical test known as a significance test is used in the interpretation of analytical 
data. 
• Student t-test (Null hypothesis) 
Here comparison is made between two sets of replicate measurements made 
by two different methods, one is the test method while other is accepted (reference 
method). 
s 
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A statistical't' value is calculated and compared with a tabulated value for the 
given number of tests at the desired confidence level. If tcai> ttab then these is a 
significant difference between the results obtained by the two methods at the given 
confidence level. But if, tcai < ttab then these is no significant difference between the 
methods. 
• Paired t-test 
+ / ^'"^^ 
Sp \n,+n^ 
where 
X| = Mean fi-om the test method 
X2 = Mean from the accepted (reference) method 
ni and n2 = Number of measurements. 
Sp = Pooled standard deviation of the individual measurements of two sets is 
given by 
S \{n,-\)S^+(n,-l)S, 
• F-test 
For comparing the variance that is the square of the standard deviation of the 
two methods. If Si and S2 are the standard deviations, then 
S] 
where 
If Fcai> Ftab at the selected confidence level, then there is a significant 
difference between the variances of the two methods. 
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• Interval hypothesis 
In statistical terms, the hypothesis can be tested as 
where 0L and 0u represent the lower and the upper acceptance limits respectively, 
when |i2 is expressed as a portion of the reference method JAJ. The lower limit 0L and 
the upper limit 0u of the confidence interval are obtained as: 
« . = 
' • 
-b- -^/ft^-
2a 
-b + W-
-Aac 
-4ac 
where 
-2 S/t,J 
a = xi — 
b = -2x\ X2 
-2 S\,J 
C = X2 
«2 
• Testing for outliers 
Frequently, when a series of replicate measurements of same quantity are 
made, one of the results will appear too different markedly from the other. There is 
then a great temjptation to discard this "outlier" before calculating the mean and the 
standard deviation of the data or applying statistical tests to compare the data with 
other measurements. The best known method used for this purpose is Dixon's Q 
test. 
^ _ I Suspected value - Nearest value | 
(Largest value - smallest value) 
If Qcai> Qtab at a given confidence level, then the outlier can be rejected. 
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CLASSIFICATION OF DRUGS 
All the drugs according to their chemical nature can be divided into organic 
and inorganic compounds. They can be prepared synthetically (from chemicals) or 
can be directly obtained or reconstituted from natural sources product. All the drugs 
having medicinal importance can be broadly divided into two classes. 
Chemical classification 
The drugs are classified according to their chemical structure and properties 
without taking the pharmacological action under consideration. In this class most of 
the drugs are having at least an organic substrate, the further classification is done in 
the relevant manner. 
Pharmacological classification 
In this class the drugs are divided according to their action on the organism's 
organ (viz. heart, brain, lymphatic system, respiratory system, endocrine system, 
central nervous system etc). Hence these drugs are named like antianginal, narcotics, 
analgesics, antibiotics, diuretics, anesthetics etc. Further classification of each group 
is done according to the therapeutic/ pharmacological specificity with the relevant 
organ. A detailed classification of drugs based on pharmacological action on human 
organs has been given in Scheme 1.1. 
The present thesis deals with the determination of the following drugs: 
NORFLOXACIN 
Norfloxacin, 1 -ethyl-6-fluoro-1,4-dihydro-4-oxo-7-( 1 -piperazinyl)-3-quinoline 
carboxylic acid is a synthetic broad spectrum antibacterial drug, which is very much 
active against many gram positive and gram negative bacteria. It is mainly used in 
the treatment of urinary tract infections. 
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Norfloxacin 
NICORANDIL 
Nicorandil, N-[2-(nitroxy) ethyl] 3-pyridine carboxamide, is a relatively new 
antianginal drug belongs to potassium channel activators. It is a potent vasodilator of 
the coronary and peripheral and vascular beds. The nitrate moiety in the chemical 
structure may in part contribute to the anti-ischaemic action. In human and animals, 
nicorandil is metabolized to several metabolites with inactive denitrated nicorandil 
as major matabolite. The main route of elimination from the plasma appears to be 
denitration of the drug by the liver to the pharmacologically inactive alcohol 
metabolite, denitrated nicorandil (N-(2-hydroxyethyI)-nicotinamide) followed by 
further side chain degradation to nicotinamide and related metabolites, including 
nicotinic acid and N-methyl-nicotinamide (Scheme 1.2). 
SILYMARIN 
Silymarin i.e. 3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxy phenyl)-2-
(hydroxy-methyl)-l,4-benzodioxan-6-yl]-4-chromanone is a free radical scavanger 
and an important antihepatotoxic drug. It has been used for the treatment of liver 
diseases of different etiology due to its hepatoprotective activity that is considered to 
involve antioxidation, inhibition of lipid peroxidation and the membrane stabilizing 
effects. 
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C-N-CH2-CH2-ONO2 
Nicorandil 
t 
H 
C-N-CH2-CH2-OH 
Denitrated nicorandil 
I 
C-N-CH2-C00H 
Nicotinuric acid 
C-NH2 
N Nicotinamide 
9 
C-NH2 
N-methyi nicotinamide 
N ^ 
-COOH 
Nicotinic acid 
Scheme 1 ^ Nicorandil and its metabolites 
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OH 0 
O. /CH2OH 
OCH-: 
Silymarin 
RAMIPRIL 
Ramipril is an angiotensin converting enzyme (ACE) inhibitor tiiat 
lowers peripheral vascular resistance without affecting heart rate. It is used in 
the treatment of hypertension and congestive heart failure. The role of this 
drug is to inhibit last step of the biosynthesis of angiotensin II, a potent 
vasoconstrictor, and therefore, it causes a general vasodilatation and lowers 
blood pressure. The drug is chemically known as 2-[N- [(S)-l-ethoxy 
carbony 1-3-phenyl propyI]-L-alanyl]-(lS, 3S, 5S)-2-azabicyclo [3,3,0]-
octane-3-carboxylic acid. 
C2H5O—C ^^? H 
H O 
Ramipril 
,j.t»-' 
47 
REFERENCES 
[I] T. De Quincey, in Confessions of an English Opium-Eater, p. 183, T.M. 
Dent and Sons Ltd., London (1972). 
[2] H.J. Barber, in Historical Aspects of Chemotherapy, May and Baker 
Ltd., Dagenham, UK (1978). 
[3] L.G. Mathews, History of Pharmacy in Britain, London, 1962, p. 67. 
[4] Roy Porter and Mikul's Teich: Drugs and Narcotics in History, Cambridge 
University Press, 1997, p. 171 
[5] J.C. Berridge; J. Pharm. Biomed. Anal. 14 (1995) 7. 
[6] K. Basavaiah, H.C. Prameela, Oxidation Communications 27 (2004) 177. 
[7] H.R.N. Marona, C.C.G.O. Lopes, S.G. Cardoso, Acta Farmaceutica 
Bonaerense 22 (2003) 339. 
[8] K. Basavaiah, V.S. Charan, Oxidation Communications 26 (2003) 351. 
[9] D. Oprescu, M. Stoia, V. Chiriac, Buletinul Stiintific al Universitatii 
"politehnica" din Timisoara Romania, Seria Chimie Si Mediului 45 (2000) 
25. 
[10] B. Janoszka, T. Wielkoszynski, K. Tyrpien, C. Dobosz, D. Bodzek, Acta 
Chromatographica 13 (2003) 95. 
[II] L. Zhang, F. Dang, Y. Baba, J. Pharm. Biomed. Anal. 30 (2003) 1645. 
[12] D.I. Papac, Z. Shahrokh, Pharm. Res. 18 (2001) 131. 
[13] L.I. Bebawy, A.A. Moustafa, N.F. Abo-Talib, J. Pharm. Biomed. Anal. 27 
(2002) 779. 
[14] L.I. Bebawy, A.A. Moustafa, H.H. Refaat, J. Pharm. Biomed. Anal. 25 (2001) 
425. 
48 
[15] B. Renger, J. AOAC Int. 81(1998) 333. 
[16] B. Renger, J. Planar Chromatogr. - Mod. TLC. 10 (1997) 420. 
[17] L. Zhou, C.F. Poole, J. Triska, A. Zlatkis, J. High Resol. Chromatograph. 
CC. 3 (1980) 440. 
[18] B. Liawruangrath, S. Liawruangrath, Chromatographia 54(2001)405. 
[19] S.A. Shah, I.S. Rathod B.N. Suhagia, S.S. Savale, J.B. Patel, J. AOAC Int. 84 
(2001)1715. 
[20] S. Stahlmann, J. Herkert, C. Roseler, I. Rager, K.V. Kovar, Eur. J. Pharm. 
Sci. 12(2001)461. 
[21] T. Mirza, H.S.I. Tan, J. Pharm. Biomed. Anal. 21 (2001) 39. 
[22] H.B. Li, F. Chen, Y. Jiang, J. Chromatgr. A 822 (2000) 243. 
[23] C.V. Garcia, A.R. Breier, M. Steppe, E.E.S. Schapoval, T.P. Oppe, J. Pharm. 
Biomed. Anal. 31 (2003)596. 
[24] M. Spangler, E. Mularz, Chromatographia 54 (2001)329. 
[25] W.F. Samanidou, E.A. Hapeshi, I.N. Papadoyannis, J. Chromatogr. B 788 
(2003) 147. 
[26] R. Gonzalez-Hernandez, L.Nuevas-Paz, L. Soto-Mulet, M. Lopez-Lopez, J. 
Hoogmartens, J. Liq. Chromatogr. Relat. Technol. 24 (2001) 2315. 
[27] C. Tasconas, M. Devissaguet, P. Padieu, J. Chromatogr 488 (1989) 249. 
[28] G. Guetens, G. De Boeck, M. Wood, R.A.A. Maes, A.A.M. Eggermont, M.S. 
Highley, A.T. Van Oosterom, E.A. de Bruijn, U.R. Tjaden, J. Chromatogr. A 
976 (2002) 229. 
[29] A. Kankaapaa, T. Gunnar, K. Ariniemi, P.Lillsimde, S. Mykkanen, T. 
Seppala; J. Chromatogr. B 810(2004)57. 
[30] M. -J. Rocheleau, M. Titley, J. Bolduc, J. Chromatogr. B 805 (2004) 77. 
49 
[31] A.J. Kueh, P.J. Marriott, P.M. Wynne, J.H. Vine, J. Chromatogr. A 1000 
(2003) 109. 
[32] C. Meadway, S. George, R. Braithwaite, Foren. Sci. Int. 127 (2002) 136. 
[33] A. Vailaya, T. Wang, Y. Chen, M. Huffman, J. Pharm. Biomed. Anal. 25 
(2001) 577. 
[34] J.R. Peterson, A.O. Okorodudu, A. Mohamed, D.A. Payne, Clin. Chim Acta 
330(2003)1. 
[35] A.M. Enlund, G. Hagman, R. Isaksson, D. Westerlund, Trends Anal. Chem. 
21 (2002)412. 
[36] I.S. Lurie, S. Panicker, P.A. Hays, A.D. Garcia, B.L. Geer, J. Chromatogr. 4 
(2003) 1099. 
[37] W. Maruszak, M. Trojanowicz, M. Margasinska, H. Engelhardt, J. 
Chromatogr. A 926 (2001) 327. 
[38] H. Matsunaga, T. Tanimoto, J. Haginaka, J. Sep. Sci. 25 (2002) 1175. 
[39] D. Dogrukol-AK, M. Tuncel, H.Y. Aboul-Enein, Chromatographia 54 (2001) 
527. 
[40] M.A. Raggi, G. Casamenti, R. Mandrioli, G. Izzo, E. Kenndler, J. Pharm. 
Biomed. Anal. 23 (2000) 973. 
[41] I. Velikinac, O. Cudina, Ivana Jankovi, Danica Agboda, Sote Viadimirov, IL 
Farmaco59(2004)419. 
[42] H. Fonge, E. Kaale, C. Govaerts, K. Desmet, A.V. Schepdael, Jus. 
Hoogmarten, J. Chromatogr. B 810 (2004) 313. 
[43] M.K. Srinivasu, D.S. Rao, G. O. Reddy, J. Pharm. Biomed. Anal. 28 (2002) 
493. 
50 
[44] G. Altiokka, Z. Atkosar, E. Sener, M. Tuncel, J. Pharm. Biomed. Anal. 25 
(2001)339. 
[45] M. Albin, P.D. Grossman, S.E. Moring, Anal. Chem. A 65 (1993) 489A. 
[46] R.I. Chien, D.S. Borgi, Anal. Chem. A 64 (1992) 489A. 
[47] L. Nozal, L. Arce, A. Rios, M. Valcarcel, Anal. Chim. Acta 523 (2004) 21. 
[48] A.B. Wey, J. Caslavska, W. Thormann, J. Chromatogr. A 895 (2000) 133. 
[49] J.P. Liu, S. Abid, M.S. Lee, Anal. Biochem. 229 (1995) 221. 
[50] G.S. Srivatsa, M. Bait, J. Schuette, R.H. Carlson, J. Fitchett, C. Lee, D.L. 
Cole, J. Chromatogr. A 601 (1994) 469. 
[51] A.M. Lasdun, R.R. Kurumbail, N.K. Leimgruber, A.S. Rathore, J. 
Chromatogr. A 917 (2001) 147. 
[52] X. Liu, Z. Sosic, LS. Krull, J. Chromatogr. A 735 (1996) 165. 
[53] Y. Mrestani, R.H.H. Neubert, J. Pharm. Biomed. Anal. 24 (2001) 637. 
[54] J.J. Matinez-Pla, Y. Martin-Biosca, S. Sagrendo, R.M. Villanueva-Camanas, 
M. J. Medina-Hernandez, Anal. Chim. Acta 507 (2004) 175. 
[55] British Pharmacopoeia, Her Majesty Stationary Office, London (1988) p. 
1353. 
[56] The United States Pharmacopoeia XXII. National Formulary XVII, The 
United States Pharmacopoeia Convention Inc Rockville, M.D. USA (1990) p. 
559. 
[57] The Indian Pharmacopoeia, The controller of Publications, Government of 
India, Delhi (1996) p. 634. 
[58] M.M. Correia dos Santos, V. Famila, M.L. Simoes Goncalves, Anal. Bioanal. 
Chem. 374 (2002) 1074. 
51 
[59] A.E.A. Salem, B.N. Barsoum, G. Blaschke, J. Pharm. Biomed. Anal. 27 
(2002) 153. 
[60] A.A. Al - Majed, F. Belal, A. Abadi, A.M. Al-Obaid, IL Farmaco 55 (2000) 
233. 
[61] Jose Angel prieto, R.M. Jimenez, R.M. Alonso, IL Farmaco 58 (2003) 343. 
[62] U. Tamer, M. P. Ozcicek, O. Atay, A. Yildiz, J. Pharm. Biomed. Anal. 29 
(2002)43. 
[63] F. Bilal, LA. Al-Zaggi, M.A. Abounassif, J. AOAC Int. 84 (2001)1. 
[64] M.S. Rizk, S.S. Toubar, M.A. Sultan, S.H. Assaad, Microchim. Acta 143 
(2003)281. 
[65] P.R. Topale, N.J. Gaikwad, M.R. Tajane, Indian Drugs 40 (2003) 119. 
[66] C.F. Ferreyra, C.S. Ortiz, J. Pharm. Biomed. Anal. 29 (2002) 811. 
[67] D.P. Ip, J.D. De Marco, M.A. Brooks, Anal. Profiles Drug Subst. Excipients. 
21 (1992)233. 
[68] S.Z. Qureshi, A. Saeed, N. Rahman, Chem. Anal. (Warsaw) 37 (1992) 227. 
[69] N. Rahman, N.A. Khan, S.N.H Azmi, Anal. Sci. 20 (2004) 1231. 
[70] N. Rahman, S.N.H. Azmi, Anal. Sci. 16 (2000) 1353 
[71] N. Rahman, S.N.H. Azmi, II Farmaco 56 (2001) 731. 
[72] N. Rahman, M.N. Hoda, J. Pharm. Biomed. Anal. 31 (2003) 381. 
[73] M.I.H. Helaleh, N. Rahman, R.M.A.Q. Jamhour, Chem. Anal. (Warsaw) 42 
(1997)261. 
[74] A.S. Ahmad, N. Rahman, F. Islam, J. Anal. Chem. 59 (2004) 119. 
[75] S.Z. Qureshi, A. Saeed, S. Haq, N. Rahman, Anal. Lett. 23 (1990) 995. 
[76] R.T. Sane, M. Phadke, P.S. Hijji, M. Shah, P. Patel, Indian Drugs 35 (1998) 
79. 
52 
[77] I. Kramancheva, I. Dobrev, L. Brakalov, A. Andreeva, Anal. Lett. 30 (1997) 
2235. 
[78] N. Rahman, S.N.H. Azmi, Microchem. J. 65 (2000) 39. 
[79] N. Rahman, S.N.H.Azmi, J. Pharm. Biomed. Anal. 24 (2000) 33. 
[80] N. Rahman, M. Kashif, Anal. Sci.l9 (2003) 907. 
[81] N. Rahman, M. Kashif, II Farmaco 58 (2003) 1045. 
[82] A.F.M. El Walily, A. El Gindy, A.A.M. Wahbi, J. Pharm. Biomed. Anal. 13 
(1995)115. 
[83] M.I.H. Helaleh, N. Rahman, E.S.M. Abu Nameh, Anal. Sci.l3 (1997) 1007. 
[84] M.I.H. Helaleh, N. Rahman, R.M.A.Q. Jamhour, E.S.M. Abu Nameh, J. 
Pharm. Biomed. Anal. 16 (1997) 269. 
[85] M.I.H. Helaleh, N. Rahman, R.M.A.Q. Jamhour, Armali di chimica (Rome) 
86(1996)509. 
[86] M.I.H. Helaleh, N. Rahman, Anal. Sci. 13 (1997) 489. 
[87] D. Pal, U.K. Mazumdar, M. Gupta, Indian J. Hosp. Pharmacy 39 (2002) 227. 
[88] M.I.H. Helaleh, S.Z. Qureshi, N. Rahman, R.M.A.Q. Jamhour, Acta Poloniae 
Pharmaceutica-DrugResearch 54 (1997) 111. 
[89] N. Rahman, N.A. Khan, S.N.H Azmi, II Farmaco 59 (2004) 519. 
[90] N. Rahman, S.N.H. Azmi, Acta Pharm. (Zagreb) 49 (1999) 113. 
[91] N. Rahman, M. N. Hoda, II Farmaco 57 (2002) 435. 
[92] N. Rahman, N.A. Khan, S.N.H. Azmi, II Farmaco 59 (2004) 47. 
[93] N. Rahman, Y. Ahmad, S.N.H. Azmi, Eur. J. Pharm. Biopharm. 57 (2004) 
359. 
[94] S. Mishra, M. Yadav, Asian J. Chem. 16 (2004) 933. 
[95] N. Rahman, N.A. Khan, S.N.H. Azmi, Pharmazie 59 (2004) 112. 
53 
[96] S.Z. Qureshi, M.I.H. Helaleh, N. Rahman, R.M.A.Q. Jamhour, Fresenius J. 
Anal. Chem. 357 (1997) 1005. 
[97] S.Z. Qureshi, M.I.H. Helaleh, N. Rahman, R.M.A.Q. Jamhour, Chem. Anal. 
(Warsaw) 42 (1997) 65. 
[98] N. Rahman, M.N. Hoda, Anal. Bioanal. Chem. 374 (2002) 484. 
[99] N. Rahman, S.N.H Azmi, II Farmaco 59 (2004) 529. 
[100] A. Espinosa-Mansilla, A. Munoz de la pena, F. Salinas, M.M. Galera, Anal. 
Chim. Acta 276 (1993) 141. 
[101] M.S. Pena, A. Munoz de la pena, F. Salinas, M.C. Mahedero, J.J. Aaron, 
Analyst 119(1994) 1177. 
[102] I.D. Meras, A. Munoz de la pena, M.I.R. Caceres, F. Salinas, Talanta 45 
(1998) 899. 
[103] A.G. Cabanillas, T.G. Diaz, N.M.M. Diez, F. Salinas, J.M.O. Burguillos, J.C. 
Vire, Analyst 125 (2000) 909. 
[104] M. Blanco, J. Coello, H. Iturriaga, S. Maspoch, C. De. la pezuela. Anal. 
Chim. Acta 333 (1996) 147. 
[105] B.K. Lavine, Anal. Chem. 72 (2000) 91 R. 
[106] H.C. Goicoechea, M.S. Collado, M.L. Satuf, A.C. Olivieri, Anal. Bioanal. 
Chem. 374 (2002) 460. 
[107] V.P. Shah, J.J. Konecny, R.L. Everett, B. Mc CuUough, A.C Noorizadeh, 
J.P. Skelly, Pharm. Res. 6 (1989) 612. 
[108] V.J. Hammond, W.C. Price, J. Opt. Soc. Am. 43 (1953) 924. 
[109] J.D. Morrison, J. Chem. Phys. 21 (1953) 1767. 
[110] A.T. Giese, C.S. French, Applied Spectrosc. 9 (1955) 78. 
[111] I.G. Mc Williams, Anal. Chem. 41 (1969) 674. 
54 
[112] W. Shellemen, T.C. Rains, K.W. Yee, H.D. Cook, O. Menis, Anal. Chem. 42 
(1970)394. 
[113] W.K. Fowler, D. O. Knapp, J.D. Winefordner, Anal. Chem. 46 (1974) 601. 
[114] T.C. O'Haver, In: E.L. Wehry (Ed.), Modem Flourescence Spectrometry, Vol 
1, Plenum Press, New York (1976). 
[115] P. John, I. Soutar, Anal. Chem. 48(1976) 520. 
[116] T.C. O'Haver, T. Begley, Anal. Chem. 53 (1981) 751. 
[117] D. Boyd, B. Maguire, Near Infrared Spectroscopy: Proceedings of the ninth 
International Conference, Verona, Italy, 1999, NIR Publications, Charlton, 
Chichester, West Sussex, UK, 2000, p. 357. 
[118] H. Mark, G. Kemney, Chemical Processing 54 (1991) 54. 
[119] Pharmacopoeial Forum 24 (1998) 6463. 
[120] Pharmacopoeial Forum 26 (2000) 237. 
[121] A.A. Al-Majed, J. Al-Zehouri, IL Farmaco 56 (2001) 291. 
[122] C. Lopez-Erroz, P. Vinas, F.J. Cerdan, M. Hemandez-Corboda, Talanta, 53 
(2000) 47. 
[123] P. Damiani, M. Bearzotti, M.A. Cabezon, J. Pharm. Biomed. Anal. 29 (2002) 
229. 
[124] J.A. Arancibia, G.M. Escandar, Analyst 126 (2001) 917. 
[125] J.H.M. Miller, Amer. Lab. 10 (1978) 41. 
[126] F. Rousselet, F. Thuillier, Prog. Anal Atom. Spectrosc. 1 (1979) 353. 
[127] G.D. Christian, F.J. Feldman, Atomic Absorption Spectroscopy: Application 
in Agriculture, Biology and Medicine, Wiley-Inter-Science, New York, 1970. 
I 
[128] R.V. Smith, Amer. Lab. 5 (1973) 27. 
[129] H.E. Abdellatef, M.M. Ayad, E.A. Taha, J. PharmA^ioVied. Anal. 1 
1021. ^ 
[130] M.M. Ayad, A.A. Shalaby, H.E. Abdellatef, M.M. Hosny, J. Pharm. Biomed. 
Anal. 28(2002)311. 
[131] G.M. Hana, C.A. Lau-Cam, J. Pharm. Biomed. Anal. 11 (1993) 855. 
[132] T.A Schmedake, L.E. Welch, J. Chem Educ. 73 (1996) 1045. 
[133] J.K. Baker, C.W. Myers, Pharm. Res. 8 (1991) 761. 
[134] J.K. Roberts, R.J. Smith, J. Chromatogr. A 677 (1994) 385. 
[135] S.C. Connor, J.R. Everett, K.R. Jennings, J.K. Nicholson, G. Woodnutt, J. 
Pharm. Pharmacol. 46 (1994) 128. 
[136] R. Suryanarayanan, T.S. Wiedmann, Pharm. Res. 7 (1990) 184. 
[137] P. Gao, Pharm. Res. 13 (1996) 1095. 
[138] K. Kanamori, B.D. Ross, Biochem. J. 305 (1995) 329. 
[139] J.D. Bell, Spectroscopy Europe 8 (1996) 18. 
[140] P.C. Dagnelie, D.K. Menon, I.J. Cox, J.D. Bell, J. Sargentoni, G.A. Coutls, J. 
Urenjak, R.A. lies, Clin. Sci. Colch. 83 (1992) 183. 
[141] I.F. Al-Momani, J. Pharm. Biomed. Anal. 25 (2001) 751. 
[142] M.S. Bloomfield, Talanta 580 (202) 1301. 
[143] P. Masawat, S. Liawruangrath, Y. Vaneesom, B. Liawruangrath, Talanta 58 
(2002)1221. -
[144] S. Garcia, C. Sanchez-Pedreno, I. Albero, C. Garcia, Mikrochim Acta 136 
(2001). 
[145] M.E. Palomeque, B.S.F. Band, J. Pharm. Biomed. Anal. 30 (2002) 1547. 
[146] X. Zheng, Z. Zhang, B. Li, Electroanalysis 13 (2001) 1046. 
[147] J.C. Berridge, Analyst 112 (1987) 385. 
56 
[148] D.L. Massart, L. Buyden, J. Pharm. Biomed. Anal. 6 (1988) 535. 
[149] B.V. Fisher, R. Jones, J. Pharm. Biomed. Anal. 5 (1987) 455. 
[150] S. Wold, J. Pharm. Biomed. Anal. 9 (1991) 589. 
[151] J.C. Berridge, P. Jones, A.S. Roberts Mc-Intosh, J. Pharm. Biomed. Anal. 9 
(1991)597. 
[152] N.B. Vogt, Chemom. Intell. Lab. Syst. 14 (1992) 93. 
[153] R.L. Tranter, Chemom. Intell. Lab. Syst. 14 (1992) 85. 
[154] D. Perez-Bendito, M. Silva, Kinetic Methods in Analytical Chemistry, Ellis; 
Harwood, Chichester (1988) p. 149. 
[155] H.L. Pardue, Anal. Chim. Acta 216 (1989) 69. 
[156] H.A. Mottola, Kinetic Aspects of Analytical Chemistry, Wiley, New York 
1988. 
[157] A. Espinosa-Mansilla, M.I. Acedo Valenzuela, F. Salinas, F.C. Canada, Anal. 
Chim. Acta 376 (1998) 365. 
[158] S.M. Ahmad, Mansoura J. Pharm. Sci. 19 (2003) 1. 
[159] M.I. Walash, M.E.-S. Metwally, A.M. El-Brashy, A.A. Abdelal, II Farmaco 
58(2003)1325. 
[160] H.M. Saleh, Mansoura J. Pharm. Sci. 18 (2002) 7. 
[161] L. de la Pena, A. Gomez-Hens D. Perez-Bendito, Anal. Chim. Acta 283 
(1993)471. 
[162] R. Jimenez-Prieto, M. Silva, Analyst 123 (1998) 2389. 
[163] R. Jimenez-Prieto, M. Silva, Anal. Chim. Acta 389 (1999) 131. 
[164] C. Hervas, S. Ventura, M. Silva, D. Perez-Bendito, J. Chem. Inf. Comput. 
Sci. 38(1998)1119. 
[165] M. Marquez, M. Silva, D. Perez-Bendito, Anal. Chim. Acta 237 (1990) 353. 
57 
[166] M. Marquez, M. Silva, D. Perez-Bendito, J. Pharma. Biomed. Anal. 8 (1990) 
563. 
[167] M. Marquez, M. Silva, D. Perez-Bendito, Anal. Lett. 22 (1989) 2485. 
[168] L. Monferrer-Pons, L. Alvarez-Rodriguez, J. Esteve-Romero, M.C. Garcia-
Alvarez-Coque, Anal. Lett. 32 (1999) 51. 
[169] X.R. Huang, W.J. Zhang, S.H. Han, G.Y. Hu, Chin. Chem. Lett. 10 (1999) 
51. 
[170] C.A. Georgiou, M.A. Koupparis, T.P. Hardjiiionnov, Talanta. 38 (1991) 689. 
[171] S.M. Sultan, A. D. Walmsley, Analyst 122 (1997) 1601. 
[172] Y. -Z. Ye, Y. Luo, Lab. Rob. Autom. 10 (1998) 283. 
[173] J.M. Pena, S. Rubio, D. Perez-Bendito, Anal. Chim. Acta. 244 (1991) 81. 
[174] F. Bosch-Reig, P. Compins-Falco, A. Sevillano-Cabeza, R. Hervaez-
Hemandez, C. Molins-Legua, Anal. Chem. 63 (1991) 2424. 
[175] H.J. Pieniaszek, Short Course on Bioanalytical Method Development: 
validation and transfer, lO"^  International Symposium on Pharmaceutical and 
Biomedical Analysis, Washington, D.C., USA, May 9, 1999, Short course 
Materials. 
[176] ICH: Q2A, Validation of analytical procedures (Definitions and 
Terminology), Geneva, 1995. 
[177] ICH: Q2B, Validation of analytical procedures: Methodology, Geneva, 1996. 
[178] R.L. Tranter, Anal. Proc. 27 (1990) 1229. 
[179] H. Kaiser, Two papers on the limit of detection of a complete analytical 
procedures, Adam Hilger, London, 1968, p. 52. 
[180] H. Kaiser, Spectrochim. Acta B 33 (1978) 551. 
[181] P.W.J.M. Boumans, Spectrochim. Acta B 13 (1978) 625. 
58 
[182] ICH: Stability Testing of New Drug substance and products, IFPMA, Geneva, 
1996. 
[183] ICH: Impurities in New Drug products, IFPMA, Geneva, 1996. 
[184] ICH Specifications: Test procedures and Acceptance criteria for New Drug 
substances and New Drug products: Chemical substances, IFPMA, Geneva, 
1999. 
[185] ICH: Quality of Biotechnological products: stability testing of 
Biotechnological Biological Products, IFPMA, Geneva, 1995. 
[186] FDA, Guideline for submitting Documentation the stability of Human Drugs 
and Biologies, Food and Drug Administration, Rockville, MD, 1987. 
[187] FDA, Guidance for Industry: Stability Testing of Drug substances and Drug 
Administration, Rockville, MD, 1998. 
[188] WHO, Guidelines for stability Testing of pharmaceutical products containing 
well established drug substances in conventional dosage forms in WHO 
expert committee on specifications for pharmaceutical preparations. 
Technical Report Series 863 World Health Organization, Geneva, 1996 p. 65. 
[189] CPMP, Note for Guidance on Stability' Testing of existing Active Substances 
and Related Finished products", Committee for proprietary Medicinal 
product, EMEA, London, 1988. 
[190] TPD, Stability Testing of Existing Drug Substances and Products. 
Therapeutic Products, Directorate, Ottawa, 1997. 
[191] L. Chafetz, J. Pharm. Sci. 60 (1997) 335. 
[192] V. Kumar, N. Sunder, East. Pharm. 38 (1989) 47. 
[193] C. Ho, G. -L. Chen, J. Food Drug. Anal. 4 (1996) 271. 
[194] C. Ho. G. -L. Chen, J. Food Drug. Anal. 5 (1997) 1. 
59 
[195] Q.A. Xu. L.A. Trissel (Eds), Stability Indicating HPLC Methods for Drug 
Analysis, American Pharmaceutical Association, Washington, 1999. 
[196] D.D. Hung, M. Shah, Development and Validation of HPLC Stability 
indicating Assays, In: Drug Stability: Principle and Practices, J.T. 
Carstenesen, C.T. Rhodes (Eds.), Marcel Dekker, New York, 2000, p. 329. 
[197] V.G. Dabbene, M.C. Brinon, M.M. de Bert Orello, J. Pharm. Sci. 83 (1994) 
1617. 
[198] R.J. Forsyth, D.P.I.P, J. Pharm. Biomed Anal. 12 (1994) 1243. 
[199] M.I. Walash, A.M. El - Brashy, M.A. Sultan, Acta Pharm. Hung. 64 (1994) 5. 
[200] E.F. Khamis, M. Abdel-Hamid, E.M. Hassan, A. Eshra, M.A. El-sayed, J. 
Clin. Pharm. Ther. 18 (1993) 97. 
[201] J.P. Salo, H. Salmoies, J. Pharm. Biol. Med. Anal. 14 (1996) 1261. 
[202] V.B. Patravale, V.B. Nair, S.P. Gore, J. Pharm. Biomed. Anal. 23 (2000) 623. 
[203] P.N. Kotiyan, P.R. Vavia, J. Pharm. Biomed. Anal. 22 (2000) 667. 
[204] S.P. Kulkarani, P.D. Amin, J. Pharm. Biomed. Anal. 23 (2000) 983 
[205] M.M. Al - Oman, M.K. Abdelah, A.A. Badwan, A.M. Jaber, J. Pharm. 
Biomed. Anal. 25 (2001) 893. 
[206] B.A. Persson, J. Vessman, R.D. Mc Dowall, LC-GC International March 
(1998) 160. 
[207] J. Vessman, J. Pharm. Biomed. Anal. 14 (1996) 867. 
[208] DIN ISO 5725-2; Acctiracy (trueness and precision) of measurement methods 
and results a basic method for the determination of repeatability and 
reproducibility of a standard Measurement method, 1990. 
[209] MVA-Method validation in analytics (PC-Software, Windows NT), NOVIA, 
GmbH, Saarbrucken, Germany. 
60 
[210] M. Thompson, S. Ellison, R. Word, Pure Appl. Chem. 74 (2002) 835. 
[211] The United State Pharmacopoeia, USA, USP 26, 2003, p. 2439. 
[212] European Community; Official Journal of the European Communities, L 221 
2002, pp. 8-36. 
[213] S. Braggio, R.J. Bamaby, G.M. Cugola, J. Pharm. Biomed. Anal. 14 (1996) 
375. 
[214] J.D. Ingle, Jr., S.R. Crouch, Spectrochemical Analysis (Engle wood Cliffs, 
N.J. Prentice Hall) 1988, p. 172. 
[215] P.W.J.M Boumans, Anal. Chem. 66 (1994) 459A. 
[216] American Chemical Society Committee on Environmental Improvement, 
Principles of Environmental Analysis, Anal. Chem. 55 (1983) 2210. 
[217] lUPAC Commission on spectrochemical and other optical procedures for 
analysis. Anal. Chem. 48 (1976) 2294. 
[218] J.D. Ingle, Jr. J. Chem. Edu. 51 (1974) 100. 
[219] ICH: Harmonised Tripartite Guideline Prepared within The Third 
International Conference on Harmonisation of Technical Requirements for 
the Registration of Pharmaceuticals for Human Use, Text on Validation 
Procedures, 1994. 
[220] ICH: Test on validation of Analytical Procedures, Geneva, 1994. 
[221] W.J. Youden, E.H. Steiner, Statistical Manual of the AOAC, Association of 
Official Analytical Chemists, Arlington, 1975, p.33, 70, 72. 
[222] J.A. Van Leeuwen, L.M.C. Buydens, B. G.M. Vandeginste, G. Kateman, P.J. 
Schoenmakers, M. Mulholl, Res, Chemo. Intell. Labo. Sys. 10 (1991) 337. 
[223] M. MulhoUand, TRAC. 7 (1988) 383. 
61 
[224] Y. Vander Heyden, F. Questier, D.L. Massart, J. Pharm. Biomed. Anal. 18 
(1998)43. 
[225] F.J. Vande Vaart, Het. Pharma. Weekbl. 127 (1992) 1229. 
[226] J. Caporal-Gautier, J.M. Nivet, P. Algranti, M. Guilloteau, M. Histe, M. 
Lallier, J.J. N'Guyen-Huu, R. Russtto, STP Pharm. Pratiques. 2 (1992) 205. 
[227] The United States Pharmacopoeia, 23rd edition, National Formulary 18, 
United States Pharmacopocial convention, Rockville, USA, 1995. 
[228] Drugs Directorate Guidelines, Acceptable methods, health Protection Branch-
health and Welfare Canada, 1992, pp.20-22. 
[229] US-FDA, Technical Review Guide: Validation of Chromatographic Methods, 
Centre for Drug Evaluation and Research (CDER), Rockville, MD, 1993. 
[230] D. Dadgar, P.G. Burnett, M.G. Choc, K. Gallicano, J.W. Hooper, J. Pharm. 
Biomed. Anal. 13 (1995) 89. 
[231] H. Fabre, J. Pharm. Biomed. Anal. 14 (1996) 1125. 
62 
APTEM 
KINETIC SPECTROPHOTOMETRIC 
METHOD FOR THE DETERMINATION OF 
NORFLOXACIN IN PHARMACEUTICAL 
FORMULATIONS 
63 
INTRODUCTION 
Norfloxacin, 1 -ethyl-6-fluoro-1,4-dihydro-4-oxo-7-( 1 -piperazinyl)-3 -quinoline 
carboxylic acid is a synthetic broad spectrum antibacterial drug, which is very much 
active against many gram positive and gram negative bacteria. It is mainly used in 
the treatment of urinary tract infections. 
The drug and its formulations are listed in the United States Pharmacopoeia 
[1] and European Pharmacopoeia [2]. The USP describes an HPLC method for its 
determination while the European Pharmacopoeia recommended a non-aqueous 
titration method. Other techniques used for its quantification include high 
performance liquid chromatography [3-13], high performance thin layer 
chromatography [14], fluorimetry [15-19], titrimetry [20] and differential scanning 
potentiometry [21]. 
Spectrophotometry still belongs to the most frequently used analytical 
techniques in pharmaceutical analysis, which provides practical and significant 
economic advantages over other methods. A review of literature revealed that the 
charge transfer reactions of norfloxacin wdth 7i-acceptors such as 2,3-dichloro-5,6-
dicyano-p-benzoquinone, 7,7,8,8,tetra cyano quinodimethane, p-chloranil and p-
chloranilic acid have been used for its assay in bulk and dosage forms [22]. El 
Walily et al. [23] have developed two spectrophotometric methods based on the 
interaction of norfloxacin with 2,4-dinitrofluorobenzene in aqueous borate buffer 
and dimethylsulphoxide medium to form coloured chromophores which absorb 
maximally at 365 nm and 410 run, respectively. The drug content in pharmaceutical 
formulations has been determined by the formation of an oxidative coupling product 
of the drug with 3-methyl-2-benzothia2olinone-HCl in the presence of cerric 
ammonium sulphate [24]. The quantification of norfloxacin [25] was done utilizing 
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the reaction between drug and Fe(III) in sulphuric acid medium. Two extractive 
spectrophotometric methods [26] have been recommended based on chloroform 
extractable ion-association complex of the drug with each of the dye such as 
supracene violet 3B and tropaeolin 000. The determination of norfloxacin is done on 
the basis of the formation of precipitate between drug and ammonium reineckate. 
The precipitated drug-reagent complex is dissolved in aqueous 50% acetone and 
absorbance is measured at 524 nm [27]. However, many of these methods are 
limited in their applications or rather much tedious and time consuming. The 
literature is still poor in analytical procedures based on kinetics especially for the 
determination of drug in commercial dosage forms. However, some specific 
advantages in the application of kinetic methods can be expected [28] such as, 
selectivity due to the meastirement of the evolution of the absorbance with the time 
of reaction. There is, therefore, a need for a simple and sensitive kinetic 
spectrophotometric method for the assay of norfloxacin in commercial dosage 
forms. 
This chapter describes a simple and sensitive kinetic spectrophotometric 
method for the determination of norfloxacin in drug formulations. The method 
involves the oxidation of drug with alkaline potassium permanganate at room 
temperature and subsequent measurement of absorbance at 603 nm. The initial rate 
and fixed time methods are adopted for its determination in commercial dosage 
forms after fiill investigation. 
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EXPERIMENTAL 
Materials and methods 
Apparatus 
A Shimadzu UV-Visible spectrophotometer (model-1601, Japan) with 
matched quartz cells was used to measure absorbance. 
Reagents and standards 
All chemicals used were of analytical or pharmaceutical grade. Norfloxacin was 
provided by Cipla, India and was used as received. A standard solution of 
norfloxacin (1.0 mg/ml) was prepared by dissolving 100 mg in 1.0 ml of 0.75 M 
NaOH, and further diluted to 100 ml with doubly distilled water. A working test 
solution of norfloxacin (0.2 mg ml"') was prepared by dilution of 10 ml of the 
standard solution to 50 ml with doubly distilled water. The tablets, containing the 
norfloxacin such as Alflox (Alkem), Negaflox (Zydus Alidac), Norflox (Cipla), 
Uroflox (Torrent) were purchased from local market. Aqueous solutions of sodium 
hydroxide (0.75 M) and potassiiun permanganate (0.006 M) were prepared in doubly 
distilled water. Potassium permanganate solution should be freshly prepared and its 
apparent purity was checked titrimetrically [29]. 
Recommended procedure for the determination of norfloxacin 
Initial rate method 
Aliquots of 0.1-1.0 ml of 0.02% norfloxacin test solution were pipetted into a 
series of 10 ml standard flasks. 2.0 ml of 0.75 M NaOH followed by 2.0 ml of 0.006 
M potassium permanganate were added to each flask and then diluted with doubly 
distilled water at 30±1°C. The contents of the mixture of each flask were mixed 
well and the increase in absorbance was recorded as a function of time at 603 imi. 
The initial rate of the reaction (v) at different concentrations was obtained from the 
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slope of the tangent to the absorbance time curve. The calibration graph was 
constructed by plotting the logarithm of the initial rate of the reaction (log v) versus 
the logarithm of the molar concentration of norfloxacin (log C). The amount of the 
drug in each sample was calculated either from the calibration graph or the 
regression equation. 
Fixed time method 
In this method, the absorbance of each sample solution at a preselected fixed 
time was accurately measured and plotted against the final concentration of the drug. 
The content of the drug was estimated either from calibration graph or regression 
equation. 
Determination of norfloxacin in dosage forms 
An accurately weighed quantity of the mixed contents of the tablets equivalent 
to 50 mg of the drug was extracted into 50 ml of 1,2-dichloromethane with shaking 
and the residue was filtered using Whatmann No. 42 filter paper. The filtrate was 
evaporated to dryness and the residue was dissolved in 1.0 ml of 0.75 M NaOH and 
transferred to a 50 ml standard volumetric flask, diluting to volume with doubly 
distilled water. The stock solution of drug was diluted according to the need and 
analyzed by the recommended procedures. 
RESULTS AND DISCUSSION 
The absorption spectrum of aqueous potassium permanganate solution in the 
alkaline mediuiri exhibits an absorption band peaking at 530 nm. The addition of 
norfloxacin to this solution produces a new characteristic band at 603 nm. ^ ig . 2.1/ 
This band is due to the formation of manganate ion, which resulted on the oxidation 
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Fig. 2.1: Absorption spectra of (a) 2.0 ml of 0.75 M NaOH + Iml of 0.006 
M KMn04 (b) 20 ^g ml' norfloxacin + 2.0 ml NaOH (0.75 M) + 2 
ml KMn04 (0.006 M) in doubly distilled water. 
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of norfloxacin by potassium permanganate in alkaline medium. The intensity of the 
colour increases with time, and therefore, a kinetically based method was developed 
for the determination of norfloxacin in drug formulations. The optimum conditions 
affecting the formation of manganate ion were studied and maintained throughout 
the experiment. 
Effect of KMn04 Concentration 
The effect of KMn04 concentration on the initial rate of the reaction was 
studied in the range of 3.0x10"^ - 15.0x10"^ M. The initial rate of reaction (Fig. 2.2) 
increased with increasing the concentration of KMn04 and became constant at 
10.2x10'^ M. Thus, the adoption of IZ.OxlO"^  M KMn04 in the final solution proved 
to be adequate for the maximum concentration of norfloxacin used in the 
determination process. 
Effect of NaOH concentration 
The influence of the NaOH concentration on the formation of Mn04^' was also 
examined by taking 20 ^g ml'' norfloxacin, 2.0 ml of 0.006 M KMn04 solution and 
varied volume (0.25-2.0 ml) of 0.75 M NaOH. The maximum absorbance was 
obtained with 1.5 ml of 0.75 M NaOH, after which fiirther increase in volume of 
NaOH caused no change in absorbance. Hence, 2.0 ml of 0.75 M NaOH was used as 
an optimimi value. 
Stoichiometry and reaction mechanism 
The stoichiometric ratio between potassium permanganate and norfloxacin 
was determined by the limiting logarithmic method [30]. This was established by 
performing two sets of experiments. In the first set, KMn04 concentration was 
varied while keeping a constant concentration of norfloxacin. In the second set. 
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10'^x 12 
10 12 14 16 xlO-* 
[KMnOJ (mole/litre) 
Fig.2.2: Effect of the concentration of KMn04 (3x10"^  - ISxlO"* M) 
on the initial rate of reaction (v) vcith 20 ^g ml' norfloxacin 
and 2.0 ml NaOH (0.75 M) in doubly distilled water. 
70 
the KMn04 concentration was kept constant while varying the concentration of 
norfloxacin. The logarithms of the absorbance were plotted against the logarithm of 
the respective varied concentration ^ ig . 2.3/ The slopes of the two straight lines 
were calculated and found to be unity in each case. Thus, it is concluded that the 
combining molar ratio between norfloxacin and KMn04 is in the ratio of 1:1. 
A review of literature indicated that the norfloxacin undergoes oxidation when 
treated with oxidants such as chloramine-B and N-chlorobenzotriazole [31]. In this 
study, the potassium permanganate oxidizes the norfloxacin in alkaline medium. 
Therefore, the following reaction mechanism (Scheme 2.1) is proposed on the basis 
of literature background and our experimental findings. 
Initial rate method 
The initial rates of the reaction were determined fi-om absorbance time curves 
(Fig. 2.4 and 2.5) by measuring the slopes of the initial tangent to the absorbance 
time curves. The order with respect to permanganate was determined by studying the 
reaction at different concentration of permanganate with fixed norfloxacin 
concentration. The plot of initial rate, dA/dt, against the initial absorbance was linear 
passing through the origin indicated that the order of the reaction with respect to 
permanganate at the start was one. The order with respect to norfloxacin was 
evaluated by plotting the logarithm of the initial rate of the reaction versus the 
logarithm of the molar concentration of norfloxacin and was found to be one. 
Under the optimized experimental conditions, the concentration of norfloxacin 
was determined using an excess of KMn04 and NaOH solution with respect to the 
initial concentration of norfloxacin. As a result, a pseudo zero order condition 
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Fig. 2.3: Limiting logarithmic plot for molar combining ratio 
between norfloxacin and KMn04: (a) log A vs. log [Drug] (b) log A 
vs. log [KMn04]. 
Norfloxacin 
COOH 
Mn04 
C2H5 
COOH 
OH 
Mn04 2-
1-Ethyl-6-fluoro-2-hyclroxy-4-oxo-7-piperazin 
-1-yl-1,4-dihyclro-quinoline-3-carboxylic acid 
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Scheme 2.1 
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6 8 10 
Time (min) 
Fig. 2.4: Absorbance vs. time curves for the reaction between 
norfloxacin and KMn04: KMn04, 1.2x10'' molL'' and 
norfloxacin (a) 6.263x10-* molL' (b) 1.253x10*' molL' (c) 
1.879x10-^ molL' (d) 2.505x10'^ molL* (e) 3.758x10-^ molL* (f) 
S.OlOxlO-^  molL' (g) 5.637x10 ^ moIL ' (h) 6.263x10 ^ molL'. 
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6 8 10 12 
Time (min) 
14 16 
Fig. 2.5: Absorbance vs. time curves for the reaction between norfloxacin 
and KMn04: norfloxacin, 6.263 x 10"^  molL'' and KMn04(a) 3 x 10"^  
molL' (b) 6 x 10-^  moIL' (c) 9 x 10"^  molU^ (d) 10.2 x 10"* molL'' 
(e) 12 xlO"* molL\ 
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was obtained with respect to their concentrations. However, the initial rate of the 
reaction would follow a pseudo first order and was found to obey the following 
equation: 
Rate = AA/At = K'c" 
where K is the pseudo first order rate constant, C is the concentration of 
norfloxacin, n is the order of the reaction. The logarithm form of the above equation 
is written as: 
Log (rate) = log k + n log C 
The linear regression analysis using the method of least square was made to 
evaluate slope, intercept and correlation coefficient. Under the optimized 
experimental conditions a calibration curve was constructed by plotting log initial 
rate versus log molar concentration of norfloxacin (log C), which showed a linear 
relationship over norfloxacin concentration range of 2.0-100 |ig ml"'. The regression 
of log rate versus log C gave a linear regression equation 
Log (rate) = 3.213 + 0.9975 log C 
with a correlation coefficient (r) of 0.9999. The value of n in regression equation 
also confirmed that the reaction is first order with respect to the norfloxacin 
concentration. The confidence limits for the slope of the line of regression and 
intercept were computed using the relation b ± tSb and a ± tSa [32] at 95% 
confidence level and found to be 0.9975 ± 3.557 x 10"^  and 3.213 + 1.632 x 10"^  
respectively. This indicated the high reproducibility of the proposed method. The 
limit of detection was established using the equation [33]. 
Limit of detection = Ls^^ x — 
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where t is the value of student's t for n-2 degree of freedom at 95% confidence level 
and So^  = variance. The variance and detection limit were calculated and found to be 
1.833 X 10"^  and 3.100 x 10"^  |ag ml"', which confirmed negligible scattering of 
experimental data points around the line of best fit and good sensitivity of the 
method, respectively. 
Fixed time method 
In this method, the absorbance of a green coloured solution containing varying 
amounts of norfloxacin was measured at a preselected fixed time. Calibration plots 
of absorbance versus initial concentrations of norfloxacin were established at a fixed 
time of 3, 6, 9, 12 and 15 min. The regression equations, coefficient of correlation, 
detection limit, variance, relative standard deviation, and standard analytical error 
are given in Table 2.1. The lowest detection limit was obtained with a fixed time of 
15 min, whereas the fixed time of 3 min showed a wider concentration range for 
quantification. According to ICH guidelines [34] detection limit is not required to be 
part of the validation procedure for assays. Therefore, on the basis of wider 
concentration range and less time of analysis, the fixed time of 3 min was 
recommended for determination. 
Regression analyses of the calibration data also make it possible to evaluate 
the error, Sc, in the determination of a given concentration of norfloxacin using the 
equation [35]. 
S - ^ 
^'' b 
1 . 1 . . ^y-y^' 
n b'Y{C,-Cf 
1/2 
Where y and C are average initial rate of reaction or average absorbance at a fixed 
time of 3 min and concentration values, respectively, for n standard samples. It is 
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clear from the graph in Fig. 2.6 fa and b) that the error is reached minimum, when the 
initial rate (v) (or actual absorbance) was equal to the average initial rate (v ) (or 
average absorbance) in the calibration graphs corresponding to 8.32 |ag ml"' and 9.65 
fxg ml"' for initial rate and fixed time method, respectively. The value of Sc also allows 
to establish the confidence limit at the selected level of significance for the 
determination of unknown concentrations by using the relation, Ci±tSc. Fig. 2.7 (a and 
b) shows the variation in the confidence limit in the form of percentage uncertainty [36] 
in the concentration at the 95% confidence level and used to calculate the relative 
uncertainty in the concentration over the full range of concentration tested. It is, 
therefore, a useful way to establish the confidence limit. 
The accuracy and precision was determine by measuring the norfloxacin content 
of pure sample and dosage forms five times within one day by initial rate and fixed time 
methods fTable 2.2 and 2.3). The daily precision was measured by assaying the pure 
samples and tablets on five consecutive days by both initial rate and fixed time methods 
^able 2.4 and 2.5). The standard deviations, relative standard deviations and standard 
analytical errors obtained in intra day and inter day assays can be considered to be very 
satisfactory. 
The accuracy of the proposed methods was also checked by performing recovery 
experiments. For this, a known amount of the pure drug was added to preanalysed 
dosage forms and then determined by the recommended procedures. The results ^ab le 
2.6> obtained from the investigations showed that the mean recoveries and relative 
standard deviations were in the range of 99.82 - 100.56% and 0.056 - 1.137 %, 
respectively. No interference from the common excipients was observed. 
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1Cr'x25 
I 
2 4 6 8 10 12 14 16 18 20 22 
Concentration of norfloxacin (|ugml"^) 
Fig. 2.6 a: Variation of the confidence limit at 95% confidence level in the 
form of uncertainty percentage on the concentration of norfloxacin with 
initial rate method. 
80 
5 10 15 20 
Qxioertraticin of norfioxadn, jog ni- l 
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Fig. 2.6 b: Variation of the confidence limit at 95 % confidence 
level in the form of uncertainty percentage on the concentration 
of norfloxacin with fixed time method (3 min). 
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^ 1.60 CO, 
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Fig. 2.7 a: Error in the determination of the concentration of norfloxacin using 
statistical analysis of standard calibration data - initial rate method. 
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Fig. 2.7b: Error in the determination of the concentration of norfloxacin using 
statistical analysis of standard calibration data - fixed time method (3 min). 
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Table 2.2 
Intra day assay: Evaluation of the accuracy and precision of the initial rate and fixed time 
methods 
Proposed methods Amount taken Amount found ± SD' RSD SAE*" C.L.'' 
(^gml"') (ligml"') 
Initial rate method 
Fixed time method 
4.0 
12.0 
20.0 
4.0 
12.0 
20.0 
4.02 ± 0.043 
12.02 ± 0.043 
20.06 ± 0.080 
04.02 ± 0.056 
12.02+ 0.056 
20.02 ± 0.056 
1.09 
0.36 
0.40 
1.39 
0.47 
0.28 
0.019 
0.019 
0.036 
0.025 
0.025 
0.025 
0.054 
0.054 
0.100 
0.069 
0.069 
0.069 
"Mean ± SD for five determinations. 
'' SAE, standard analytical error. 
" C.L., confidence limit at 95 % confidence level and four degrees of freedom (t = 2.776). 
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Table 2.4 
Inter day assay: Evaluation of the accuracy and precision of the initial rate 
and fixed time methods 
Proposed methods 
Initial rate method 
Fixed time method 
Amount taken 
(MgmlV 
4.0 
12.0 
20.0 
4.0 
12.0 
20.0 
Amount found ± SD' 
(^gm!-') 
4.04 ±0.052 
12.03 ±0.049 
20.00 ±0.160 
4.01 ±0.076 
12.01 ±0.076 
20.05 ±0.087 
RSD 
(%)' 
1.28 
0.41 
0.80 
1.89 
0.63 
0.43 
SAE*" 
0.023 
0.022 
0.072 
0.034 
0.034 
0.039 
C.L."^  
0.064 
0.061 
0.199 
0.094 
0.094 
0.108 
b 
' Mean ± SD for five determinations performed over a period of five days. 
SAE, standard analytical error. 
C.L., confidence limit at 95 % confidence level and four degrees of freedom (t = 2.776). 
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The initial rate and fixed time methods for determining norfloxacin have been tested on 
commercial pharmaceutical formulations. The concentration of the drug was computed 
from its corresponding regression equations. The results of the proposed method (initial 
rate or fixed time) were compared with those of the reference method [23] using point 
hypothesis. Table 2.7 shows that the calculated t- and F- values [37] are less than 
theoretical ones, confirming no significant difference between the performance of the 
proposed method and the reference method at 95 % confidence level. The interval 
hypothesis tests [38] have also been performed to compare results of proposed method 
(initial rate or fixed time) with those of reference method at 95% confidence level 
(Table 2.8), It was decided that a bias, based on recovery experiments, of ± 2% is 
acceptable. Therefore, the limit of acceptance interval is within 6i=0.98 and 92=1.02. It 
is apparent from Table 2.8 that the true bias of all samples is smaller than ± 2%. The 
interval hypothesis leads to the same conclusion as the point hypothesis. 
The initial rate and fixed time methods can be easily applied to the determination 
of norfloxacin in pure and dosage forms which do not require elaborate treatment of the 
analyte and tedious extraction of the chromophore produced. The proposed method 
(initial-rate or fixed-time) is sensitive enough to enable determination of lower amount 
of the drug. These advantages encourage the application of the proposed methods in 
routine quality control. 
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Table 2.8 
Interval hypothesis: comparison of the proposed methods with the 
reference method at 95% confidence level 
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Formulations Initial rate method Fixed time method 
Lower limit' Upper limit' 
(OL) (OU) 
Lower limit* Upper limit" 
(OL) (OU) 
Alflox 
(Alkem) 
Negaflox 
(Zydus Alidac) 
Norflox 
(Cipla) 
Uroflox 
(Torrent) 
0.995 
0.997 
0.993 
0.995 
1.004 
1.009 
1.007 
1.004 
0.993 
0.996 
0.993 
0.993 
1.004 
1.005 
1.005 
1.004 
'In pharmaceutical analysis, a bias, based on recovery experiments, of ± 2% (0|=O.98 and 
02=1.02) is acceptable. 
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SELECTIVE AND VALIDATED 
SPECTROPHOTOMETRIC METHODS FOR 
THE DETERMINATION OF NICORANDIL 
I N PHARMACEUTICAL FORMUALTIONS 
. 
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INTRODUCTION 
Nicorandil is chemically known as N-[2-(nitroxy)ethyl]3-pyridine carboxamide, 
which belongs to the class of compounds known as potassium channel activators. 
Nicorandil has venodilating properties owing to the presence of nitrate group in its 
chemical structure. The potassium channel activation may also exert direct 
cytoprotective effects by augmenting normal physiological processes, which protect the 
heart against ischemic events [1,2]. Thus, nicorandil causes vasodilation of coronary 
and systematic arteries and has been investigated in the treatment of angina pectoris. 
Nicorandil undergoes biotransformation predominantly by denitration of nicorandil to 
the pharmacologically inactive alcohol metabolite, N-(2-hydroxyethyl)-nicotinamide, 
followed by side chain degradation to nicotinamide and related metabolites, including 
nicotinic acid and N-methyl-nicotinamide. The denitration occurs primarily in the liver. 
The drug is officially listed in Martindale The Extra Pharmacopoeia [3]. The 
literature revealed that the assay of the drug in pure and dosage forms is not official in 
any pharmacopeia and, therefore, requires much more investigation. Several analytical 
methods that have been reported for the estimation of nicorandil in biological fluids 
and/or pharmaceutical formulations include high-performance thin layer 
chromatography (HPTLC) [4], high-performance liquid chromatography (HPLC)[5-11], 
and gas chromatography coupled with mass spectrometry [12]. A review of literature 
revealed no UV-visible spectrophotometric method for the assay of nicorandil in 
pharmaceutical formulations. 
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This chapter describes two simple, sensitive, selective, and economical validated 
visible spectrophotometric methods for the assay of nicorandil in drug formulations. 
The assay of drug is based on exploiting the oxidizing property of the drug due to the 
presence of nitrate moiety in the chemical structure of the drug. The first method is 
based on the reaction of the drug with phloroglucinol-sulfanilic acid reagent in 
sulphuric acid medium. The second method uses the oxidative coupling of 3-methyI-2-
benzothiazolinone hydrazone hydrochloride (MBTH) with DL-dopa in the presence of 
nicorandil as oxidant in sulphuric acid medium, resulting in the formation of an 
intensely coloured product. The proposed methods are optimized and validated [13] as 
per the international Conference on Harmonisation (ICH) guidelines. 
EXPRIMENTAL 
Materials and methods 
Apparatus 
A Shimadzu UV-visible spectrophotometer (model 1601, Shimadzu, Kyoto, 
Japan) was used for all UV-visible absorbance measurements with matched quartz cells. 
A water bath shaker (NSW 133, New Delhi, India) was used to control the heating 
temperature for the development of the colour. 
Reagents and Standards 
Phloroglucinol-sulfanilic acid reagent (0.01 M) was prepared by dissolving 
0.0631 g of phloroglucinol in 2 ml of 8 M HCl and 0.0867 g of sulfanilic acid in 25 ml 
of doubly distilled water, separately, and then mixed and diluted to 50 ml with doubly 
distilled water. The solution is stable for 15 days if kept in the dark! For methods A and 
B, 12 and 15 M H2SO4 (BDH), respectively, were prepared and cooled before use. 
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Aqueous solutions of MBTH (0.25%; Otto Chemie, Mumbai, India) and DL-dopa 
(0.1%; Sigma Chemical, St Louis, MO) were freshly prepared in doubly distilled water. 
Nicorandil was kindly provided by Zydus Medica, Ahmedabad, India, and was 
used as received. Commercial dosage forms of nicorandil such as Corflo (Wockhardt, 
Mumbai, India), Korandil (Sun Pharma, Mumbai, India), Nikron (Torrent, Ahmedabad, 
India), and Zynicor (Zydus Medica, Ahmedabad, India) were purchased locally. 
The standard solution of nicorandil (0.05%; 0.5 mg mP') was prepared in doubly 
distilled water. 
Recommended procedures for the determination of nicorandil 
Method A 
Into a series of boiling test tubes, different volumes (0.05-1.0 ml) of 0.05% 
nicorandil were pipetted. To each test tube, 2.5 ml of 12 M sulphuric acid and 2.5 ml of 
0.01 M phloroglucinol-sulfanilic acid reagent were added, mixed well, and heated on a 
water bath at 100°C ± 1°C for 32 min. The tubes were cooled at room temperature (25°C 
± 1°C), and then the contents of the tubes were transferred to 10-ml volumetric flasks 
and diluted to volume with doubly distilled water. The absorbance was measured at 425 
nm against a reagent blank treated similarly except without drug within the stability 
period of 1 hour. The concentration of nicorandil was calculated either from calibration 
curve or from regression equation. 
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Method B 
Aliquots of 0.05 to 0.75 ml of 0.05% nicorandil solution corresponding to 25.0 to 
375.0 fig were pipetted into a series of boiling test tubes. Eight milliliters of 15 M 
H2SO4, 2.5 ml of 0.25% MBTH, and 0.5 ml of 0.1% DL-dopa were added to each tube. 
The contents of each tube were mixed well and heated in a water bath at 100°C ± 1°C 
for 12 min. After cooling at room temperature, the contents of the tubes were 
transferred to 25-ml standard flasks and diluted to volume with doubly distilled water. 
The colour was stable up to 4 hours. The absorbance was measured at 530 nm against 
the reagent blank treated similarly except without drug. A calibration graph was drawn 
and the corresponding regression equation was computed to obtain the concentration of 
nicorandil. 
Preparation of denitrated nicorandil 
Nicorandil (500 mg) was hydrolyzed with 4N HCl and 4N NaOH at 100 ± 1°C for 
30 min. Preparative thin layer chromatography was applied using silica gel G plate and 
chloroform:methanol:ethyl acetate (4:1:5 vol/vol/vol) as mobile phase. The band 
corresponding to the degradation product was located under UV lamp at 254 nm. The 
band was scrapped and extracted with chloroform. The solvent was removed and pure 
degradation product was obtained. 
Procedure for the assay of nicorandil in pharmaceutical formulations 
To minimize a possible variation in the composition of the tablets, the mixed 
contents of 20 tablets were weighed and grounded; then the powder equivalent to 50 mg 
nicorandil was stirred well with dichloromethane and filtered through Whatman No. 42 
filter paper (Whatman International Limited, Kent, UK). The residue was washed with 
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dichloromethane for complete recovery of the drug. The filtrate was evaporated to 
dryness under vacuum and the left drug was taken up with doubly distilled water and 
transferred to a 100-ml standard flask and completed to volume with doubly distilled 
water. The percentage recovery of the drug was calculated from the corresponding 
linear regression equations. 
Procedure for reference method 
Into a series of 25-ml standard volumetric flasks, different volumes containing 0.4 
to 10.0 \xg mP' of drug (0.01%; 0.1 mg ml"') solution were pipetted and diluted to 
volume with doubly distilled water. The absorbance was measured against a solvent 
blank at 262.5 nm. The amount of the drug in a given sample was computed from the 
calibration equation. 
RESULTS AND DISCUSSION 
The electrophilic substitution reaction of phloroglucinol with N2O5 in sulphuric 
acid medium has been studied [14], resulting in the formation of yellow-coloured 
species of l,3,5-trihydroxy-2,4,6-trinitrobenzene. The denitration of nicorandil occurs 
in acidic medium. [4]. Therefore, the reaction of nicorandil with phloroglucinol in 
sulphuric acid medium leads to the formation of l,3,5-trihydroxy-2,4,6-trinitrobenzene, 
which absorbs maximally at 425 nm ^ig. 3.1 %). According to TLC experiments, the 
isolated denitrated nicorandil is more polar than nicorandil due to the denitration 
process. The denitrated nicorandil did not interfere with phloroglucinol, thus confirming 
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Fig. 3.1. Absorption spectra of coloured products of nicorandil (a) 0.9 ml of 0.05% 
nicorandil + 2.5 ml of 12 M H2SO4 + 2.2 ml of 0.01 M phloroglucinol-sulfanilic acid 
and (b) 0.7 ml of 0.05% nicorandil + 8.0 ml of 15 M H2SO4 + 2.6 ml of 0.25% 
MBTH+ 0.6 ml of 0.1% DL-dopa. 
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the reaction of nicorandil with phioroglucinol. The nitrite, which is formed due to 
denitration of nicorandil, interferes positively and must be destroyed by sulfanilic acid. 
Therefore, based on the literature background and experimental findings, the reaction 
mechanism was proposed and is given in Scheme 3.1. 
Nicorandil, being an oxidant, oxidizes MBTH (1) in acidic medium resulting in 
the formation of an electrophilic intermediate (2), which is an active coupling species 
[15,16]. The intermediate of MBTH undergoes electrophilic substitution with the 
phenolic moiety of DL-dopa to form a coloured product showing an absorption peak at 
530 nm (Tig. 3.1 b). The proposed reaction mechanism is presented in Scheme 3.2. 
Optimization of variables 
The spectrophotometric properties of the coloured species formed with methods A 
and B were extensively studied. The optimum conditions for the assay procedures 
(methods A and B) have been established by studying the reactions as a function of 
heating time, concentration of reagents, sulfanilic acid, and stability of the coloured 
species. 
Method A 
Effect of heating time 
To study the effect of heating time for maximum colour development, 0.9 ml of 
0.05% nicorandil was mixed with 2.5 ml of 0.01 M phloroglucinol-sulfanilic acid 
reagent and 2.5 ml of 12 M H2SO4. The contents of the mixture were heated up to 35 
min on water bath at 100 ± 1°C. It is apparent from investigations that the maximum 
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intensity of colour was attained after 30 min of heating and remained constant up to 35 
min. Therefore, the optimum heating time was fixed at 32 min throughout the 
experiment. 
Effect of the concentration of sulphuric acid 
The influence of the volume of 12 M H2SO4 was observed during the formation of 
yellow-coloured product. To study this, an aliquot of drug containing 450 |ag was 
pipetted followed by varying volumes (0.1-2.5 ml) of 12 M H2SO4 and 2.2 ml of 0.01 M 
phloroglucinol-sulfanilic acid. It is evident from (Fig. 3.2 a) that the highest absorbance 
was attained with 2.2 ml of 12 M H2SO4; above this volume the absorbance remained 
unchanged. Therefore, 2.5 ml of 12 M H2SO4 was used in all further measurements. 
Effect of the concentration of phloroglucinol-sulfanilic acid 
To investigate the effect of volume of 0.01 M phloroglucinol-sulfanilic acid reagent for 
colour development, different volumes (0.3-2.5 ml) were mixed with 0.9 ml of 0.05% nicorandil 
and 2.5 ml of 12 M H2SO4. The results are presented in ^ig. 3.2 b) which reveals that the 
addition of 2.2 ml gave the highest absorbance, which remained constant up to 2.5 ml. 
Therefore, 2.2 ml of the reagent was taken for the determination of the drug throughout the 
experiment. 
Method B 
Effect of heating time 
The optimum heating time for the reaction to complete was evaluated by heating a 
mixture containing 0.7 ml of 0.05% nicorandil, 8 ml of 15 M H2SO4, 2.6 ml of 0.25% 
MBTH, and 0.6 ml of 0.1% DL-dopa in a water bath at 100 ± 1°C. The intensity of the 
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Volume (ml) 
Fig. 3.2. Effect of the volume of (a) 12 M H2SO4 and (b) 0.01 M phloroglucinol-
sulfanilic acid reagent (method A); (c) 0.25% MBTH and (d) 0.1% DL-dopa 
(method B). 
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coloured product reached maximum at 10 min and remained constant up to 15 min. 
Therefore, the optimum heating was fixed at 12 min. 
Effect of the concentration of sulphuric acid 
The effect of the volume of 15 M sulphuric acid on colour development of the 
product was investigated by taking 0.7 ml of 0.05% nicorandil with varying volumes 
(0.5-9 ml) of 15 M H2SO4, 2.6 ml of 0.25% MBTH, and 0.6 ml of 0.1% DL-dopa into a 
series of test tubes. The reaction mixture of each test tube was heated in a water bath for 
12 min and transferred to 25-ml standard flasks and diluted to volume with doubly 
distilled water. The highest absorbance was obtained with 7 ml of 15 M H2SO4; above 
this volume, no change in absorbance was recorded. Therefore, 8 ml of 15 M H2SO4 
was used in all determinations. 
Effect of MBTH concentration 
The effect of volume of 0.25% MBTH on the colour development was 
investigated over the range 0.5-3.0 ml. The results are presented in (Fig. 3.2 c) which 
showed that 2.4 ml was adequate to give maximum intensity of the colour. Hence, 2.6 
ml of 0.25% MBTH was used as an optimum value for colour development. 
Effect of DL-dopa concentration 
The effect of DL-dopa concentration was studied by adding different volumes 
(0.05-0.7 ml) of 0.1% DL-dopa, 8 ml of 15 M H2SO4, and 2.6 ml of 0.25% MBTH to a 
constant amount of 350 ^g per 25 ml of nicorandil. It was found that the maximum 
intensity of the violet colour was reached with 0.45 ml of reagent and remained so with 
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higher volumes (Fig. 3.2 d). Therefore, 0.6 ml of the reagent was used throughout the 
experiment. 
Analytical data and calibration graphs 
Under the optimized experimental conditions, straight line calibration graphs were 
obtained over the calibration ranges 2.5-50.0 and 1.0-15.0 fig mP' of nicorandil with 
molar absorptivities of 5.914 x 10^  and 1.500 x lO"* 1 moP' cm"' with methods of A and 
B, respectively. The linear regression equations for both the methods have been 
evaluated by least square treatment of the calibration data (n = 9). Table 3.1 
summarizes Beer's law limit, linear regression equation, correlation coefficient, 
confidence limits, and standard deviations for slope and intercept at 95% confidence 
level, variance, and detection limits for methods A and B. In each method, the 
correlation coefficient was high, indicating the excellent linearity of both the calibration 
graphs. The low values of confidence interval at 95% confidence level for slope and 
intercept of the regression lines pointed toward high reproducibility of the proposed 
methods. In order to verify that the developed methods are free from procedural errors, 
the experimental intercepts, a, of lines of regression were tested for significance of the 
deviation from the expected value zero [17,18]. For this justification, the values 
calculated for / from the relation, / = — were found to be 0.058 and 0.222 for methods 
A and B, respectively, which did not exceed the 95% criterion, 2.365 (v = 7). It is 
concluded that the intercepts for methods A and B are not significantly different from 
zero. Thus, the proposed methods (A and B) are free from constant errors independent 
of the concentration of nicorandil. 
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Table 3.1 
Optical and regression characteristics of the proposed methods 
Parameters 
^inK(nm) 
Beer's law limit (|ig ml"') 
Molar absorptivity (1 mol"' cm"') 
Linear regression equation" 
Intercept (a) 
s. 
tSa" 
Slope (b) 
Sb 
tSb^  
Correlation coefficient (r) 
Variance (So^) 
Detection limit (p.g ml"') 
Method A 
425 
2.5 -50.0 
5.914 X 10^ 
A = 1.164X 
2.805 X 
1.164 X 10' 
2.014 X 10^ 
4.762 X 10^ 
2.805 X 10^  
6.751 X 10' 
1.600 X 10' 
0.9999 
1.142 X 10' 
0.267 
10' + 
lO^C 
Method B 
530 
1.0- 15.0 
1.500 X 10' 
A = 7.619 X 10'+ 
7.099 xlO^C 
7.619 X 10' 
3.431 X 10' 
8.114 X 10' 
7.099 X 10^ 
3.671 X 10' 
8.662 X 10' 
0.9999 
2.830x10^ 
0.017 
"With respect to A = a + bC, where C is the concentration (^ .g ml ') and A is absorbance. 
''Confidence interval of the intercept at 95% confidence level. 
'Confidence interval of the slope at 95% confidence level.of the concentration of nicorandil 
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The detection limit (DL) at 95% confidence level was established using the relation 
[19,20]. 
where n is the number of standard samples (n = 9), t is the value of Student / test for n-2 
degrees of freedom at 95% confidence level and Sg'' = variance. Both the DL and the 
slope of the calibration graphs indicated good sensitivity. The variance was calculated 
using the equation [21]: 
2_|(^exp' Ao/c.) 
n-2 
and was found to be very low for methods A and B, indicating negligible scattering of 
the experimental data points around the line of regression. 
The absolute error, 5„ was calculated in the determination of nicorandil for methods A 
and B by means of statistical analysis of calibration data using the relation [22]: 
-^t 1 , (A-A)' + - + n b'^(C,-Cy 
1/2 
where C and A are the average concentration and absorbance values, respectively, for 
n standard solutions. Figs. 3.3 a and b show the graph of Sc versus the final 
concentration of nicorandil. The error has reached minimum when the actual 
absorbance is equal to the average absorbance corresponding to ~24.7 and 8.0 )ag ml -1 
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Fig. 3.3 a. Error in the determination of tlie concentration of nicorandil obtained 
by statistical analysis of standard calibration data for Method A. 
10"3x8.8 
I 
Nicorandil (^ g ml ) 
Fig. 3.3 b. Error in the determination of the concentration of nicorandil obtained 
by statistical analysis of standard calibration data for Method B. 
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for methods A and B, respectively. The confidence limits for unknown concentrations 
for nicorandil can be determined using the relation Cj ± tSc at a selected confidence 
level and n-2 degrees of freedom. The results are shown in Figs. 3.4 a and b in the form 
tS 
of percentage uncertainty [23], —^x 100 against the concentration of nicorandil at 95% 
confidence level. Thus, the relative uncertainty can be estimated directly on the 
concentration level tested. 
Solution Stability 
The stability of nicorandil solution was examined by recording absorption spectra 
of the solution for several days and by TLC studies, too. The band corresponding to 
degradation product was not observed under UV lamp at 254 nm, and there was also no 
change in the spectra for at least 4 days, when the solution was stored at room 
temperature. 
Specificity 
The specificity of the proposed methods was evaluated by determining the 
nicorandil concentration in the presence of varying amounts of denitrated nicorandil. It 
was found that the degradation product did not react with either reagent. 
Ruggedness 
The ruggedness of the method relative to each operational parameter was 
challenged. The operational parameters investigated were: 
For Method A 
• volume of 12 M H2SO4 (± 0.3 ml) 
• volume of 0.01 M phloroglucinol-sulfanilic acid reagent (± 0.3 ml) 
13 
o 
o 
Nicorandil (^ g ml* ) 
Fig. 3.4. Variation of the confidence limits for (a) method A and (b) method B 
at 95% confidence level and n-2 degrees of freedom. 
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• heating time (± 2.0 min) 
• cooling temperature (± 5°C) 
For Method B 
• volume of 15 M H2SO4 (± 1.0 ml) 
• volume of 0.1% DL-dopa (±0.15 ml) 
• volume of 0.25% MBTH (± 0.2 ml) 
• heating time (± 2.0 min). 
The ruggedness of the proposed methods relative to each operational parameter 
was examined by analyzing the nicorandil tablets under variable experimental 
conditions. For this, a sample solution containing 10 |ag mP' (Korandil-10) was assayed 
5 times using both the methods. The results showed a mean value of 9.99 ± 0.06 \ig mp' 
and 10.02 ± 0.05 |ag mP' with relative standard deviations of 0.60% and 0.54% for 
methods A and B, respectively. These results indicated the ruggedness of the proposed 
methods. 
Robustness 
The method robustness was evaluated by a second analyst using a different 
instrument and freshly prepared standard and sample solutions. The analysis of the 
nicorandil tablets was performed five times at one concentration level by the robustness 
chemist and developing chemist following the recommended procedures. The results 
agreed well within the acceptable limits and no degradate was found to interfere with 
the determination process. These results demonstrated acceptable method robustness. 
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Precision and accuracy 
The short-term precision (intraday precision) of methods A and B were evaluated 
by measuring five independent samples of nicorandil in pure form at three different 
concentration levels (10.0, 30.0, 50.0 ^g mp' for method A and 4.0, 10.0, 15.0 ng ml"' 
for method B), and in pharmaceutical formulations at one concentration level (10 p.g 
ml"'). The standard deviations and relative standard deviations for methods A and B 
were in the range of 0.04 to 0.42 ^g ml"', 0.16% to 0.92%, and 0.05 to 0.12 \ig ml"', 
and 0.50% to 1.13%, respectively. In the same manner, the assay for daily precision 
(inter day precision) at each concentration level was repeated for five consecutive days. 
The standard deviations and relative standard deviations for methods A and B were 
found to vary over the range 0.05 to 0.56 ^g ml"', 0.19% to 1.12%, and 0.05 to 0.15 ng 
ml"', and 0.55% to 1.29%, respectively. The values of standard deviation and relative 
standard deviation can be considered to be very satisfactory, and thus the proposed 
methods (A and B) are very effective for the determination of nicorandil in pure form 
and pharmaceutical formulations. 
The reliability and accuracy of the proposed methods were further ascertained through 
recovery studies using the standard addition method. For this purpose, a fixed amount 
of nicorandil from preanalyzed tablets was taken and an amount of the pure drug 
(standard) at two different concentration levels was added and the total amount was 
estimated by the proposed methods A and B. Each level was repeated five times using 
four different commercial pharmaceutical formulations. The results obtained for 
methods A and B through the standard addition method showed that the mean 
recoveries and relative standard deviations were in the range of 99.93% to 100.53%, 
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0.14% to 0.87%, 99.95% to 100.97%, and 0.45% to 1.15%, respectively, which can be 
considered to be very satisfactory. No interference from commonly encountered tablet 
excipients such as talc, starch, gum acacia, lactose, sodium alginate, and magnesium 
stearate was observed in the determination. Methods A and B were successfully applied 
to the determination of nicorandil in pharmaceutical formulations. The results of the 
proposed methods (A and B) were compared with those of the reference method using 
point hypothesis tests. Table 3.2 shows that the calculated / and F values are less than 
theoretical ones [24], confirming accuracy and precision are within the acceptable limits 
and indicating no significant difference between the performance of the proposed 
methods and the reference method at 95% confidence level. The interval hypothesis 
tests [25] have also been performed to compare results of the proposed methods (A and 
B) with those of the reference method at 95% confidence level (Table 3.3). The usual 
practice in attempting the point and interval hypothesis tests in hospitals and 
laboratories is to make sure that the standard deviation values of each assay are within 
the acceptable limits. Once this is established, the actual analytical error is usually 
ignored and not reported along with the concentration itself [26]. Hence, it was decided 
that a bias of ±2% is acceptable. Therefore, the limit of acceptance interval is within 9L 
= 0.98 and 9u =1.02. It is clear from Table 3.3 that the true bias of all samples is smaller 
than ±2%. The interval hypothesis tests draw the same conclusion as the point 
hypothesis tests. Thus, the proposed methods shown here are accurate, precise, and 
validated. 
The proposed methods are sensitive and selective owing to the oxidizing nature of 
the drug, which preferentially interacts with reagents described in the subsection 
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Table 3.3 
Interval hypothesis test: comparison of the proposed methods with the reference 
method at 95% confidence level 
Pharmaceutical 
Formulations 
Corflo-10 
(Wockhardt) 
Korandil-10 
(Sun Pharm) 
Niicron-10 
(Torrent) 
Zynicor-10 
(Zydus Medica) 
Lower Limit 
(60 
0.990 
0.989 
0.991 
0.990 
Method A 
;' Upper Limit* 
(Ou) 
1.007 
1.007 
1.011 
1.012 
Method B 
Lower Limit* 
(OL) 
0.991 
0.992 
0.990 
0.990 
Upper Limit* 
(Ou) 
1.008 
1.009 
1.009 
1.011 
* In pharmaceutical analysis, a bias, based on recovery experiments, of ± 2% (9L=0.98 and 9u 
=1.02) is acceptable. 
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Reagents and Standards, but its major metabolite (denitrated nicorandil) did not give the 
positive results with the reagents used. Point and interval hypothesis tests and recovery 
data clearly proved that the proposed methods have acceptable precision, accuracy, and 
linearity. 
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KINETIC SPECTROPHOTOMETRIC 
METHOD FOR THE DETERMINATION OF 
RAMIPRIL IN PHARMACEUTICAL 
FORMULATIONS 
123 
INTRODUCTION 
Ramipril is an angiotensin converting enzyme (ACE) inhibitor that lowers 
peripheral vascular resistance without affecting heart rate. It is used in the treatment 
of hypertension and congestive heart failure [1]. The role of this drug is to inhibit 
last step of the biosynthesis of angiotensin II, a potent vasoconstrictor, and 
therefore,it causes a general vasodilatation and lowers blood pressure [2]. The drug 
is chemically known as 2-[N- [(S)-l-ethoxy carbonyl-3-phenyl propyl]-L-alanyl]-
(IS, 3S, 5S)-2-azabicyclo [3,3,0]-octane-3-carboxylic acid and is official in 
Martindale The Extra Pharmacopoeia [3]. The drug is also officially listed in British 
Pharmacopoeia [4], which describes a potentiometric titration procedure for its assay 
in bulk and dosage form. The different analytical methods that have been reported 
for its determination include high performance liquid chromatography [5-13], liquid 
chromatography [14], liquid chromatography coupled with mass spectrometry [15], 
gas chromatography [16,17], capillary electrophoresis [18,19], radio immunoassay 
[20], potentiometry [21-23], and voltammetry [24-26]. 
The estimation of ramipril along with hydrochlorothiazide in binary mixture 
was carried out by derivative compensation technique [27] as well as zero crossing 
derivative technique [28,29]. Two spectrophotometric methods have been reported 
for the assay of drug in commercial dosage forms, which are based on the formation 
of ternary complex of the drug with Cu (II) and eosin [30]; and Fe (III) and 
ammonium thiocyanate [31]. The drug content in pharmaceutical formulations has 
been determined spectrophotometrically in visible region based on the charge 
transfer reaction of ramipril with 7i-acceptors such as 7,7,8,8-
tetracyanoquinodimethane and p-chloranilic acid and subsequently 
measuring the absorbance at 840 and 520 run, respectively [32]. Two 
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extractive spectrophotometric methods [33] have been recommended based 
on extractive ion pair complex of the drug with picric acid and bromocresol 
green. Potassium permanganate oxidizes ramipril in alkaline medium 
resulting in the formation of bluish green coloured complex peaking at 610 
nm [34]. The quantitation of ramipril [35] has been done by 
spectrophotometry and fluorimetry utilizing the reaction of the drug with 7-
fluoro-4-nitrobenzo-2-oxo-l, 3-diazole which exhibits maximum absorbance 
at 460 nm, and maximum fluorescence intensity at 530 nm after excitation at 
465 nm. However, a simple kinetic spectrophotometric method based on the 
oxidation of ramipril with any oxidant is not known. Therefore, there is a 
need for a simple kinetic spectrophotometric method for the determination of 
ramipril in commercial dosage forms. 
This chapter describes the development and validation of a kinetic 
spectrophotometric method for the determination of ramipril in 
pharmaceutical formulations. The method is based on the reaction of — 
COOH group of ramipril with a mixture of iodide-iodate in aqueous medium 
resulting in the formation of yellow colour, which absorbs maximally at 352 
nm. The absorbance increases with time and therefore, two calibration 
procedures i.e. initial-rate and fixed time methods are adopted for the 
determination of ramipril in commercial dosage forms. 
EXPERIMENTAL 
Apparatus 
A Shimadzu UV-visible 1601 spectrophotometer (Japan) with matched quartz 
cells was used for all spectral and absorbance measurements. 
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Materials 
All chemicals and reagents used were of analytical or pharmaceutical grade. 
Market product and Test solution 
Pure drug of ramipril was kindly gifted by Dr. Reddy's Laboratories Limited, 
(Andhra Pradesh, India) and was used as received. Pharmaceutical preparations of 
ramipril such as Hopace-5 (Cardicare, Bangalore, India), Ramipres-5 (Cipla, 
Mumbai, India), Ramace-5 (AstraZeneca, Mumbai, India) and Variace-5 (Win 
Medicare, New Delhi, India) were purchased from local market. 
The standard test solution of ramipril (0.05 %) was prepared in doubly 
distilled water. The solution is stable if kept in amber-coloured bottle in the cold. 
Reagents 
A 0.15 M KI (FLUKA Chemie AG, Switzerland) solution was freshly 
prepared in doubly distilled water. The solution was standardized by the 
recommended procedure [36]. A 0.1 M KIO3 (FLUKA Chemie AG, Switzerland) 
was also freshly prepared in doubly distilled water. 
Recommended procedures for the determination of ramipril 
Initial rate method 
Aliquots of 0.2-1.4 ml standard solution of ramipril (0.5 mg ml'') were 
pipetted into a series of 10 ml standard volumetric flasks. In each flask, 2.2 ml of 0.1 
M KIO3 followed by 3.3 ml of 0.15 M KI were added and then diluted to volume 
with doubly distilled water at 25±1°C. The contents of each flask were mixed well 
and the increase in absorbance at 352 nm was recorded as a function of time against 
the reagent blank prepared similarly. The initial rate of the reaction (v) at different 
concentrations was obtained from the slope of the tangent to the absorbance-time 
curve. The calibration curve was constructed by plotting the logarithm of the initial 
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rate of reaction (log v) versus the logarithm of the molar concentration of the 
ramipril (log C). The amount of the drug was obtained either from the calibration 
graph or the regression equation. 
Fixed-time method 
In the fixed time method, the absorbance at 352 nm of each sample solution 
was measured at a preselected fixed time against a reagent blank prepared similarly. 
The calibration curve was constructed by plotting the absorbance against the final 
concentration of the drug. The amount of the drug in each sample was computed 
either from calibration curve or regression equation. 
Procedure for the determination of ramipril in drug formulations 
An amount of the tablet or capsule equivalent to 50 mg of ramipril was 
extracted into 5 x 10ml portions of methanol and filtered through Whatmann No. 42 
filter paper. The residue was washed well with methanol for complete recovery of 
the drug. The methanol was evaporated to dryness under vacuum and the remaining 
drug was dissolved in doubly distilled water and diluted to 100 ml. The assay was 
completed following the recommended procedures for the determination of ramipril. 
Procedure for reference method 
Aliquots of 0.2-1.0 ml of 0.1 % ramipril were pipetted into a series of 50.0 ml 
separating funnels. Into each separating fimnel, volume of solution was adjusted to 
10.0 ml with doubly distilled water and 3.0 ml of 0.2% Cu (II) sulfate solution 
followed by 1.0 ml of 0.1% eosin solution were added successively and mixed well. 
The ftinnels were shaken vigorously with 3.0x3.0 ml portions of chloroform for 1.0 
min, and then allowed to pass the organic layer through anhydrous sodivun sulfate 
into a 10.0 ml standard volumetric flask. The volume of chloroform layer was made 
up to 10.0 ml and the absorbance was measured at 535 nm against the reagent blank 
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prepared similarly. The amount of the drug in a given sample was computed either 
from calibration graph or regression equation. 
RESULTS AND DISCUSSION 
Spectral studies 
The absorption spectrum of aqueous solution of ramipril shows two absorption 
bands at 210 nm and 234 nm. The addition of aqueous solutions of KI and KIO3 to 
the drug solution causes change in the absorption spectrum with new characteristic 
bands peaking at 298 and 352 nm (Fig. 4.1). The blank solution prepared similarly 
as the sample solution except drug shows one peak at 275 nm and a negligible 
absorbance at 352 nm. In order to avoid the maximum interference from the reagent 
blank, the absorbance measurements for the sample solution were made at 352 nm. 
The equilibrium is attained in about 50 min. Therefore, a kinetically based 
spectrophotometric method was developed for the quantitative determination of 
ramipril by measuring the increase in absorbance at 352 nm as a function of time. 
Mechanism of the colour reaction 
It has been suggested that water-soluble acidic compoimds liberate iodine 
from a solution containing both KIO3 and KI according to the reaction [37]: 
Sr +10; +6H' -^3H^O + 3I^ 
The occurrence of the reaction is revealed by a yellowing of the solution. The yellow 
colour of the solution is due to the formation of I2, which immediately converted 
into triiodide ions in the presence of iodide ions {I2+1' ^ I-^ ) exhibiting 
absorption maxima at 290 run and 360 nm [38]. 
Ramipril, a water-soluble ACE inhibitor, possesses -COOH group in its 
moiety and hence imdergoes a similar reaction with iodide-iodate mixture resulting 
in the evolution of iodine. The liberated iodine immediately combines with 
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200 220 240 260 280 300 320 340 360 380 400 420 
Wavelength (nm) 
Fig. 4.1. Absorption spectra of (a) drug solution: ramipril (50.0 ^g ml'') in 
doubly distilled water; (b) blank solution: 3.3 ml of 0.15 M potassium iodide 
and 2.2 ml of 0.1 M potassium iodate and (c) sample solution: ramipril (50.0 ^ g 
ml') + 3.3 ml of 0.15 M potassium iodide and 2.2 ml of 0.1 M potassium iodate. 
Each set is diluted to 10 ml with doubly distilled. 
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potassium iodide to give triiodide ions showing absorption maxima at 293 nm and 
352 nm. The reaction sequence is shown in Scheme 4.1. The confirmatory test for 
the presence of iodine in the final solution of the drug is established by the blue 
colour, which appears on addition of starch solution [39]. 
Optimization of variables 
Preliminary experiments were carried out to determine the optimum 
conditions of the variables used in the estimation of ramipril. The optimum values of 
the variables were maintained throughout the experiment. 
Effect of the concentration of potassium iodate 
The effect of the concentration of potassium iodate was studied by treating 
50.0 ^g ml"' ramipril with 3.3 ml of 0.15 M KI and varying volumes (0.5-2.5 ml) of 
0.10 M KIO3. The kinetic slope (tan a =dA/dt) of the absorbance-time curves 
obtained at different volumes of KIO3 showed that the initial rate of reaction was 
increased with increasing volume of KIO3 and became constant at 2.0 ml; above this 
volume, the initial rate of reaction remained unchanged (Fig. 4.2 a). Therefore, 2.2 
ml of KIO3 (0.10 M) was used in all measurements. 
Effect of the concentration of potassium iodide 
The influence of the volume of 0.15 M KI on the rate of reaction was investigated in 
the range of 0.5-3.5 ml. The initial rate of reaction (Fig. 4.2 b) was increased with 
increasing volume of KI and became constant at 3.0 ml; beyond this volume, the 
initial rate remained constant. Therefore 3.3 ml of 0.15 M KI was recommended for 
determination procedures. 
Analytical data 
The kinetic plots (Fig. 4.3) are all sigmoid in nature and therefore, the initial 
rate of reaction was determined by measuring the slopes (tan a = dA/dt) of the 
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[1] 
C2H5O-C 
H O 
Ramipril 
medium 
C2H5O—C 
+ 3I2 + 3H2O 
[2] I2 +1 
—" I3 
Colored species 
Scheme 4.1 
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0.40 
1 2 3 
Volume Of KIO3/KI (ml) 
Fig. 4.2. Effect of the volume of (a) 0.10 M potassium iodate and (b) 0.15 M 
potassium iodide on the initial rate of reaction. 
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4 6 
Time (min) 
10 
Fig. 4.3. Absorbance-time curves for the reaction of varying concentration of 
ramipril with potassium iodate and potassium iodide. Concentration of 
ramipril (^ g ml-^ ): (a) 10, (b) 20, (c) 30, (d) 40, (e) 50, (f) 60 and (g) 70. 
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initial tangent to the absorbance-time curves at different concentrations of the drug. 
The order with respect to ramipril was evaluated by plotting logarithm of the initial 
rate of reaction versus logarithm of the molar concentration of ramipril and was 
found to be one. 
Under the optimized experimental conditions, the assay of ramipril was 
carried out in presence of excess concentration of KIO3 and KI in aqueous solutions 
with respect to ramipril concentration. Therefore, a pseudo zero order reaction 
condition was worked out with respect to the reagents concentrations. The initial rate 
of reaction would follow a pseudo first order and obeyed the following rate 
equation: 
Rate = AA/At= K'C 
where A!"'is the rate constant, C is the concentration of ramipril, n is the order of 
reaction. The logarithmic form of the equation is written as: 
Log (rate) = log A:' + n log C. 
A calibration curve was constructed by plotting the logarithm of the initial rate 
of reaction (log v) versus logarithm of initial concentration of ramipril (log C), 
which showed a linear relationship over ramipril concentration of 10.0-70.0 ^g ml"'. 
The linear regression analysis using the method of least square treatment of 
calibration data (n=7) was made to evaluate slope, intercept and correlation 
coefficient. The regression of log rate versus log C gave the following linear 
regression equation: 
Log (rate) = 3.5665 + 1.0277 log C 
with a correlation coefficient (r) of 0.9998. 
The value of 'n' representing order of reaction in the regression equation is 
one, confirming the first order reaction with respect to the ramipril concentration. 
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The limit of detection (LOD) for initial rate method was calculated [40] by 
statistical treatment of calibration data (n=7) by considering seven calibration points 
using the following equation: 
LOD = c 2 n-2 So X 
n-\ 
1/2 
1 
where n is the number of standard samples (n = 7), t is the value of student's t for n-
2 degrees of freedom at 95% confidence level, b is the slope of the regression line 
and So^  is the variance characterizing the scatter of the experimental data points with 
respect to the line of regression. The variance was calculated using the equation 
[41]: 
" n-2 
Linear dynamic range, correlation coefficient, variance, detection limit, 
standard deviations and confidence limits for slope and intercept of the calibration 
line are summarized in Table 4.1. The low values of variance confirmed negligible 
scattering of the experimental data points around the line of regression and good 
sensitivity of the proposed method. 
Fixed time method 
In this method, the absorbance of a yellow coloured solution Q^max= 352 nm) 
was recorded at a preselected fixed time. Calibration graphs of absorbance 
versus initial concentration of ramipril at seven concentration levels were plotted at 
a fixed time of 2, 4, 6, 8, and 10 min. Beer's law limit, molar absorptivity, linear 
regression equation, coefficient of correlation, detection limit, variance, standard 
deviation and confidence limits for slope and intercept are summarized in Table 4.2. 
Test of significance of the intercepts, a, of regression lines of the fixed time method 
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Table 4.1 
Spectral and statistical data for the determination of ramipril by initial rate 
method 
Parameters Initial rate method 
^ax(nm) 
Linear dynamic range (jig ml'') 
Regression equation 
S„^  
Intercept (a) 
Sa 
itSa" 
Slope (b) 
Sb 
±tSb^ 
Correlation coefficient (r) 
Variance (So )^ 
Detection limit (fig ml"') 
352 
10.0-70.0 
log (rate)= 3.5665 + 1.0277 log C 
6.388x10-^ 
3.5665 
3.595x10"^ 
9.243x10-^ 
1.0277 
8.768x10-^ 
2.254x10"' 
0.9998 
4.080x10"' 
0.020 
"Standard deviation of the calibration line 
b Confidence interval of the intercept at 95 % confidence level. 
Confidence interval of the slope at 95 % confidence level. 
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at different intervals of time showed that these values of 'a' did not differ 
significantly from the theoretical value, zero. For this, a simplified method was used 
to calculate the quantities 't' from the relation t =a/Sa [42,43] and their comparison 
with the tabulated data fi'om the student's t-distribution [44]. The t-values for fixed 
time method at 2, 4, 6, 8 and 10 min do not exceed the 95 % criterion (t = 2.571). It 
confirmed that the calculated intercepts for the fixed time method are not 
significantly different from zero. Thus, the fixed time methods are free from 
constant errors independent of the concentration of ramipril. It is apparent from 
Table 4.2 that the most acceptable values of the intercept, standard deviation of the 
slope and intercept and detection limit were obtained at a fixed time of 6 min. 
Therefore, the fixed time of 6 min was recommended for the assay of ramipril in 
drug formulations. 
Accuracy and precision of the proposed methods 
The accuracy and precision of the proposed methods was established by measuring 
the content of ramipril in pure form at three different concentration levels. The intra 
day precision of the proposed methods was performed by carrying out five 
independent analyses at each concentration level within one day (Table 4.3). The 
standard deviations (SD) and relative standard deviations (RSD) for initial rate and 
fixed time methods were in the range of 0.105-0.117 |ag ml"', 0.167-0.563 % and 
0.053-0.072 fig ml'', 0.103-0.264 %, respectively. The inter day precision was 
evaluated by measuring the ramipril content at each concentration level on five 
consecutive days by initial rate and fixed time methods (Table 4.4). The results 
(Table 4.3 and 4.4) can be considered to be very satisfactory. Thus the proposed 
methods are veiy effective for the assay of ramipril in drug formulations. 
138 
Table 4.3 
Intra day assay: test of precision of the proposed methods for the determination of 
ramipril 
Proposed methods 
Initial rate method 
Fixed time method 
Amount 
Taken 
20.0 
40.0 
70.0 
20.0 
40.0 
70.0 
Found ± SD' 
20.012 ±0.113 
39.994 ±0.105 
69.988 ±0.117 
20.031 ±0.053 
39.993 ± 0.053 
70.037 ± 0.072 
Recovery ± RSD* 
(%) 
100.058 ±0.563 
99.985 ± 0.264 
99.983 ±0.167 
100.153 ±0.264 
99.980 ±0.133 
100.053 ±0.103 
SAE' ' 
0.050 
0.047 
0.052 
0.024 
0.024 
0.032 
C.L.'= 
0.140 
0.131 
0.145 
0.066 
0.066 
0.089 
"Mean for five determinations. 
''SAE, standard analytical error. 
"C.L., confidence limit at 95% confidence level and four degrees of freedom (t =2.776). 
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Table 4.4 
Inter day assay: test of precision of the proposed methods for the determination of 
ramipril 
Proposed methods 
Initial rate method 
Fixed time method 
Amount 
Taken 
20.0 
40.0 
70.0 
20.0 
40.0 
70.0 
(Hgml ' ) 
Found ± SD' 
19.992 ±0.124 
40.105 ±0.253 
70.044 ±0.182 
20.005 ± 0.056 
40.031 ±0.085 
69.987 ± 0.072 
Recovery 
± RSD' (%) 
99.957 ±0.618 
100.262 ±0.631 
100.062 ±0.260 
100.026 ±0.282 
100.077 ±0.213 
99.981 ±0.103 
SAE*" 
0.055 
0.113 
0.082 
0.025 
0.038 
0.032 
C.L.' 
0.1 53 
0.314 
0.260 
0.070 
0.106 
0.089 
*Mean for five determinations. 
""SAE, standard analytical error . 
*^C.L., confidence limit at 95% confidence level and four degrees of freedom (t =2.776). 
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The validity of the proposed methods was presented by recovery studies using the 
standard addition method. For this purpose, a known amount of pure drug was 
added to preanalysed tablets and capsules and then analyzed following the 
recommended procedures. The results (Table 4.5) were reproducible with low SD 
and RSD. No interference from the common excipients was observed. 
The applicability of the proposed methods for the determination of ramipril has been 
tested on commercially available pharmaceutical formulations. The results of the 
proposed method (initial rate or fixed time) were compared with those obtained by 
the reference method [30] using point hypothesis test. The student's t- and F-values 
(Table 4.6) at 95% confidence level did not exceed the tabulated t and F-values, 
confirming no significant differences between the performance of the proposed 
methods and the reference method. Once this is done, the evaluation of the bias is 
made using the interval hypothesis test as an alternate. Therefore, the interval 
hypothesis test [45] has been performed to compare the results of the proposed 
methods with those of the reference method at 95% confidence level (Table 4.7). 
The Canadian Health Protection Branch has recommended that a bias, based on 
recovery experiments, of ± 2 % is acceptable [46]. It is evident fi-om Table 4.7 that 
the true bias of all samples is smaller than ± 2 %. The interval hypothesis test has 
also confirmed that accuracy and precision are within the acceptable limits and 
indicated no significant differences between the performance of the methods 
compared at 95% confidence level. 
The proposed methods are quite simple and do not require any pretreatment of 
the drug and tedious extraction procedure. The methods have wider linear dynamic 
range with good accuracy and precision. Point hypothesis and interval hypothesis 
tests proved that the proposed methods have acceptable bias of ± 2 %. Hence, the, 
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Table 4.7 
Interval hypothesis test: comparison of the proposed methods with the reference 
method at 95% confidence level 
Formulations 
Tablet 
Hopace 
Ramipres 
Capsule 
Ramace 
Variace 
Initial rate method 
Lower limit" Upper limit* 
(eo 
0.981 
0.986 
0.982 
0.982 
(Ou) 
1.017 
1.015 
1.018 
1.017 
Fixed time method 
Lxjwer limit* Upper limit* 
(OL) 
0.987 
0.986 
0.988 
0.986 
(eu) 
1.013 
1.013 
1.012 
1.013 
*In pharmaceutical analysis, a bias, based on recovery experiments, of 
±2% (eL= 0.98 and 0u= 1.02) is acceptable. 
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the, the proposed methods (initial rate and fixed time methods) can be recommended for 
routine analysis of ramipril in quality control laboratories. 
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OPTIMIZED AND VALIDATED KINETIC 
SPECTROPHOTOMETRIC METHOD FOR 
THE DETERMINATION OF SILYMARIN 
I N DRUG FORMULATIONS 
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INTRODUCTION 
Silymarin i.e. 3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxy phenyl)-2-
(hydroxy-methyl)-l,4-benzodioxan-6-yI]-4-chromanone is a free radical scavenger 
and an important antihepatotoxic drug. It has been used for the treatment of Hver 
diseases of different etiology due to its hepatoprotective activity [1-4] that is 
considered to involve antioxidation, inhibition of lipid peroxidation and the 
membrane stabilizing effects. Thus its broad pharmacological effects have generated 
a keen interest in the drug and therefore, the analysis of its dosage form is very 
important. 
The drug is officially listed in Martindale The Extra Pharmacopoeia [5]. The 
assay of the drug in pure and dosage forms is only listed in the monograph of The 
Italian Pharmacopoeia [6], which describes UV-vis spectrophotometric method, and 
therefore require much more investigation. The different analytical methods that 
have been reported for its determination include high performance liquid 
chromatography [7-18], thin layer chromatography [19-25], high performance thin 
layer chromatography [26], potentiometric titration [27], diffuse-reflectance fourier 
transform infrared spectroscopy [28] and UV spectrophotometry [29,30]. 
Few spectrophotometric methods have been reported for the assay of silymarin 
based on the formation of coloured complex of the drug wdth 2,4-dinitrophenyl 
hydrazine in the presence of tetramethyl amine hydroxide [31]; reaction with 
diazotized sulfanilic acid in alkaline medium to form orange-red coloured 
chromogen [32]; oxidation by Fe (III) and reduced Fe (II) was estimated with 1,10-
phenanthroline at 510 nm and reaction with Folin-Ciocalteau reagent to form a blue 
coloured complex in the presence of NaOH and subsequent determination was done 
at 740 rmi [33]. It has also been determined in drug formulations based on its 
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oxidation with potassium permanganate at neutral pH by measuring a decrease in 
absorbance at 530 nm [34]. The Hterature is still poor with regard to analytical 
methods based on kinetics for the determination of silymarin in dosage forms. 
Therefore, there is a need for another kinetic approach to evaluate the drug for its 
determination in commercial dosage forms. 
This chapter describes a new optimized and validated kinetic 
spectrophotometric method for the determination of silymarin in commercial dosage 
forms. The method is based on the oxidation of silymarin with potassium persulfate 
in alkaline medium and further coupling of the oxidized product of drug with the 
electrophilic intermediate of 3-methyl-2-benzothiazolinone hydrazone hydrochloride 
(MBTH) resulting in the formation of an intensely coloured species, which absorbed 
maximally at 430 nm. The initial-rate and fixed-time methods are applied for the 
determination of silymarin. 
EXPERIMENTAL 
Apparatus 
All spectral and absorbance measurements were made on a Shimadzu UV-
visible 1601 spectrophotometer (Japan) with matched quartz cells. 
Materials 
All reagents used were of analytical or pharmaceutical grade. Aqueous 
solutions of 1.11 x 10"^  M potassium persulfate and 1.07 x 10'^  M MBTH were 
freshly prepared. A 0.3 M sodium carbonate solution was prepared by dissolving 
3.18 g of sodium carbonate in 100 ml doubly distilled water. 
Test Solution 
Pure drug of silymarin was kindly provided by Micro Labs, Bangalore, India 
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and was used as received. Commercial dosage forms of silymarin such as silybon 
(Micro Labs), silyrin (Talent Labs), sivylar (Ranbaxy), silimar (German Remedies) 
were purchased locally. The standard test solution of silymarin (0.2 %) was prepared 
in ethanol. 
Recommended procedures for the determination of silymarin 
Initial-rate method 
Aliquots of 0.20-2.40 ml standard solution of silymarin were pipetted into a 
series of 25 ml standard volumetric flasks followed by 3.5 ml each of 1.11 x 10"^  M 
potassium persulfate, 0.3 M sodium carbonate and 1.07 x 10"^  M MBTH and then 
diluted to volume with ethanol at 15±1°C. After mixing, the contents of each flask 
were immediately transferred to spectrophotometric cell and the increase in 
absorbance was recorded at 430 nm as a function of time for 15 min. The initial rate 
of the reaction (v) at different concentrations was obtained from the slope of the 
tangent to the absorbance-time curve. The calibration curve was constructed by 
plotting the logarithm of the initial rate of reaction (log v) versus the logarithm of 
the molar concentration of the silymarin (log C). The amount of the drug was 
evaluated either from the calibration graph or the regression equation. 
Fixed-time method 
In the fixed time method, the absorbance of each sample solution was 
measured at 430 nm against a reagent blank prepared similarly except drug at a 
preselected fixed time. The calibration curve was obtained by plotting the 
absorbance against the final concentration of the drug. The amount of the drug was 
computed either from calibration curve or regression equation. 
Procedure for the determination of silymarin in drug formulations 
An amount of the tablet or capsule equivalent to 50 mg of silymarin was 
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weighed accurately, and extracted into 3 x 20 ml portions of chloroform with 
shaking. The residue was filtered using Whatmann No. 42 filter paper. The filtrate 
was evaporated to dryness under vacuum and the remaining drug was dissolved in 
ethanol and diluted to 25 ml. The assay was completed following the recommended 
procedures. 
RESULTS AND DISCUSSION 
Spectral studies 
The alcoholic solution of silymarin exhibits two absorption maxima located at 
227 and 290 nm. The addition of aqueous solutions of potassium persulfate, MBTH 
and sodium carbonate to the solution of drug produced a new characteristic band 
peaking at 430 nm. The blank solution was prepared similarly as the sample solution 
except drug, which does not show any peak at 430 nm. This characteristic band is 
due to the formation of an oxidative coupling product between oxidized drug and 
MBTH in the presence of potassium persulfate in alkaline medium at room 
temperature. The intensity of the colour increases with time and the equilibrium is 
attained in about 50 min. Therefore, a kinetically based spectrophotometric method 
was developed for the determination of silymarin by measuring the increase in 
absorbance at 430 nm as a fimction of time. 
Optimization of variables 
The influence of the variables on the rate of reaction was studied and thus 
optimized. The optimum values of the variables were maintained throughout the 
experiment. 
Effect of Potassium persulfate concentration 
The influence of the potassium persulfate concentration on the rate of reaction 
was studied by treating 160.0 \ig ml'' silymarin with 4.0 ml of 1.07 x 10"^  M MBTH, 
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4.0 ml of 0.3 M NaaCOa and varying volumes (0.5 - 4.0 ml) of 1.11 x 10'^  M 
potassium persulfate. The slope (tan a = dA/dt) of the absorbance-time plots 
obtained at different volumes of the reagent concentration showed that the initial 
rate of reaction increased with increasing volume of potassium persulfate and 
became constant at 2.5 ml, above this volume initial rate of reaction remained 
constant (Fig. 5.1a). Thus the adoption of 3.5 ml of 1.11 x 10"^  M potassium 
persulfate proved to be sufficient for the maximum concentration of silymarin used 
in the determination process. 
Effect ofMBTH concentration 
The effect of the volume of 1.07 x 10"^  M MBTH was studied in the range 0.5-
4.0 ml. As can be seen from Fig. 5.1b, the initial rate of reaction increased with 
increasing volume of 1.07 x 10"^  M MBTH and remained constant at 2.5 ml. Further 
increase in volume of the reagent up to 4.0 ml caused no change in the rate of 
reaction. Hence 3.5 ml of 1.07 x 10'^  M MBTH was used as an optimum value. 
Effect of sodium carbonate concentration 
The influence of the volume of 0.3 M Na2C03 on the rate of reaction was 
investigated in the range of 0.5 - 4.0 ml. The initial rate of reaction (Fig. 5.1c) 
increased with increasing volume of reagent and became constant at 2.5 ml, above 
which up to 4.Q ml, initial rate of reaction remained constant. Therefore, 3.5 ml of 
0.3 M Na2C03 was recommended for the determination procedures. 
Mechanism of the colour reaction 
Polyhydroxyl flavonoids undergo oxidation with potassium persulfate 
in alkaline medium [35]. In this oxidation, a hydroxyl group para to an 
existing hydroxyl group is most conveniently introduced. Silymarin is a 
naturally occurring 3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxy phenyI)-2-
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Fig. 5.1a. Effect of the volume of 1.11 x 10' M potassium persulfate on initial 
rate of reaction (silymarin, 160.0 ^g ml"'). 
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(hydroxy-methyl)-l,4-benzodioxan-6-yl]-4-chromanone. It is believed that silymarin 
as other polyhydroxyl flavonoids follows the same Elbs reaction and para nuclear 
oxidation takes place with persulfate in alkaline medium. At the same time MBTH 
also reacts with the reagents forming an electrophilic intermediate, which is an 
active coupling species [36,37]. Finally, the coupling of the oxidized form of the 
drug v^th electrophilic intermediate of MBTH results in the formation of an 
intensely coloured product, which absorbs maximally at 430 nm. The possible 
reaction sequence is shown in Scheme 5.1. 
Analytical data 
The oxidation of silymarin by potassium persulfate in alkaline medium and 
coupling of the oxidized product of the drug with MBTH at 15±1°C was studied 
spectrophotometrically by measuring the increase in absorbance at 430 nm. The 
absorbance-time curves are shown in Fig.5.2, which are all sigmoid in nature. The 
initial rates of reaction were determined by measuring the slopes (tan a = dA/dt) of 
the initial tangent to the absorbance-time curves at different concentrations of the 
drug. The order with respect to silymarin was evaluated by plotting logarithm of the 
initial rate of reaction versus logarithm of the molar concentration of silymarin and 
was found to be one. 
Under the optimized experimental conditions, the determination of silymarin 
was carried out in presence of large excess of potassium persulfate, sodium 
carbonate and MBTH solutions with respect to the initial concentration of silymarin. 
As a result pseudo zero order reaction condition was obtained with respect to their 
concentrations. Therefore, the rate of reaction would follow a pseudo first order and 
was found to obey the following rate equation: 
Rate = AA/ At = K'C" 
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[1] 
OH O 
alkaline medium 
Chromanone (I) 
OH O 
OH 
H a ^ O' 
OH 
O. /CH2OH 
OCH. 
Quinol (II) 
[2] 
~N ^N-NH2 K2S2O8 
CH3 
MBTH (III) 
N = N H 
alkaline medium Q|^ 
Intermediate of MBTH (IV) 
13] II + IV Oxidative coupling 
OH O 
N = OH 
CH, 
OH 
Oxidative coupling product (colored) 
Scheme 5.1 
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1.50 
8 10 
Time (min) 
16 
Fig. 5.2. Absorbance-time curves at different concentrations of silymarin: (a) 
3.317x10-^  M, (b) 6.634x10-^  M, (c) 9.950xl0' M, (d) 13.267x10-^  M, (e) 
16.584x10-^  M, (f) 26.534x10-^  M, (g) 33.168x10-' M, (h) 36.484x10-' M, (i) 
39.801x10-' M, in 1.554x10-^  M potassium persulfate, 1.498x10 ^ M MBTH and 
0.042 M Na2C03. 
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where K is the rate constant, C is the concentration of silymarin, n is the order of 
reaction. The logarithmic form of the equation is written as: 
Log (rate) = log K + n log C. 
A calibration curve was constructed by plotting the logarithm of the initial rate 
of reaction (log v) versus logarithm of initial concentration of silymarin (log C), 
which showed a linear relationship over silymarin concentration range of 16.0-192.0 
fig ml"'. The linear regression equation for the initial rate method was obtained by 
the method of least square treatment of calibration data (n=9). The regression of log 
rate versus log C gave the following regression equation: 
Log (rate) = 2.798 + 1.00 log C 
with a correlation coefficient of r = 0.9999. 
The value of n in the regression equation is one, confirming the first order 
reaction with respect to the silymarin concentration. 
The limit of detection (LOD) for initial rate method was calculated using 
statistical treatment of calibration data at seven-concentration levels [38]. The 
variance was calculated using the equation [39]. 
.Z^Qg^xpr- logt^^g? 
n-2 
Beer's law limit, correlation coefficient, variance, detection limit, standard 
deviations and confidence limits for slope and intercept of the calibration line are 
summarized in Table 5.1. The values of confidence limits at 95 % confidence level 
for slope and intercept of the calibration line pointed towards high reproducibility of 
the initial rate method. The low value of variance speaks of negligible scattering of 
the experimental data points around the line of regression. 
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Table 5.1 
Optical and statistical profiles of the initial rate method 
Parameters 
Xmax(nm) 
Linear dynamic range {\xg ml"') 
Regression equation 
Intercept (a) 
Sa 
itSa" 
Slope (b) 
Sb 
itSb" 
Correlation coefficient (r) 
Variance (SQ^) 
Detection limit (jig ml'') 
Initial rate method 
430 
16.0-192.0 
log (rate)= 2.798 + 1.000 log C 
2.798 
8.713 X 10-^  
2.062 X 10-^  
1.000 
2.283 X lO-" 
5.398 X lO-" 
0.9999 
5.709 X 10"* 
5.286 X 10"^  
"Confidence limit for intercept. 
** Confidence limit for slope. 
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Fixed-time method 
The absorbance of the oxidative coupling product (A^ ax = 430 nm) having varying 
amounts of silymarin was recorded at a preselected fixed time after reagents mixing. 
The absorbance measured at a fixed time of 3, 6, 9, 12 and 15 min was plotted 
against initial concentration of silymarin. Beer's law limit, molar absorptivity, 
regression equation, coefficient of correlation, detection limit, variance, standard 
deviation and confidence limits for slope and intercept are summarized in Table 5.2. 
It is apparent from Table 5.2 that the fixed time method at different intervals of time 
was fi"ee fi-om procedural errors, the experimental intercepts, a, of lines of regression 
were tested for the significance of deviation from the expected value zero [40]. The 
values calculated for t, never exceed the 95% criterion, 2.365, which denotes that the 
intercepts of all regression lines are not significantly different from zero. It was 
observed that the most acceptable values of the intercept, standard deviation of the 
slope and intercept, detection limit and variance were obtained at a fixed time of 12 
min, and therefore, the fixed time of 12 min was considered to be the most suitable 
time interval for estimation of drug under this condition. 
Accuracy and precision of the proposed methods 
Once the experimental conditions have been optimized, the accuracy and 
precision of the initial rate and fixed time methods should be established. In order to 
do this, three different concentration levels i.e. 48, 80, and 160 |^ g ml"' of pure 
silymrin were selected. The short-term precision (intra day assay) was performed by 
measuring five independent analyses at each concentration level within one day 
(Table 5.3). The daily precision (inter day assay) was evaluated by measuring the 
silymarin content at each level on five consecutive days by initial rate and fixed time 
methods (Table 5.4). The standard deviations (SD), 
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Table 5.3 
Intra day assay: repeatability data of the proposed methods 
Proposed methods 
Initial rate method 
Fixed time method 
Amount 
(tig ml') 
Taken 
48.0 
80.0 
160.0 
48.0 
80.0 
160.0 
Found ± SD' 
48.02 ± 0.064 
80.02 ± 0.064 
160.08 ±0.100 
47.99 ±0.074 
80.06 ± 0.086 
160.03 ±0.072 
Recovery ± RSD^ 
(%) 
100.04 ±0.13 
100.02 ±0.08 
100.05 ±0.06 
99.98 ± 0.07 
100.07 ±0.11 
100.02 ±0.05 
SAE'' 
0.029 
0.029 
0.045 
0.033 
0.039 
0.032 
C.L.' 
0.080 
0.080 
0.125 
0.092 
0.107 
0.089 
* Mean for five independent analyses. 
'' SAE, standard analytical error. 
" C.L., confidence limit at 95% confidence level and four degrees of freedom (t =2.776). 
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Table 5.4 
Inter day assay: repeatability data of the proposed methods 
Proposed methods 
Initial rate method 
Fixed time method 
Amount 
(^gml') 
Taken 
48.0 
80.0 
160.0 
48.0 
80.0 
160.0 
Found ± SD' 
48.08 ± 0.077 
80.02 ±1.000 
160.04 ±0.100 
48.00 ±0.080 
80.09 ±0.145 
160.09 ±0.116 
Recovery ± RSD* 
(%) 
100.17±0.16 
100.02 ±0.13 
100.02 ±0.07 
100.00 ±0.17 
100.12±0.18 
100.05 ±0.07 
SAE*" 
0.034 
0.045 
0.052 
0.036 
0.065 
0.052 
C.L.^  
0.096 
0.124 
0.144 
1.000 
0.179 
0.145 
" Mean for five independent analyses. 
b SAE, standard analytical error. 
'C.L., confidence limit at 95% confidence level and four degrees of freedom (t=2.776). 
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mean percent recoveries and relative standard deviations (RSD) obtained in intra 
day and inter day assays can be considered to be very satisfactory and thus, the 
proposed methods are very effective for the determination of silymarin. 
The validity of the proposed methods was tested by adding a fixed amount of 
pure drug to the preanalysed tablets and capsules at two concentration levels and 
then analysed following the recommended procedures. Each level was repeated five 
times using four different marketed formulations. The results are summarized in 
Table 5.5, which indicated that common excipients and additives did not interfere 
with the determination process. The results obtained were reproducible with low 
standard deviation and relative standard deviation. 
The initial rate and fixed time methods were applied to the determination of 
silymarin in commercial dosage forms. The concentration of the drug was computed 
from the corresponding regression equations. The results of the proposed method 
(initial rate or fixed time) were statistically compared with those obtained by the 
reference method [34] using point hypothesis test. The student t-test and F-test 
values (Table 5.6) at 95% confidence level did not exceed the theoretical values 
[41] of 2.306 and 6.39 for t- and F- tests, respectively indicating no significant 
differences between the performance of the proposed method and the reference 
method. The interval hypothesis tests [42] have also been performed to judge the 
performance of the proposed method and the results are shown in Table 5.7. The 
Canadian Health Protection Branch specified that in pharmaceutical analysis, a bias, 
based on recovery experiments, of ± 2 % is acceptable [43]. Therefore, the limit of 
acceptance interval is within (t»L= 0.98 and (j)u = 1.02. The true bias of all samples of 
drug is smaller than ± 2 % (Table 5.7), which also confirmed that there is no 
significant difference between accuracy and precision of the methods compared. 
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Table 5.7. 
Interval hypothesis test: comparison of the proposed methods with the reference method 
at 95% confidence level 
Formulations" Initial rate method Fixed time method 
Lower limit' Upper limit' Lower limit" Upper limit" 
(eo (Ou) (OL) (BU) 
Tablet 
Silibon 
Silyrin 
Capsule 
Sivylar 
Silimar 
0.986 
0.984 
0.986 
0.983 
1.013 
1.016 
1.016 
1.018 
0.985 
0.986 
0.986 
0.986 
1.014 
1.014 
1.013 
1.015 
" In pharmaceutical analysis, a bias, based on recovery experiments, of ±2% (9L= 0..98 and 
6u= 1.02) is acceptable. 
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The proposed methods (initial rate and fixed time) are usefial due to high tolerance limit 
for common excipients found in dnig formulations. The proposed methods do not require any 
elaborate treatment of the drug and tedious extraction procedure for the formation of coloured 
chromophore of the drug with the interacting reagents. The methods are selective due to the 
measurement of unstable colour in terms of absorbance with time for 15 min. The proposed 
methods have wider linear dynamic range with low values of relative standard deviation. 
Intra day and inter day assays proved that the proposed methods have acceptable precision 
and accuracy. Hence, these advantages encourage the application of the initial rate and fixed 
time methods in routine quality control analysis of sihmarin in industrial laboratories. 
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Abstract 
A simple and sensitive kinetic spectrophotometric method is described, based on the oxidation of norfloxacin with alkaline potassium 
permanganate. The reaction is followed spectrophotometrically by measuring the rate of change of absorbance at 603 nm. The initial rate and 
fixed time (at 3 min) methods are utilized for constructing the calibration graphs to determine the concentration of the drug. The calibration 
graphs are linear in the concentration ranges 2.0-20 .^g ml~' and 1.0-20 )jL.g mP' using the initial rate and fixed time methods, respectively. 
The results are validated statistically and through recovery studies. The method has been successfully applied to the determination of 
norfloxacin in commercial dosage forms. Statistical comparison of the results with the reference method shows excellent agreement and 
indicates no significant difference in accuracy and precision. 
© 2003 Elsevier B.V. All rights reserved. 
Keywords: Initial rate method; Fixed time method; Norfloxacin; Potassium permanganate; Pharmaceutical formulations; Spectrophotometry 
1. Introduction 
Norfloxacin, I -cthyl-6-fluoro-1,4-dihydro-4-oxo-7-(l -
piperazinyl)-3-quinolinc carboxylic acid is a synthetic broad 
spectrum antibacterial drug, which is very much active 
against many gram positive and gram negative bacteria. It is 
mainly used in the treatment of urinary tract infections. 
The drug and its formulations are listed in the United 
States Pharmacopoeia [ 1 ] and European Pharmacopoeia [2]. 
The USP describes a high performance liquid chromatog-
raphy (HPLC) method for its determination while the 
European Pharmacopoeia recommends a non-aqueous 
titration method. Other techniques used for its quantification 
include HPLC [ 3 - 1 3 ) , high performance thin layer 
chromatography (14), fluorimetiy {15 -19 ] , tiirimccry [20] 
and differential scanning potentiometry [21]. 
Spectrophotometry still belongs to the most frequently 
used analytical techniques in pharmaceutical analysis, 
which provides practical and significant economic advan-
tages over other methods. A review of the literature 
revealed that the charge transfer reactions of norfloxacin 
* Concsponding author. Department of Chemistry, Aligaih Muslim 
Univereity, Aligarh-202002 (U.P.), India. Tel.: 4-91-571-2703515. 
E-mail address: chtl7nr@yahoo.co.in (N. Rahman). 
with TT-accepiors such as 2,3-dichloro-5,6-dicyano-p-ben-
zoquinone, 7,7,8,8,tetra cyano quinodimethane, p-chloranil 
and ;7-chloranilic acid have been used for its assay in bulk 
and dosage forms [22]. El Walily et al. [23]have developed 
two si)ectrophotometric methods based on the interaction of 
norfloxacin with 2,4-dinitrofluorobenzene in aqueous borate 
buffer and dimethylsufoxide medium to form colored 
chromophores, which absorb maximally at 36S and 
410 nm, respectively. The drug content in pharmaceutical 
formulations has been determined by the formation of an 
oxidative coupling product of the drug with 3-methyl-2-
benzothiazolinone hydrazone-HCl in the presence of cerric 
ammonium sulfate [24]. The quantification of norfloxacin 
[25] was done utilizing the reaction between drug and 
Fe(in) in sulfuric acid medium. Two extractive spectro-
photometric methods 126] have been recommended based 
on chlorofomi extractable ion-association complex of the 
drug with each of the dyes such as supracene violet 3B and 
tropaeolin 0(X). The determination of norfloxacin was 
carried out on the basis of the formation of precipitate 
between drug and ammonium rcineckale. The precipitated 
drug-reagent complex was dissolved in aqueous 50% 
acetone and absorbance measured at 524 nm [27]. However, 
many of these methods are limited in their applications or 
rather much tedious and time consuming. The literature is 
0939-6411/$ - see front matter C 2003 Elsevier B.V. All rights reserved. 
doi:l0.1016/S0939-6411(03)00192-9 
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Still poor in analytical procedures based on kinetics, 
especially for the determination of drugs in commercial 
dosage forms. However, some specific advantages in the 
application of kinetic methods can be expected [28], such as 
selectivity due to the measurement of the evolution of the 
absorbance with the time of reaction. There is, therefore, a 
need for a simple and sensitive kinetic spectrophotometric 
method for the assay of norfloxacin in commercial dosage 
forms. 
Our present communication describes a simple and 
sensitive kinetic spectrophotometric method for the deter-
mination of norfloxacin in drug formulations. The method 
involves the oxidation of drug with alkaline potassium 
permanganate at room temperature and subsequent 
measurement of absorbance at 603 nm. The initial rate 
and fixed rate methods are adopted for its determination in 
commercial dosage forms after full investigation. 
2. Materials and methods 
2.1. Apparatus 
A Shimadzu UV-visible spectrophotometer (model-
1601, Japan) with matched quartz cells was used to measure 
absorbance. 
2.2. Reagents and standards 
All chemicals used were of analytical or pharmaceutical 
grade. Norfloxacin was provided by Cipla, India and was 
used as received. A standard solution of norfloxacin 
(1.0 mg/ml) was prepared by dissolving 100 mg in 1.0 ml 
of 0.75 M NaOH, and further diluted to 100 ml with doubly 
distilled water. A working test solution of norfloxacin 
(0.2 mg ml"') was prepared by dilution of 10 ml of the 
standard solution to SO ml with doubly distilled water. The 
tablets containing the norfloxacin such as Alflox (Alkem), 
Negaflox (Zydus Alidac), Norflox (Cipla), Uroflox (Torrent) 
were purchased locally. Aqueous solutions of sodium 
hydroxide (0.75 M) and potassium permanganate 
(0.006 M) were prepared in doubly distilled water. Potas-
sium permanganate solution should be freshly prepared and 
its apparent purity was checked titrimetrically [29]. 
2.3. Recommended procedure for norfloxacin determination 
2.3.1. Initial rale method 
Aliquots of 0.1 -1.0 ml of 0.02% norfloxacin test solution 
were pipetted into a scries of 10-ml standard flasks. Two 
milliliters of 0.75 M NaOH followed by 2.0 ml of 0.006 M 
potassium permanganate were added to each flask and then 
diluted with doubly distilled water at 30 ± 1 °C. The 
contents of the mixture of each flask were mixed well and 
the increase in absorbance at 603 nm was recorded as a 
function of time. The initial rate of the reaction (v) at 
different concentrations was obtained from the slope of 
the tangent to the absoibance time curve. The calibration 
graph was constructed by plotting the logarithm of the initial 
rate of the reaction (log v) versus the logarithm of the molar 
concentration of norfloxacin (log Q. The amount of the 
drug in each sample was calculated either from the 
calibration graph or the regression equation. 
2.3.2. Fixed time method 
In this method, the absorbance of each sample solution at 
a preselected fixed time was accurately measured and 
plotted against the final concentration of the drug. The 
content of the drug was estimated either from the calibration 
graph or regression equation. 
2.4. Determination of norfloxacin in dosage forms 
An accurately weighed quantity of the mixed contents of 
the tablets, equivalent to 50 mg of the drug was extracted 
into 50 ml of 1,2-dichloromethane with shaking and the 
residue was filtered using Whatmann No. 42 filter paper. 
The filtrate was evaporated to dryness and the residue was 
dissolved in 1.0 ml of 0.75 M NaOH and transferred to a 
50-ml standard volumetric flask, diluting to volume with 
doubly distilled water. The stock solution of drug was 
diluted according to need and analyzed by the recom-
mended procedures. 
3. Results and discussion 
The absorption spectrum of aqueous potassium per-
manganate solution in the alkaline medium exhibited an 
absorption band peaking at 530 nm. The addition of 
norfloxacin to this solution produced a new characteristic 
band at 603 nm (Fig. 1). This band is due to the formation of 
manganate ion, which resulted in the oxidation of 
sso eoo 
wavelength (nm) 
Fig. I. Absorption spectra of (a) 2.0 ml of 0.7S M NaOH + I ml of 0.006 M 
KMnOt: (b) 20 (ig ml~' notfloxacin + 2.0 ml NaOH (0.7S M) -I- 2 ml 
KMn04 (0.006 M) in double distilled water. 
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10'«12 
16 « 1 0 ' 
(KMnOJ (mole/litre) 
Fig. 2. Effect of the concentration of KMn04 (3 X 10 *to 15x10 "1^4)00 
the initial rate of reaction (v) with 20 p.g ml ~' norfloxacin and 2.0 ml NaOH 
(0.75 M) in double distilled water. 
noifloxacin by potassium permanganate in alkaline med-
ium. The intensity of the color increases with time, and 
therefore, a kinetically based method was developed for the 
determination of norfloxacin in drug formulations. The 
optimum conditions affecting the formation of manganate 
ion were studied and maintained throughout the experiment. 
3.1. Effect of KMn04 concentration 
The effect of KMn04 concentration on the initial rate of 
the reaction was studied in the range 3 .0x10"^ to 
15.0 X 10~* M. The initial rate of reaction (Fig. 2) increased 
with increasing the concentration of KMn04 and became 
•04 
•06 
-08 
•\D-8 
-1.4 
AS 
-M -SO -46 -42 -as -a4 
log [Drug] or [KMnO ]^ 
-ao -2.6 
Fig. 3. Limiting logarithmic plot for molar combining ratio between 
norfloxacin and KMn04: (a) log A vs. log (Drug); (b) log A vs. log 
[KMn04). 
62H5 
OH 
yn^yXX^, 
COOH 
+ MnO?' 
CaHs 
1 -Ethy1-6-fluoro-2-hydroxy-4-oxo-7-plpGra2ln 
-1-yl-1,4-dchydro-<iulnoline-3-oarboxylic a d d 
Scheme 1. 
constant at 10.2 x 10"" M. Thus, the adoption of 
12.0 X 10"" M KMn04 in the final solution proved to be 
adequate for the maximum concentration of norfloxacin 
used in the determination process. 
3.2. Effect of NaOH concentration 
The influence of the NaOH concentration on the 
formation of Mn04~ was also examined by taking 
20 pig ml" ' norfloxacin, 2.0 ml of 0.006 M KMn04 solution 
and varying volume (0.25-2.0ml) of 0.75 M NaOH. The 
maximum absorbance was obtained with 1.5 ml of 0.75 M 
NaOH, after which further increase in volume of NaOH 
caused no change in absorbance. Hence, 2.0 ml of 0.75 M 
NaOH was used as an optimum value. 
Time (min) 
Fig. 4. Absorbance vs. lime curves for the reaction between norfloxacin and 
KMnO :^ KMnO,, 1.2 X 10"' mol P ' and norfloxacin (a) 6.263 x 10"' 
mol 1"'; (b) 1 . 2 5 3 x 1 0 " ' mol 1"'; (c) 1 .879x10"' mol 1"'; 
(d) 2.505 X 10"' mol I"'; (e) 3.758 x 10"' mol I"'; (f) 5.0I0X 10"' 
mol r ' ; { g ) 5.637 X 10"'mol 1"'; (h) 6.263 X 10"'moll"'. 
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Time (min) 
Fig. S. Absorbance vs. lime curves for the reaction between norfloxacin and 
KMnO«: norfloxacin, 6.263 X 10"' mol 1"' and KMn04 (a) 3 X 10"* mol 
r ' (b) 6X 10"" mol !"' (c) 9 x 10"" mol 1"' (d) 10.2X 10"" mol I"' 
(e) 12x10"" moll"'. 
3.3. Stoichiometry and reaction mechanism 
The stoichiometric ratio between potassium permanga-
nate and norfloxacin was determined by the limiting 
logarithmic method [30]. This was established by perform-
ing two sets of experiments. In the first set, KMn04 
concentration was varied while keeping a constant concen-
tration of norfloxacin. In the second set, the KMn04 
concentration was kept constant while varying the concen-
tration of norfloxacin. The logarithms of the absorbance 
were plotted against the logarithm of the respective varied 
concentration (Fig. 3). The slopes of the two straight lines 
were calculated and found to be unity in each case. Thus, it 
is concluded that the combining molar ratio between 
norfloxacin and KMn04 is 1:1. 
A review of the literature indicated that norfloxacin 
undergoes oxidation when treated with oxidants such as 
chloramine-B and N-chlorobenzotriazole [31]. In this study, 
the potassium permanganate oxidizes norfloxacin in alka-
line medium. Therefore, the following reaction mechanism 
(Scheme 1) is proposed on the basis of literature background 
and our experimental findings. 
3.4. Initial rate method 
The initial rates of the reaction were determined from 
absorbance time curves (Figs. 4 and 5) by measuring the 
slopes of the initial tangent to the absorbance time curves. 
The order with respect to permanganate was determined by 
studying the reaction at different concentrations of per-
manganate with fixed norfloxacin concentration. The plot of 
initial rate, AAlAt, against the initial absorbance was linear 
passing through the origin indicating that the initial order of 
the reaction with respect to permanganate was 1. The order 
with respect to norfloxacin was evaluated by plotting the 
logarithm of the initial rate of the reaction versus the 
logarithm of the molar concentration of norfloxacin and was 
found to be 1. 
Under the optimized experimental conditions, the 
concentration of norfloxacin was determined using an 
excess of KMn04 and NaOH solution with respect to the 
initial concentration of norfloxacin. As a result, a pseudo 
zero order condition was obtained with respect to their 
concentrations. However, the initial rate of the reaction 
would follow a pseudo first order and was found to obey the 
following equation 
Rate = AAlAt = K'C 
where K' is the pseudo first order rate constant, C is the 
concentration of norfloxacin, n is the order of the reaction. 
Table I 
Optical and regression characteristics of fixed time method 
Parameters 
Beer's law limit ()ig ml"') 
Rcfmtioa equation 
s. 
±«S. 
Sb 
±«Sfc 
Coefficient of correlation (r) 
Detection limit ()ig ml"') 
Variance ( ^ 
Fixed-time method 
3 min 
1.0-20 
A = 2.905X10"' 
+ 1.500 X10"'C 
3.318x10"" 
7.846x10"" 
2.821 x 10"' 
6.671 X 10"' 
0.9999 
0.08 
3.214 X 10"' 
6 min 
1.0-12 
A = 2.899X10"' 
+2.756 X 10"^C 
3.925X10"" 
1.090x10"' 
5.906X10"' 
1.639X10"* 
0.9999 
0.05 
2.913 X 10"' 
9 min 
1.0-12 
A = 2.898X10"' 
+ 3.604 X 10"^C 
5.212 X 10"" 
1.447 X 10"' 
7.843 X 10"' 
2.177 X 10"* 
0.9999 
0.05 
5.136x10"' 
12 min 
1.0-12 
A = 2.907X10"' 
+4.346 X10"^C 
4.571 X 10"" 
1.269X10"' 
6.878 X 10"' 
1.909X10"" 
0.9999 
0.04 
6.285 X 10"' 
15 min 
1.0-12 
A = 2.907X10"' 
+4.996x10"^ 
4.234X10"" 
1.175X10"' 
6.372 X 10"' 
1.769X10"" 
0.9999 
0.03 
3.390 X 10"' 
±iS, = confidence limit for intercept; ± iSt, = confidence limit for slope. 
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(a) CDnoenlrationofnorflcoacin Oigmr') 
(b) Concentratton of nocflooodn Oig mf') 
Fig. 6. Variation of the confidence limit at 9S% confidence level in the fonn 
of unceitainty percentage on the concentration of norfloxacin with (a) initial 
rate method (b) fixed time meltiod (3 min). 
The logarithmic form of the above equation is written as. 
Log (rate) = log *' + « logC 
The linear regression analysis using the method of least 
square was made to evaluate slope, intercept and correlation 
coefficient. Under the optimized experimental conditions a 
calibration curve was constructed by plotting log initial rate 
versus log tnolar concentration of norfloxacin (log O, which 
showed a linear relationship over norfloxacin concentration 
range of 2.0-1 OOjig ml"'. The regression of log rate versus 
log C gave a linear regression equation 
Log(rate) = 3.213 + 0.9975 logC 
With a correlation coefficient (r) of 0.9999. The value of 
n in the regression equation also confirmed that the reaction 
was first order with respect to the norfloxacin concentration. 
The confidence limits for the slope of the line of regression 
and intercept were computed using the relation b ± tS\, and 
a ± r5a [32] at 95% confidence level and found to be 
0.9975 + 3 .557x10"^ and 3.213 ± 1.632 X 10"^ 
respectively. This indicated the high reproducibility of the 
proposed method. The limit of detection was established 
using the equation [33]. 
/ 2 n - 2 \ " 2 , 
Limit of detection = 15o X — 
V n- \ ) b 
where t is the value of student's / for n — 2 degree of 
freedom at 95% confidence level and Si = variance. The 
variance and detection limit were calculated and found to be 
1.833 X 10~* and 3.100 X 10" ' (jig ml" ' , which confirmed 
negligible scattering of experimental data points around the 
line of best fit and good sensitivity of the method, 
respectively. 
3.5. Fixed time method 
In this method, the absorbance of a green colored 
solution containing varying amounts of norfloxacin was 
10 'xl.75 
(a) 
0 2 4 6 8 10 12 14 16 18 29 22 
Conoentralicn of norikixacin (|ig mf') 
(0 
(b) 
S 10 15 20 
Conoertraticn of norfksadn (pg mf') 
Fig. 7. Error in the determination of the concentration of norfloxacin using 
statistical analysis of standard calibration data (a) initial rate method (b) 
fixed time method (3 min). 
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Table 2 
Intra day assay: evaluation of the accuracy and precision of the initial rate and fixed time methods 
Proposed methods 
Initial rate method 
Fixed time method 
Amount taken 
((ig ml" 
4.0 
12.0 
20.0 
4.0 
12.0 
20.0 
') 
Amount found ± S.D.* 
((ig m|-') 
4.02 ± 0.043 
12.02 ± 0.043 
20.06 ± 0.080 
04.02 ± 0.056 
12.02 ± 0.056 
20.02 ± 0.056 
R.S.D. 
(%)• 
1.09 
0.36 
0.40 
1.39 
0.47 
0.28 
SAE' 
0.019 
0.019 
0.036 
0.025 
0.025 
0.025 
C.L.' 
0.054 
0.054 
0,100 
0.069 
0.069 
0.069 
' Mean ± S.D. for five determinations. 
SAE, standard analytical error. 
' C.L., confidence limit at 95% confidence level and four degrees of freedom (( = 2.776). 
Table 3 
Intra day assay: test of precision of the proposed methods in pharmaceutical formulations 
Formulations Initial rate method Fixed time method 
Amount taken Amount found ± S.D.' R.S.D. SAE' C.L.' Amount taken Amount found ± S.D.' R.S.D. SAE" C.L.' 
(M.grar') ( l i g m r ' ) (%)• (ngm| - ' ) ((igml"') W 
Alflox 
(Alkem) 
Negaflox 
(Zydus Alidac) 
Norflox 
(CipU) 
Uroflox 
(Tofient) 
20.00 20.02 ± 0.080 0.40 0.035 0.099 20.00 20.01 ± 0.060 
20.00 20.06 ±0 .080 0.40 0.035 0.099 20.00 20.02 + 0.056 
20.00 20.00 ±0.085 0.43 0.038 0.105 20.00 19.99 ± 0.060 
20.00 20.02 ± 0.080 0.40 0.035 0.099 20.00 20.01 ± 0.060 
0.30 0.027 0.074 
0.28 0.025 0.070 
0.28 0.027 0.074 
0.28 0.027 0.074 
* Mean ± S.D. for five detenninations. 
' SAE, standard analytical eiror. 
' C.L., confidence limit at 95% confidence level and four degrees of freedom (( = 2.776). 
Table 4 
Inter day assay: evaluation of the accuracy and precision of the initial rate and fixed time methods 
Proposed methods 
Initial rate method 
Fixed time method 
Amount taken 
(|ig ml" 
4.0 
12.0 
20.0 
4.0 
12.0 
20.0 
') 
Amount found ± S.D.* 
(M-g ml"') 
4.04 ± 0.052 
12.03 ± 0.049 
20.00 ± 0 . 1 6 0 
4.01 ± 0.076 
12.01 ± 0.076 
20.05 ± 0.087 
R.S.D. 
(%)• 
1.28 
0.41 
0.80 
1.89 
0.63 
0.43 
SAE" 
0.023 
0.022 
0.072 
0.034 
0.034 
0.039 
C.L.' 
0.064 
0.061 
0.199 
0.094 
0.094 
0.108 
* Mean ± S.D. for five determinations performed over a period of 5 days. 
" SAE, standard analytical error. 
' C.L., confidence limit at 95% confidence level and four degrees of freedom (/ = 2.776). 
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Table 5 
Inter day assay: test of precision of the proposed methods in phannaceutical formulations 
R>nmulations Initial rate method Hxed time method 
Amount taken Amount found ± S.D.* R.S.D. SAE^ C.L.' Amount taken Amount found ± S.D.' R.S.D. SAE*" C.L.' 
(M-gmP') ( l igmP') (%)• (( igmP') ((ig ml"') (%)" 
Alflox 
(Alkem) 
Negaflox 
(Zydus Alidac) 
Noiflox 
(Cipla) 
Uroflox 
(Torrent) 
20.00 20.00 + 0.109 0.55 0.049 0.135 20.00 19.98 ± 0.056 
20.00 20.02 + 0.125 0.62 0.056 0.155 20.00 19.99 + 0.076 
20.00 19.97 + 0.105 0.53 0.047 0.130 20.00 19.99 + 0.076 
20.00 19.98 + 0.109 0.55 0.049 0.135 20.00 20.02 ± 0.099 
0.28 0.025 0.069 
0.38 0.034 0.095 
0.38 0.034 0.095 
0.49 0.044 0.123 
* Mean + S.D. for five determinations performed over a period of 5 days. 
'' SAB, standard analytical error. 
' C.L., confidence limit at 95% confidence level and four degrees of freedom (/ = 2.776). 
Table 6 
Standard addition method for the determination of norfloxacin in dosage forms by initial and fixed time methods 
Formulations Initial rate method Fixed time method 
Amount Recovery (%) Amount Recovery (%) 
((igml"') Added Found ± S.D.' +R.S.D. (%)' S A E ' C.L.' ((igml"') Added Found + S.D.* ±R.S.D. (%)* SAE C.L.' 
Taken Taken 
AlRox 
(Alkem) 
Negaflox 
(Zydus Alidac) 
Norfiox 
(Cipla) 
Uroflox 
(Torrent) 
2.0 
6.0 
2.0 
6.0 
2.0 
6.0 
2.0 
6.0 
2.0 
6.0 
2.0 
6.0 
2.0 
6.0 
2.0 
6.0 
4.02 + 0.046 
12.02 ± 0.048 
4.02 ± 0.043 
12.02 + 0.043 
4.02 + 0.043 
4.01 ± 0.047 
4.01 ± 0.047 
12.02 ± 0.044 
100.56 + 1.14 
100.13 + 0.36 
100.47 ± 1.09 
100.19 + 0.36 
100.19 ± 1.09 
100.18 ± 1.18 
100.18+ 1.18 
100.13 +0.36 
0.020 
0.020 
0.020 
0,020 
0.020 
0.020 
0.021 
0.020 
0.057 
0.054 
0.054 
0.054 
0.054 
0.054 
0.060 
0.054 
2.0 
6.0 
2.0 
6.0 
2.0 
6.0 
2.0 
6.0 
2.0 
6.0 
2.0 
6.0 
2.0 
6.0 
2.0 
6.0 
3.99 + 0.060 
11.99 + 0.060 
4.02 ± 0.056 
12.02 + 0.056 
4.02 + 0.056 
11.99 ±0 .060 
4.02 ± 0.056 
12.02 ± 0.056 
99.82 + 1.49 0.027 0.074 
99.94 ±0 .50 0.027 0.074 
100.49 ± 1.39 0.025 0.070 
100.16 ±0.47 0.025 0.070 
100.49 ±0 .06 0.025 0.070 
99.94 + 0.50 0.027 0.074 
100.49 ± 1.40 0.025 0.070 
100.16 + 0.47 0.025 0.070 
* Mean ± S.D. for five determinations. 
'' SAE, standard analytical error. 
' C.L., confidence limit at 9596 confidence level and four degrees of freedom (/ = 2.776). 
Table 7 
Point hypocheus: compaiison of the proposed methods with the reference method at 95% confidence level 
FonnulatiaM 
Alflox 
(Alkem) 
r4eganox 
(Zydus Alidac) 
Norfiox (Cipla) 
Uroflox (Torrent) 
Initial rate method 
Recovery 
(») 
100.11 
100.30 
100.02 
100.11 
R.S.D.* 
(%) 
0.40 
0.40 
0.43 
0.40 
r-value"" 
0.39 
1.40 
0.19 
0.39 
F-value' 
1.91 
3.22 
1.37 
1.91 
Fixed time method 
Recovery 
(%) 
100.03 
100.10 
99.97 
100.03 
R.S.D. 
(%)• 
0.30 
0.28 
0.30 
0.28 
/-value"" 
0.89 
0.52 
0.46 
0.89 
f-value" 
1.08 
1.58 
1.50 
1.05 
Reference method 
Recovery 
(%)• 
100.20 
100.02 
100.06 
100.20 
R.S.D. 
(%)• 
0.29 
0.22 
0.36 
0.29 
' Mean of five determinations. 
Theoretical r-value (v = 8) and f-value (v = 4, 4) at 95% confidence level are 2.306 and 6.39, respectively. 
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Table 8 
Interval hypothesis: comparison of the proposed methods with the ieference 
method at 93% confidence level 
Formulations 
Alflox 
(Alkcm) 
Negaflox 
(Zydus Alidac) 
Norflox 
(Cipla) 
Uroflox 
(Torrent) 
Initial rate method 
Lower 
limit" (BL) 
0.995 
0.997 
0.993 
0.995 
Upper limit* 
(Ou) 
1.004 
1.009 
1.007 
1.004 
Fixed time method 
Lower 
limit* ( 6 0 
0.993 
0.996 
0.993 
0.993 
Upper limit* 
(eu) 
1.004 
1.005 
1.005 
1,004 
* In pharmaceutical analysis, a bias, based on recovery experiments, of 
±2% (6, = 0.98 and 63 = 1.02) is acceptable[38]. 
measured at a preselected fixed time. Calibration plots of 
absorbance versus initial concentrations of norfloxacin were 
established at a fixed time of 3, 6, 9, 12 and 15 min. The 
regression equations, coefficient of correlation, detection 
limit, variance, relative standard deviation, standard analy-
tical error are given in Table 1. The lowest detection limit 
was obtained with a fixed time of 15 min, whereas the fixed 
time of 3 min showed a wider concentration range for 
quantification. According to ICH guidelines [34], the 
detection limit is not required to be part of the validation 
procedure for assays. Therefore, on the basis of wider 
concentration range and less time of analysis, the fixed time 
of 3 min was recommended for determination. 
Regression analyses of the calibration data also make it 
possible to evaluate the error, Sc, in the determination of a 
given concentration of norfloxacin using the equation [35]. 
'. = l(-i iy-f) 1/2 i-^ClC^ - nC^) 
where y and C are average initial rate of reaction or average 
absorbance at a fixed time of 3 min and concentration 
values, respectively, for n standard samples. It is clear from 
the graph in Fig. 6a,b that the error reaches a minimum, 
when the initial rate (v) (or actual absorbance) was equal to 
the average initial rate (T) (or average absorbance) in the 
calibration graphs corresponding to 8.32 \i.g mP ' and 
9.65 |xg ml"' for the initial rate and fixed method, 
respectively. The value of Sc also allows one to establish 
the confidence limit at the selected level of significance for 
the determination of unknown concentrations by using the 
relation, Q ± tSc. Fig. 7a,b shows the variation in the 
confidence limit in the form of percentage uncertainty [36] 
in the concentration at the 95% confidence level and used to 
calculate the relative uncertainty in the concentration over 
the full range of concentration tested. It is, therefore, a 
useful way to establish the confidence limit. 
The accuracy and precision was determined by measur-
ing the norfloxacin content of pure sample and dosage forms 
five times within 1 day by initial rate and fixed time methods 
(Tables 2 and 3). The daily precision was measured by 
assaying the pure samples and tablets on 5 consecutive days 
by both initial rate and fixed time methods (Tables 4 and 5). 
The standard deviations, relative standard deviations and 
standard analytical errors obtained in intra day and inter day 
assays can be considered to be very satisfactory. 
The accuracy of the proposed methods was also checked 
by performing recovery experiments. For this, a known 
amount of the pure drug was added to preanalyzed dosage 
forms and then determined by the recommended pro-
cedures. The results (Table 6) obtained from the investi-
gations showed that the mean recoveries and relative 
standard deviations were in the range 99.82-1(X).56% and 
0.056-1.137%, respectively. No interference from the 
common excipients was observed. 
The initial rate and fixed time methods for determining 
norfloxacin have been tested on commercial pharmaceutical 
formulations. The concentration of the drug was computed 
from its corresponding regression equations. The results of 
the proposed method (initial rate or fixed time) were 
compared with those of the reference method [23] using 
point hypothesis. Table 7 shows that the calculated t- and 
F-values [37] are less than theoretical ones, confirming no 
significant difference between the performance of the 
proposed method and the reference method at a 95% 
confidence level. The interval hypothesis tests [38] have 
also been performed to compare results of proposed method 
(initial rate or fixed time) with those of reference method at 
95% confidence level (Table 8). It was decided that a bias of 
±2% is acceptable. Therefore, the limit of acceptance 
interval is within Oi = 0.98 and 02 = 1.02. It is apparent 
from Table 8 that the true bias of all samples is smaller than 
± 2%. The interval hypothesis leads to the same conclusion 
as the point hypothesis. 
4. Conclusion 
The initial rate and fixed time methods can be easily 
applied to the determination of norfloxacin in pure and 
dosage forms, which do not require elaborate treatment of 
the analyte and tedious extraction of the chromophore 
produced. The proposed method (initial-rate or fixed-time) 
is sensitive enough to enable determination of a lower 
amount of the drug. These advantages encourage the 
application of the proposed methods in routine quality 
control of norfloxacin in industrial laboratories. 
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ABSTRACT 
Two simple and sensitive validated spectrophotometric 
methods have been described for the assay of nicorandil in 
drug formulations. Method A is based on die reaction of the 
drug with phloroglucinol-sulfanilic acid reagent in sulfiiric 
acid medium to give yellow-colored product, which absorbs 
maximally at 425 nin. Method B uses the oxidative coupling 
of 3-methyl-2-benzothiazolinone hydrazone hydrochloride 
(MBTH) widi DL- 3,4 - dihydroxyphenylalanine (DL-dopa) 
in the presence of nicorandil as oxidant in sulfuric acid medi-
um to fonn an intensely colored product having maximum 
absorbance at 530 nm. Beer's law is obeyed in the concentra-
tion range 2.5 to 50.0 and 1.0 to 15.0 (ig mL"' with methods 
A and B, respectively. Both methods have been successfully 
applied for the analysis of drug in pharmaceutical formula-
tions. The reliability and the performance of the proposed 
methods are established by point and interval hypothesis and 
tlirough recovery studies. The experimental true bias of all 
samples is smaller than ±2%. 
K E Y W O R D S : nicorandil, phloroglucinol, DL-dopa, 3-
methyl-2-benzothiazoIinone hydrazone hydrochloride, phar-
maceutical formulations, validation parameters. 
INTRODUCTION 
Nicorandil is chemically known as N-[2-(nitroxy)ethyl]3-
pyridine carfooxamide, which belongs to the class of com-
pounds known as potassium channel activators. Nicorandil 
has venodilating properties owing to the presence of nitrate 
group in its chemical stmcture. The potassium channel acti-
vation may also exert direct cytoprotective effects by aug-
menting normal physiological processes, which protect the 
heart against ischemic events.'-^ Thus, nicorandil causes 
vasodilation of coronary and systematic arteries and has been 
investigated in the treatment of angina pectoris. Nicorandil 
undergoes biotransformation predominantly by denitration 
of nicorandil to the pharmacologically inactive alcohol 
metabolite, N-{2-hydroxyethyl)-nicotinamide, followed by 
side chain degradation to nicotinamide and related metabo-
Corresponding Author: Nafisur Rahman, Department of 
Chemisdy, Aligaih Muslim University, Aligarh-202002, 
Uttar Pradesh, India. Tel: +91-571-2703515. Email: 
cht 17nr@yahoo.co.in. 
lites, including nicotinic acid and N-metliyl-nicotinamide. 
The denitration occurs primarily in the liver. 
The drug is officially listed in Martindale: The Extra 
Phannacopoeia? The literature revealed that the assay of the 
drug in pure and dosage forms is not official in any pharma-
copeia and, therefore, requires much more investigation. 
Several analytical methods that have been reported for the 
estimation of nicorandil in biological fluids and/or pharma-
ceutical formulations include high-performance thin layer 
chromatography (HPTLC),^ high-performance liquid chro-
matography (HPLC),'"" and gas chromatography coupled 
with mass spectrometry.'^ A review of literature revealed no 
UV-visible .spectrophotometric method for the assay of nico-
randil in pharmaceutical formulations. 
This paper describes 2 simple, sensitive, selective, and eco-
nomical validated visible spectrophotometric methods for tlic 
assay of nicorandil in drug formulations. The assay of drug is 
based on exploiting the oxidizing property of tlie drug due to 
the presence of nitrate moiety in the chemical stmcture of the 
drug. The fu t^ method is based on the reaction of the drug 
with phloroglucinol-sulfanihc acid reagent in sulfuric acid 
medium. The second method uses the oxidative coupling of 3-
methyl-2-benzothiazolinone hydrazone hydrochloride 
(MBTH) with DL-dopa in the presence of nicorandil as oxi-
dant in sulfiiric acid medium, resuhing in the formation of an 
intensely colored product The proposed methods are opti-
mized and validated'^  as per the International Conference on 
Harmonisation (ICH) guidelines. 
MATERIALS AND METHODS 
Apparatus 
A Shimadzu UV-visible spech^ophotometer (model 1601, 
Shimadzu, Kyoto, Japan) was used for all UV-visible 
absorbance measurements with matched quartz cells. A water 
bath shaker (NSW 133, New Delhi, India) was used to con-
ti-ol the heating temperature for the development of the color. 
Reagents and Standards 
Phloroglucinol-sulfanilic acid reagent (0.01 M) was prepared 
by dissolving 0.0631 g of phloroglucinol in 2 mL of 8 M HCl 
and 0.0867 g of sulfanilic acid in 25 mL of doubly distilled 
water, separately, and then mixed and diluted to 50 mL witii 
doubly distilled water. The solution is stable for 15 days if 
1 
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kept in the daik. For methods A and B, 12 and IS M H2SO4 
(BDH), respectively, were prepared and cooled before use. 
Aqueous solutions of MBTH (0.25%; Otto Chemie, 
Mumbai, India) and DL-dopa (0.1%; Sigma Chemical, St 
Louis, MO) were freshly prepared in doubly distilled water. 
Nicorandil was kindly provided by Zydus Medica, 
Ahmedabad, India, and was used as received. Commercial 
dosage fomis of nicorandil such as Corflo (Wockhardt, 
Mumbai, India), Korandil (Sun Pharma, Mumbai, India), 
Nikron (Torrent, Ahmedabad, India), and Zynicor (Zydus 
Medica, Ahmedabad, India) were purchased locally. 
The standard solution of nicorandil (0.05%; 0.5 mg mL"') 
was prepared in doubly distilled water. 
Recommended Procedures for the Determination of 
Nicorandil 
Method A 
Into a series of boiling test tubes, different volumes (0.05-1.0 
mL) of 0.05% nicorandil were pipetted. To each test tube, 2.5 
mL of 12 M sulfuric acid and 2.5 mL of O.OI M phlorogluci-
nol-sulfanilic acid reagent were added, mixed well, and heat-
ed on a water bath at 100°C ± l^ C for 32 minutes. The tubes 
were cooled at room temperature (25°C ± 1°C), and then the 
contents of the tubes were transferred to 10-mL volumetric 
flasks and diluted to volume with doubly distilled water. The 
absorbance was measured at 425 run against a reagent blank 
treated similarly except without drug within the stability peri-
od of I hour. The concentration of nicorandil was calculated 
either from calibration curve or from regression equation. 
Method B 
Aliquots of 0.05 to 0.75 mL of 0.05% nicorandil solution cor-
responding to 25.0 to 375.0 fig were pipetted into a series of 
boiling test tubes. Eight milliliters of 15 M H2SO4.2.5 mL of 
0.25% MBTH, and 0.5 mL of 0.1% DL-dopa were added to 
each tube. The contents of each tube were mixed well and 
heated in a water bath at 100"C ± PC for 12 minutes. After 
cooling at room temperature, die contents of tte tubes were, 
transferred to 25-mL standard flasks aiid diluted to voliune 
with doubly distilled water. The color was stable up to 4 
hours. The absoibance was measured at 530 nm against the 
reagent blank treated similarly excq)t without drug. A calibra-
tioo graph was drawn and the corresponding regression equa-
tion was computed to obtain the concentration of nicorandil 
PrqKration of Denitrated Nicorandil 
Nicorandil (500 mg) was hydrolyzed with 4N HCI and 4N 
NaOH at 100°C ± 1*^ for 30 minutes. Preparative thin layer 
chromatography was applied using silica gel G plate and 
chlorofonn:methanol:ethyl acetate (4:1:5 vol/vol/vol) as 
mobile phase. The band corresponding to the degradation 
product was located under UV lamp at 254 nm. The band 
was scrapped and extracted with chloroform. The solvent 
was removed and pure degradation product was obtained. 
Procedure for the Assay of Nicorandil in Pharmaceutical 
Formulations 
To minimize a possible variation in the composition of tlic 
tablets, the mixed contents of 20 tablets were weighed and 
grounded; then the powder equivalent to 50 mg nicorandil 
was stirred well witli dichloromethane and filtered through 
Whatman No. 42 filter paper (Whatman International 
Limited, Kent. UK). The residue was washed with 
dichloromethane for complete recovery of the drug. The fil-
trate was evaporated to dryness under vacuum and the left 
drug was taken up with doubly distilled water and transferred 
to a 100-mL standard flask and completed to volume with 
doubly distilled water. The percentage recovery of tlie drug 
was calculated from the corresponding linear regression 
equations. 
Procedure for Reference Method 
Into a series of 25-mL standard volumetric flasks, different 
volumes containing 0.4 to 10.0 jrg mL '^ of dmg (0.01%; 0.1 
mg mL"') solution were pipetted and diluted to voliune with 
doubly distilled water. The absorbance was measured against 
a solvent blank at 262.5 nm. The amount of the drug in a 
given sample was computed from the calibration equation. 
RESULTS AND DISCUSSION 
The electrophilic substitution reaction of phloroglucinol with 
N2O5 in sulfuric acid mediiun has been studied,'^  resulting in 
the formation of yellow-colored species of 1,3,5-trihydroxy-
2,4,6-trinitn>benzene. The denitration of nicorandil occurs in 
acidic medium.^  Therefore, the reaction of nicorandil with 
phloroglucinol in sulfuric acid medium leads to the forma-
tion of I,3,5-trihydroxy-2,4,6-trinitrobenzene, which absorbs 
maximally at 425 nm (Figure 1 A). According to TLC exper-
iments, the isolated denitrated nicorandil is more polar than 
nicorandil due to the denitration process. The denitrated 
nicorandil did not interfere with phloroglucinol, thus con-
firming the reaction of nicorandil with phloroglucinol. The 
nitrite, which is formed due to denitration of nicorandil, 
interferes positively and must be destroyed by sulfanilic acid. 
Therefore, based on the literature background and experi-
mental findings, the reaction mechanism was proposed and is 
given in Scheme 1. 
Nicorandil, being an oxidant, oxidizes MBTH (1) in acidic 
medium resulting in the formation of an electrophilic inter-
1.< 
1:2 -
1.0 -
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Figure 1. Absoiption spectra of colored products of nicorandil 
(A) 0.9 mL of 0.05% nicorandil + 2.5 mL of 12 M HjSO^ + 2.2 
mL of 0.01 M phloroglucinol-sulfanilic acid and (B) 0.7 mL of 
0.05% nicorandil + 8.0 mL of 15 M H2SO4 + 2.6 mL of 0.25% 
MBTH + 0.6 mL of 0.1% DL-dopa. 
mediate (2), which is an active coupling species.'^'* The 
intermediate of MBTH undergoes electrophilic substitution 
with the phenolic moiety of DL-dopa to form a colored prod-
uct showing an absorption peak at 530 nm (Figure IB). The 
proposed reaction mechanism is presented in Scheme 2. 
Optimization of Variables 
The spectrophotometric properties of the colored species 
formed with methods A and B were extensively studied. The 
optimum conditions for the assay procedures (methods A and 
B) have been established by studying the reactions as a func-
tion of heating time, concentration of reagents, sulfanilic 
acid, and stability of the colored species. 
Method A 
Effect of Healing Time 
To study the effect of heating time for maximum color devel-
opment, 0.9 mL of 0.05% nicorandil was mixed with 2.5 mL 
of 0.01 M phloroglucinol-sul&nilic acid reagent and 2.5 mL 
of 12 M H2SO4. The contents of the mixture were heated up 
to 35 minutes in a water bath at lOOX ± TC. It is apparent 
from investigations that the maximum intensity of color was 
attained after 30 minutes of heating and remained constant 
up to 35 minutes. Therefore, the optimum heating time was 
fixed at 32 minutes throughout the experiment. 
H O ' - OH 
Phlorcglucinol 
-A-CHrCHj-OH 
H2SO4 
+ 
heal 
Nicoraa<i( 
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OiN^ I NO2 
Scheme 2. 
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MO 
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Effect of the Concentration of Sulfuric Acid 
The influence of the volume of 12 M H2SO4 was observed dur-
ing the formation of yellow<olored product. To study this, an 
aliquot of dmg containing 450 ng was pipetted followed by 
varying volumes (0.1-2.5 mL) of 12 M H2SO4 and 2.2 mL of 
0.01 M phloroglucinol-sulfanilic acid. It is evident from Figure 
2A that the highest absort»ance was attained with 2.2 mL of 12 
M H2SO4; above this volume the absorbance remained 
luichanged. Therefore, 2.5 mL of 12 M H2SO4 was used in all 
further measurements. 
Effect of the Concentration of Phloroglucinol-Sulfanilic Acid 
To investigate the effect of volume of 0.01 M phloroglucinol-
sulfanilic acid reagent for color development, different vol-
umes (0.3-2.5 mL) were mixed with 0.9 mL of 0.05% nico-
randil and 2.5 mL of 12 M H2SO4. The results arc presented 
in Figm* 2B, which reveals that the addition of 2.2 mL gave 
the highest absorbance, which remained constant up to 2.5 
mL. Therefore, 2.2 mL of the reagent was taken for the deter-
mination of the drug throughout the experiment 
Methods 
Effect of Heating Time 
The optimiun heating time for the reaction to complete was 
evaluated by heating a mixture containing 0.7 mL of 0.05% 
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Figure 2. Effect of the volume of (A) 12 M HjSO. and (B) 0.01 
M phloroglucinol-sulfanilic acid reagent (method A); (C) 0.25% 
MBTH and (D) 0.1 % DL-dopa (method B). 
nicorandil, 8 mL of 15 M H2SO4, 2.6 mL of 0.25% MBTH. 
and 0.6 mL of 0.1 % DL-dopa in a water bath at 100°C ± TC. 
The intensity of the colored product reached maximum at 10 
minutes and remained constant up to 15 minutes. Therefore, 
the optimum heating was fixed at 12 minutes. 
Effect of the Concentration of Sulfuric Acid 
The eflfect of the volume of 15 M sulfuric acid on color develop-
ment of the product was investigated by taking 0.7 mL of 0.05% 
nicorandil with varying vohimes (0.5-9 mL) of 15 M H2SO4,2.6 
mL of 0.25% MBTH, and 0.6 mL of 0.1% DL-dopa into a series 
of test tubes. The reaction mixture of each test tube was heated in 
a water bath for 12 minutes and transferred to 25-mL standard 
flasks and diluted to vohune widi doubly distilled water. The 
highest absotbance was obtained with 7 mL of 15 M H2SO4; 
above this volume, no change in absoibance was recorded. 
Therefore, 8 mL of 15 M H2SO4 was used in all determinations. 
Effect of MBTH Concentration 
The efifect of volume of 0.25% MBTH on the cokir develop-
ment was investigated over the range 0.5-3.0 mL The results are 
presented in Figure 2C. which showed that 2.4 mL was adequate 
to give maximum intensity of the color. Hence, 2.6 mL of 0.25% 
MBTH was used as an optimum value fat color devek>pment 
Effect of DL-dopa Concentration 
The effect of DL-dopa concentration was studied by adding 
different volumes (0.05-0.7 mL) of 0.1% DL-dopa, 8 mL of 
15 M H2SO4, and 2.6 mL of 0.25% MBTH to a constant 
amount of 350 ng per 25 mL of nicorandil. It was found that 
the maximum intensity of the violet color was reached with 
0.45 mL of reagent and remained so with higher volumes 
(Figure 2D). Therefore, 0.6 mL of the reagent was used 
throughout tlie experiment. 
Analytical Data and Calibration Graphs 
Under tlie optimized experimental conditions, straight line cal-
ibration graphs were obtained over the calibration ranges 2.5-
50.0 aiid 1.0-15.0 ngmL"' of nicorandil witli molar absorptiv-
ities of 5.914 x 10^  and 1.500 x 10* Lmol"' cm-' with meth-
ods of A and B, respectively. The linear regression equations 
for both the methods have been evaluated by least square treat-
ment of the calibration data (n = 9). Table 1 simunarizes Beer's 
law limit, linear regression equation, correlation coefficient, 
confidence limits, and standard deviations for slope and inter-
cept at 95% confidence level, variai)ce, and detection limits for 
mctliods A and B. In each method, the correlation coefificient 
was high, indicating the excellent linearity of both the calibra-
tion graphs. The low values of confidence interval at 95% con-
fidence level for slope and intercept of the regression lines 
pointed toward high reproducibility of the proposed methods. 
In order to verify that the developed methods are fi-ee fi-om 
procedural errors, the experimental intercepts, a, of lines of 
regression were tested for significance of the deviation fix)m 
the expected value zero."'* For this justification, the values 
calculated for / from the relation, ' = T T were found to be 
•Jo 
0.058 and 0.222 for methods A and B, respectively, which did 
not exceed the 95% criterion, 2.365 (v = 7). It is concluded that 
the intercepts for methods A and B are not significantly differ-
ent fix)m zero. Thus, the proposed methods (A and B) are fiiee 
from constant errors independent of the concentration of nico-
randil. The detection limit (DL) at 95% confidence level was 
established using the relation"-": 
DL t I 2 n-2 
= -bf^ " ^ • (1) 
uhere n is (lie number of standard sa/nples (n = 9). t is the 
value of Student / test for n 2 degrees of freedom at 95% 
confidence lc\cl and SQ^ = variance. Both the DL and the 
slope of the calibration graphs indicated good sensitivity. The 
variance was calculated using the equation-': 
Jo 
n-2 
(2) 
and was found to be very low for methods A and B, indicat-
ing negligible scattering of the experimental data points 
around the line of regression. 
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Table 1. Optical and Regression Characteristics of the Proposed Methods 
Parameters 
^ ( n m ) 
Beer's law limit (ng mL"') 
Molar absorptivity (L mo!'' cm"') 
Linear regression equation* 
Intercept (a) 
S. 
tSJ 
Slope (b) 
Sb 
tSbJ 
Correlation coefficient (r) 
Variance (SQ^) 
Detection limit (ng mL') 
Method A Method B 
425 
2.5 - 50.0 
5.914 X 10^  
A = 1.164 X 10-^  + 2.805 X l a^C 
1.164 X 10-* 
2.014x10-3 
4.762 X 10-3 
2.805 X /0-2 
6.751 X 10-' 
1.600 X 10-^  
0.9999 
1.142 X 10-5 
0.267 
530 
1.0-15.0 
1.500 X 10" 
A = 7.619 X 10-5 +7.099 X 10-2^ 
7.619 X 10-' 
3.431 X 10-" 
8.114 X 10-" 
7.099 X 10 2 
3.671 X 10-5 
8.662 X 10-5 
0.9999 
2.830x10-7 
0.017 
•With respect to A = a + bC, where C is the concentration (ug niL"') and A is absorbancc. 
'Confidence interval of the intercept at 95% confidence level. 
^Confidence Interval of the slope at 95% confidence level. 
10-' X 1.42 i0-3«88 
NlcorantfH(MinL") NIcorandl (|ig ml ) 
Figure 3. Error in the dctcimination of the concentration of nicorandil obtained by statistical analysis of standard calibration data for 
(A) method A and (B) method B. 
The absolute error, 5^ was calculated in the determination of 
nicorandil for methods A and B by means of statistical analy-
sis of calibration data using the relation -^: 
I K : 
1 + - + 
1 , (A-Af 
n 6'2(C,-C)^ (3) 
where C and ^ are the average concentration and absorbancc 
values, respectively, for n staixiard solutions. Figures 3A and 
3B show the graph of 5^  versus the final concentration of nico-
randil. The error has reached minimum when the actual 
absorbance is equal to the average absorbancc corresponding 
to -24.7 and K.O ng mL"' for methods A and B, respectively. 
The confidence limits for unknown coiKentrations for nico-
randil can be dctcimincd iLsing the relation Q ± tS^  at a select-
ed confidence level and n - 2 degrees of freedom. The results 
are shown in Figures 4A and 4B in the form of percentage 
iS 
uncertainty," -^ x loO against the concentration of nico-
randil at 95% confidence level. Thus, the relative uncertainty 
can be estimated directly on the concentration level tested. 
u 
Nicorandil(MmL'^) 
Figure 4. Variation of the confidence limits for (A) method A and 
(B) method B at 95% confidence level and n - 2 degrees of freedom. 
Solution Stability 
The stability of nicorandil solution was examined by record-
ing absorption spectra of the solution for several days and by 
TLC studies, too. The band corresponding to degradation 
product was not observed under UV lamp at 254 nm, and 
there was also no change in the spectra for at least 4 days, 
when the solution was stored at room temperature. 
Specificity 
The specificity of the proposed methods was evaluated by 
determining the nicorandil concentration in the presence of 
varying amounts of denitrated nicorandil. It was foimd that 
the degradation product did not react with either reagent. 
Ruggedness 
The ruggedness of the method fclative to each operational 
parameter was challenged. The operational parameters inves-
tigated were; 
For Method A 
• volume of 12 M HjSO^ (±0.3 mL) 
• volume of 0.01 M phloroglucinol-sulfanilic acid 
reagent (±0.3 mL) 
• heating time (±2.0 minutes) 
• cooling temperature (±5°C) 
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For Method B 
• volume of 15 MH2SO4 (±1.0 mL) 
• volume of0.1%DL-dopa(± 0.15 mL) 
• volume of 0.25% MBTH (±0.2 mL) 
• heating time (±2.0 minutes). 
The ruggedness of the proposed metliods relative to each 
operational parameter was examined by analyzing the nico-
randil tablets imder variable experimental conditions. For 
this, a sample solution containing 10 \ig mL"' (Korandil-10) 
was assayed 5 times using both tlie methods. The results 
showed a mean value of 9.99 ± 0.06 [xg mL"' and 10.02 ± 
0.05 ng mL"' with relative standard deviations of 0.60% and 
0.54% for methods A and B, respectively. These results indi-
cated the ruggedness of the proposed methods. 
Robustness 
The method robustness was evaluated by a second analyst 
using a different instrument and freshly prepared standard 
and sample solutions. The analysis of the nicorandil tablets 
was performed 5 times at 1 concentration level by the robust-
ness chemist and developing chemist following the recom-
mended procedures. The results agreed well within the 
acceptable limits and no degradate was found to interfere 
with the determination process. These results demonstrated 
acceptable method robustness. 
Precision and Accuracy 
The short-term precision (intraday precision) of methods A 
and B were evaluated by roeasiuing 5 independent samples 
of nicorandil in pure form at 3 different concentration levels 
(10.0, 30.0, 50.0 ng mL"' for method A and 4.0, 10.0, 15.0 
pg mL~' for method B), and in pharmaceutical formulations 
at 1 concentration level (10 ng mL~'). The standard devia-
tions and relative standard deviations for methods A and B 
were in the range of 0.04 to 0.42 \ig mL"', 0.16% to 0.92%, 
and 0.05 to 0.12 jig mL"', and 0.50% to 1.13%, respectively. 
In the same manner, the assay for daily precision (interday 
precision) at each concentration level was repeated for 5 con-
secutive days. The standard deviations and relative standard 
deviations for methods A and B were found to vaiy over the 
range 0.05 to 0.56 ng mL"', 0.19% to 1.12%, and 0.05 to 
0.15 ng mL ', and 0.55% to 1.29%, respectively. The values 
of standard deviation and relative standard deviation can be 
considered to be very satis&ctoty, and thus the proposed 
methods (A and B) are very effective for the determination of 
nicorandil in pure form and pharmaceutical formulations. 
The reliability and accuracy of the proposed methods were 
further ascertained through recovery studies using the stan-
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Table 2. Point Hypothesis Test: Comparison of the Proposed Methods With the Reference Method at 95% Confidence Level 
Pharmaceutical 
Formulations 
Corflo-10 
(Wockhardt) 
Korandil-10 
(Sun Pharm.) 
Nikron-10 
(Torrent) 
Zynicor-IO 
(Zydus Medica) 
Recovery 
% 
99.99 
99.92 
100.07 
100.14 
Method A 
RSD* % 
0.48 
0.60 
0.59 
0.71 
/-value* 
0.40 
0.59 
0.21 
0.20 
F-value'' 
1.01 
1.90 
1.05 
1.68 
Recovery 
% 
100.06 
100.17 
99.95 
100.12 
Method B 
RSD* % 
0.50 
0.54 
0.53 
0.66 
<-vaIuet 
0.17 
0.19 
0.12 
0.15 
F-value* 
1.11 
1.55 
1.15 
1.43 
Reference method 
Recovery 
% 
100.11 
100.11 
99.99 
100.06 
RSD* % 
0.48 
0.43 
0.57 
0.55 
*RSD indicates Relative standard deviation. Mean of 5 independent analyses. 
micoretical /-value (v= 8) and F-value (y= 4,4) at 95% confidence level are 2.306 and 6.39, respectively. 
Table 3. Interval Hypothesis Test: Comparison of die Proposed Methods With the Reference Method at 95% Confidence Level 
Pharmaceutical Formulations 
Corflo-10 (Wockhardt) 
Korandil-10 (Sun Pharm) 
Nikron-lO (Torrent) 
Zynicor-10 (Zydus Medica) 
Lower Limit* 
0.990 
0.989 
0.991 
0.990 
Method A 
(ej Upper Limit* 
1.007 
1.007 
1.011 
1.012 
(Ou) 
Method B 
Lower Limit* ( 6 J 
0.991 
0.992 
0.990 
0.990 
Upper Limit* (Ou) 
1.008 
1.009 
1.009 
1.011 
*ln pharmaceutical analysis, a bias, based on recovery experiments, of ± 2% (eL=0.98 and 6^=1.02) is acceptable. 
dard addition method. For this purpose, a fixed amount of 
nicorandii from preanalyzed tablets was taken and an amount 
of the pure drag (standard) at 2 different concentration levels 
was added and the total amoimt was estimated by the pro-
posed methods A and B. Each level was repeated 5 times 
using 4 different commercial pharmaceutical formulations. 
The results obtained for methods A and B through the stan-
dard addition method showed that the mean recoveries and 
relative standard deviations were in the range of 99.93% to 
100.53%, 0.14% to 0.87%, 99.95% to 100.97%, and 0.45% 
to 1.15%, respectively, which can be considered to be very 
satisfactory. No interference from commonly encountered 
tablet excipients such as talc, starch, gum acacia, lactose, 
sodium alginate, and magnesium stearatc was observed in 
the determination. Methods A and B were successfully 
applied to the determination of nicorandii in pharmaceutical 
formulations. The results of the proposed methods (A and B) 
were compared with those of the reference method using 
point hypothesis tesut. Tabic 2 shows that the calculated t and 
F values are less than theoretical ones," confirming accura-
c> and precision arc within the acceptable limits and indicat-
ing no significant difTerencc between the performance of the 
proposed methods and the reference method at 95% confi-
dence level. The interval hypothesis tests-^ have also been 
performed to compare results of the proposed methods (A 
and B) with those of the reference method at 95% confidence 
level (Table 3). The usual practice in attempting the point and 
interval hypothesis tests in hospitals and laboratories is to 
make sure that the standard deviation values of each assay 
are within the acceptable limits. Once this is established, the 
actual analytical error is usually ignored and not reported 
along with the concentration itself^* Hence, it was decided 
that a bias of ±2% is acceptable. Therefore, the limit of 
acceptance interval is within 9L = 0.98 and 0u =1.02. It is 
clear from Table 3 that the true bias of all samples is smaller 
than ±2%. The interval hypothesis tests draw tlie same con-
clusion as the point hypothesis tests. Thus, the proposed 
methods shown here are accurate, precise, and validated. 
CONCLUSION 
The proposed methods are sensitive and selective owing to 
the oxidizing nature of the drug, which preferentially inter-
acts with reagents described in the subsection Reagents and 
Standards, but its major metabolite (denitrated nicorandii) 
did not give the positive results with the reagents used. Point 
and interval hypothesis tests and recovery data clearly 
proved that the proposed methods have acceptable precision, 
accuracy, and linearity. 
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